

Overview for Request: cder_mpl1r_wp282

Request ID: cder_mpl1r_wp282_nsdp_v01

Request Description: In this report we characterized dispensing and administration patterns of 37 New Molecular Entities (NMEs) approved from January 1, 2022 through December 31, 2022, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 13.2.0.

Data Source: We distributed this request to five Sentinel Data Partners on November 14, 2024. The study period included data from January 1, 2022 to most recent available data (May 31, 2024). The date of the most recent available data differs across Data Partners; hence, for this request we limited distribution to those Data Partners that had data available for at least one year from December 31, 2022. This allowed for a minimum of one complete year of data to study utilization patterns for all NMEs. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 37 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2022 to December 31, 2022, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Overview for Request: cder_mpl1r_wp282

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 32 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 25 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes and Appendix E for a list of non-proprietary and proprietary names of medical products used to define characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse.
<https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

<u>Glossary (CIDA)</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of Daridorexant Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1b</u>	Aggregated Characteristics of Abrocitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1c</u>	Aggregated Characteristics of Mitapivat Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1d</u>	Aggregated Characteristics of Pacritinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1e</u>	Aggregated Characteristics of Ganaxolone Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1f</u>	Aggregated Characteristics of Lutetium Vipivotide Tetraxetan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1g</u>	Aggregated Characteristics of Oteseconazole Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1h</u>	Aggregated Characteristics of Mavacamten Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1i</u>	Aggregated Characteristics of Vonoprazan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1j</u>	Aggregated Characteristics of Tirzepatide Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1k</u>	Aggregated Characteristics of Tapinarof Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1l</u>	Aggregated Characteristics of Vutrisiran Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1m</u>	Aggregated Characteristics of Deucravacitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1n</u>	Aggregated Characteristics of Terlipressin Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1o</u>	Aggregated Characteristics of Gadopichlenol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1p</u>	Aggregated Characteristics of Omidenepeg Isopropyl Ophthalmic Solution Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1q</u>	Aggregated Characteristics of Sodium Phenylbutyrate and Taurursodiol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1r</u>	Aggregated Characteristics of Futibatinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1s</u>	Aggregated Characteristics of Olutasidenib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1t</u>	Aggregated Characteristics of Adagrasib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1u</u>	Aggregated Characteristics of Lenacapavir Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1v</u>	Aggregated Characteristics of Hyperpolarized 129-Xe Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1w</u>	Aggregated Characteristics of Tebentafusp-tebn Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1x</u>	Aggregated Characteristics of Faricimab-svoa Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Table of Contents

<u>Table 1y</u>	Aggregated Characteristics of Sutimlimab-jome Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1z</u>	Aggregated Characteristics of Nivolumab and Relatlimab-rmbw Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1aa</u>	Aggregated Characteristics of Olipudase Alfa-rpcp Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ab</u>	Aggregated Characteristics of Spesolimab-sbzo Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ac</u>	Aggregated Characteristics of Daxibotulinumtoxina-ianm Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ad</u>	Aggregated Characteristics of Eflapegrastim-xnst Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ae</u>	Aggregated Characteristics of Tremelimumab-actl Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1af</u>	Aggregated Characteristics of Teclistamab-cqyv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ag</u>	Aggregated Characteristics of Mirvetuximab Soravtansine-gynx Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ah</u>	Aggregated Characteristics of Teplizumab-mzwv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ai</u>	Aggregated Characteristics of Mosunetuzumab-axgb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1aj</u>	Aggregated Characteristics of Anacaulase-bcdb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 1ak</u>	Aggregated Characteristics of Ublituximab-xiiy Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

Table of Contents

<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

Table of Contents

<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1a</u>	Patient Entry into Study by Month for Daridorexant in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1b</u>	Patient Entry into Study by Month for Abrocitinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1c</u>	Patient Entry into Study by Month for Mitapivat in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1d</u>	Patient Entry into Study by Month for Pacritinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1e</u>	Patient Entry into Study by Month for Ganaxolone in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1f</u>	Patient Entry into Study by Month for Lutetium Vipivotide Tetraxetan in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1g</u>	Patient Entry into Study by Month for Oteseconazole in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1h</u>	Patient Entry into Study by Month for Mavacamten in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1i</u>	Patient Entry into Study by Month for Vonoprazan in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1j</u>	Patient Entry into Study by Month for Tirzepatide in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1k</u>	Patient Entry into Study by Month for Tapinarof in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1l</u>	Patient Entry into Study by Month for Vutrisiran in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1m</u>	Patient Entry into Study by Month for Deucravacitinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1n</u>	Patient Entry into Study by Month for Terlipressin in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1o</u>	Patient Entry into Study by Month for Gadopiclenol in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1p</u>	Patient Entry into Study by Month for Omidenepag Isopropyl Ophthalmic Solution in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1q</u>	Patient Entry into Study by Month for Sodium Phenylbutyrate and Taurursodiol in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1r</u>	Patient Entry into Study by Month for Futibatinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1s</u>	Patient Entry into Study by Month for Olutasidenib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1t</u>	Patient Entry into Study by Month for Adagrasib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1u</u>	Patient Entry into Study by Month for Lenacapavir in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Table of Contents

<u>Figure 1v</u>	Patient Entry into Study by Month for Hyperpolarized 129-Xe in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1w</u>	Patient Entry into Study by Month for Tebentafusp-tebn in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1x</u>	Patient Entry into Study by Month for Faricimab-svoa in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1y</u>	Patient Entry into Study by Month for Sutimlimab-jome in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1z</u>	Patient Entry into Study by Month for Nivolumab and Relatlimab-rmbw in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1aa</u>	Patient Entry into Study by Month for Olipudase Alfa-rpcp in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ab</u>	Patient Entry into Study by Month for Spesolimab-sbzo in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ac</u>	Patient Entry into Study by Month for Daxibotulinumtoxina-lanm in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ad</u>	Patient Entry into Study by Month for Eflapegrastim-xnst in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ae</u>	Patient Entry into Study by Month for Tremelimumab-actl in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1af</u>	Patient Entry into Study by Month for Teclistamab-cqyv in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ag</u>	Patient Entry into Study by Month for Mirvetuximab Soravtansine-gynx in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ah</u>	Patient Entry into Study by Month for Teplizumab-mzww in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ai</u>	Patient Entry into Study by Month for Mosunetuzumab-axgb in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1aj</u>	Patient Entry into Study by Month for Anacaulase-bcdb in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Figure 1ak</u>	Patient Entry into Study by Month for Ublituximab-xiiy in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (November 14, 2024)
<u>Appendix B</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
<u>Appendix E</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request
<u>Appendix F</u>	Specifications Defining Parameters Used in this Request
<u>Appendix G</u>	Specifications Defining Baseline Characteristic Parameters Used in this Request
<u>Appendix H</u>	Design Diagrams of Cohort Entry Requirements

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Daridorexant Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Daridorexant Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	10,520	N/A
Demographic Characteristics		
Age (years)	59.9	12.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	1,049	10.0%
41-64 years	4,943	47.0%
≥ 65 years	4,382	41.7%
Sex		
Female	6,568	62.4%
Male	3,952	37.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	171	1.6%
Black or African American	628	6.0%
Multi-racial	125	1.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,907	18.1%
White	7,630	72.5%
Hispanic origin		
Yes	285	2.7%
No	7,507	71.4%
Unknown	2,728	25.9%
Year		
2022	2,403	22.8%
2023	7,348	69.8%
2024	769	7.3%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	45	0.4%
Alzheimer's Disease and related conditions	344	3.3%
Atrial Fibrillation	581	5.5%
Diabetes Mellitus	2,040	19.4%
Heart Failure	746	7.1%
Hyperlipidemia	3,684	35.0%

Table 1a. Aggregated Characteristics of Daridorexant Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Daridorexant Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	4,264	40.5%
Depression	5,123	48.7%
Ischemic Heart Disease	1,575	15.0%
Rheumatoid Arthritis/Osteoarthritis	2,778	26.4%
Stroke/TIA	224	2.1%
Breast Cancer	214	2.0%
Colorectal Cancer	54	0.5%
Prostate Cancer	169	1.6%
Lung Cancer	61	0.6%
Endometrial Cancer	23	0.2%
Acquired Hypothyroidism	1,523	14.5%
Anemia	2,128	20.2%
Asthma	661	6.3%
Benign Prostatic Hyperplasia	463	4.4%
Chronic Kidney Disease	1,165	11.1%
COPD and Bronchiectasis	847	8.1%
Glaucoma	733	7.0%
Osteoporosis	514	4.9%
Liver Disease (Diagnosis Codes Only)	374	3.6%
Liver Disease (Diagnosis and Procedure Codes)	374	3.6%
Obesity (Diagnosis or Procedure Codes)	2,848	27.1%
Obesity (Dispensing Code)	153	1.5%
Overweight	1,271	12.1%
Smoking (Diagnosis or Procedure Codes)	1,071	10.2%
Smoking (Dispensing Code)	137	1.3%
Alcohol Abuse or Dependence	468	4.4%
Drug Abuse or Dependence	1,031	9.8%
History of Cardiac Arrest	12	0.1%
History of Coronary Angioplasty or Bypass	329	3.1%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	16.4	14.5
Mean number of emergency room encounters	0.5	1.5
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.4	7.5

Table 1a. Aggregated Characteristics of Daridorexant Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Daridorexant Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	32.4	24.7
Mean number of generics dispensed	12.3	7.0
Mean number of unique drug classes dispensed	11.3	6.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1b. Aggregated Characteristics of Abrocitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Abrocitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	609	N/A
Demographic Characteristics		
Age (years)	48.1	16.6
Age		
0-17 years	25	4.1%
18-24 years	76	12.5%
25-40 years	138	22.7%
41-64 years	221	36.3%
≥ 65 years	149	24.5%
Sex		
Female	315	51.7%
Male	294	48.3%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	37	6.1%
Black or African American	46	7.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	240	39.4%
White	265	43.5%
Hispanic origin		
Yes	16	2.6%
No	285	46.8%
Unknown	308	50.6%
Year		
2022	125	20.5%
2023	417	68.5%
2024	67	11.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	58	9.5%
Heart Failure	14	2.3%

Table 1b. Aggregated Characteristics of Abrocitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Abrocitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hyperlipidemia	94	15.4%
Hypertension	127	20.9%
Depression	97	15.9%
Ischemic Heart Disease	34	5.6%
Rheumatoid Arthritis/Osteoarthritis	75	12.3%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	11	1.8%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	36	5.9%
Anemia	68	11.2%
Asthma	43	7.1%
Benign Prostatic Hyperplasia	16	2.6%
Chronic Kidney Disease	27	4.4%
COPD and Bronchiectasis	25	4.1%
Glaucoma	20	3.3%
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	14	2.3%
Liver Disease (Diagnosis and Procedure Codes)	14	2.3%
Obesity (Diagnosis or Procedure Codes)	102	16.7%
Obesity (Dispensing Code)	*****	*****
Overweight	50	8.2%
Smoking (Diagnosis or Procedure Codes)	28	4.6%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	13	2.1%
Drug Abuse or Dependence	15	2.5%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	11.2	9.8
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2

Table 1b. Aggregated Characteristics of Abrocitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Abrocitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.8	5.0
Mean number of filled prescriptions	18.4	17.4
Mean number of generics dispensed	8.1	5.6
Mean number of unique drug classes dispensed	7.4	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1c. Aggregated Characteristics of Mitapivat Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mitapivat Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	26	N/A
Demographic Characteristics		
Age (years)	43.2	17.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	14	53.8%
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****

Table 1c. Aggregated Characteristics of Mitapivat Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mitapivat Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	25	96.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	18.2	15.7
Mean number of emergency room encounters	0.5	0.7
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	8.7	14.7

Table 1c. Aggregated Characteristics of Mitapivat Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mitapivat Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	22.5	22.3
Mean number of generics dispensed	8.1	5.8
Mean number of unique drug classes dispensed	7.5	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1d. Aggregated Characteristics of Pacritinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Pacritinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	879	N/A
Demographic Characteristics		
Age (years)	74.4	7.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	804	91.5%
Sex		
Female	396	45.1%
Male	483	54.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	41	4.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	75	8.5%
White	748	85.1%
Hispanic origin		
Yes	12	1.4%
No	760	86.5%
Unknown	107	12.2%
Year		
2022	393	44.7%
2023	460	52.3%
2024	26	3.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	14	1.6%
Alzheimer's Disease and related conditions	47	5.3%
Atrial Fibrillation	125	14.2%
Diabetes Mellitus	173	19.7%
Heart Failure	214	24.3%
Hyperlipidemia	354	40.3%

Table 1d. Aggregated Characteristics of Pacritinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Pacritinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	496	56.4%
Depression	181	20.6%
Ischemic Heart Disease	274	31.2%
Rheumatoid Arthritis/Osteoarthritis	170	19.3%
Stroke/TIA	35	4.0%
Breast Cancer	33	3.8%
Colorectal Cancer	15	1.7%
Prostate Cancer	60	6.8%
Lung Cancer	11	1.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	200	22.8%
Anemia	858	97.6%
Asthma	45	5.1%
Benign Prostatic Hyperplasia	111	12.6%
Chronic Kidney Disease	336	38.2%
COPD and Bronchiectasis	110	12.5%
Glaucoma	76	8.6%
Osteoporosis	49	5.6%
Liver Disease (Diagnosis Codes Only)	177	20.1%
Liver Disease (Diagnosis and Procedure Codes)	177	20.1%
Obesity (Diagnosis or Procedure Codes)	112	12.7%
Obesity (Dispensing Code)	*****	*****
Overweight	124	14.1%
Smoking (Diagnosis or Procedure Codes)	72	8.2%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	30	3.4%
Drug Abuse or Dependence	27	3.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	82	9.3%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	30.5	17.4
Mean number of emergency room encounters	0.9	1.7
Mean number of inpatient hospital encounters	0.6	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.7	13.9

Table 1d. Aggregated Characteristics of Pacritinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Pacritinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	22.8	14.0
Mean number of generics dispensed	10.3	5.7
Mean number of unique drug classes dispensed	9.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1e. Aggregated Characteristics of Ganaxolone Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ganaxolone Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	23	N/A
Demographic Characteristics		
Age (years)	13.9	7.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	11	47.8%
2023	12	52.2%
2024	0	0.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	*****	*****
Hyperlipidemia	*****	*****

Table 1e. Aggregated Characteristics of Ganaxolone Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ganaxolone Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Liver Disease (Diagnosis Codes Only)	0	0.0%
Liver Disease (Diagnosis and Procedure Codes)	0	0.0%
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	0	0.0%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	23.2	22.7
Mean number of emergency room encounters	0.4	0.7
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	23.4	39.6

Table 1e. Aggregated Characteristics of Ganaxolone Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ganaxolone Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	28.8	16.7
Mean number of generics dispensed	8.1	4.3
Mean number of unique drug classes dispensed	7.7	4.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1f. Aggregated Characteristics of Lutetium Vipivotide Tetraxetan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lutetium Vipivotide Tetraxetan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,303	N/A
Demographic Characteristics		
Age (years)	74.7	7.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	294	6.8%
≥ 65 years	4,009	93.2%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	64	1.5%
Black or African American	390	9.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	434	10.1%
White	3,396	78.9%
Hispanic origin		
Yes	47	1.1%
No	3,579	83.2%
Unknown	677	15.7%
Year		
2022	1,282	29.8%
2023	2,870	66.7%
2024	151	3.5%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	29	0.7%
Alzheimer's Disease and related conditions	130	3.0%
Atrial Fibrillation	579	13.5%
Diabetes Mellitus	1,001	23.3%
Heart Failure	555	12.9%
Hyperlipidemia	1,771	41.2%

Table 1f. Aggregated Characteristics of Lutetium Vipivotide Tetraxetan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lutetium Vipivotide Tetraxetan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	2,397	55.7%
Depression	686	15.9%
Ischemic Heart Disease	1,253	29.1%
Rheumatoid Arthritis/Osteoarthritis	687	16.0%
Stroke/TIA	122	2.8%
Breast Cancer	1,079	25.1%
Colorectal Cancer	82	1.9%
Prostate Cancer	4,294	99.8%
Lung Cancer	75	1.7%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	363	8.4%
Anemia	2,194	51.0%
Asthma	112	2.6%
Benign Prostatic Hyperplasia	358	8.3%
Chronic Kidney Disease	1,068	24.8%
COPD and Bronchiectasis	266	6.2%
Glaucoma	464	10.8%
Osteoporosis	224	5.2%
Liver Disease (Diagnosis Codes Only)	233	5.4%
Liver Disease (Diagnosis and Procedure Codes)	233	5.4%
Obesity (Diagnosis or Procedure Codes)	699	16.2%
Obesity (Dispensing Code)	*****	*****
Overweight	486	11.3%
Smoking (Diagnosis or Procedure Codes)	318	7.4%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	78	1.8%
Drug Abuse or Dependence	114	2.6%
History of Cardiac Arrest	11	0.3%
History of Coronary Angioplasty or Bypass	373	8.7%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	26.4	12.6
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.9	8.6

Table 1f. Aggregated Characteristics of Lutetium Vipivotide Tetraxetan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lutetium Vipivotide Tetraxetan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.9	14.1
Mean number of generics dispensed	9.1	5.2
Mean number of unique drug classes dispensed	8.3	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1g. Aggregated Characteristics of Oteseconazole Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Oteseconazole Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	161	N/A
Demographic Characteristics		
Age (years)	54.9	12.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	90	55.9%
≥ 65 years	44	27.3%
Sex		
Female	161	100.0%
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	43	26.7%
White	93	57.8%
Hispanic origin		
Yes	*****	*****
No	99	61.5%
Unknown	*****	*****
Year		
2022	*****	*****
2023	100	62.1%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	41	25.5%
Heart Failure	*****	*****
Hyperlipidemia	37	23.0%

Table 1g. Aggregated Characteristics of Oteseconazole Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Oteseconazole Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	45	28.0%
Depression	30	18.6%
Ischemic Heart Disease	11	6.8%
Rheumatoid Arthritis/Osteoarthritis	24	14.9%
Stroke/TIA	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	11.2%
Anemia	21	13.0%
Asthma	14	8.7%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	13	8.1%
COPD and Bronchiectasis	*****	*****
Glaucoma	17	10.6%
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	36	22.4%
Obesity (Dispensing Code)	*****	*****
Overweight	14	8.7%
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	14.7	10.9
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.7	6.1

Table 1g. Aggregated Characteristics of Oteseconazole Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Oteseconazole Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	23.6	21.9
Mean number of generics dispensed	11.0	7.5
Mean number of unique drug classes dispensed	10.1	6.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1h. Aggregated Characteristics of Mavacamten Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mavacamten Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,600	N/A
Demographic Characteristics		
Age (years)	69.1	10.1
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	366	22.9%
≥ 65 years	1,176	73.5%
Sex		
Female	1,072	67.0%
Male	528	33.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	38	2.4%
Black or African American	97	6.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	238	14.9%
White	1,209	75.6%
Hispanic origin		
Yes	25	1.6%
No	1,217	76.1%
Unknown	358	22.4%
Year		
2022	304	19.0%
2023	1,175	73.4%
2024	121	7.6%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	45	2.8%
Alzheimer's Disease and related conditions	25	1.6%
Atrial Fibrillation	366	22.9%
Diabetes Mellitus	339	21.2%
Heart Failure	714	44.6%
Hyperlipidemia	937	58.6%

Table 1h. Aggregated Characteristics of Mavacamten Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mavacamten Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	1,122	70.1%
Depression	323	20.2%
Ischemic Heart Disease	710	44.4%
Rheumatoid Arthritis/Osteoarthritis	265	16.6%
Stroke/TIA	52	3.3%
Breast Cancer	60	3.8%
Colorectal Cancer	11	0.7%
Prostate Cancer	32	2.0%
Lung Cancer	12	0.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	240	15.0%
Anemia	385	24.1%
Asthma	107	6.7%
Benign Prostatic Hyperplasia	64	4.0%
Chronic Kidney Disease	277	17.3%
COPD and Bronchiectasis	192	12.0%
Glaucoma	143	8.9%
Osteoporosis	122	7.6%
Liver Disease (Diagnosis Codes Only)	68	4.3%
Liver Disease (Diagnosis and Procedure Codes)	68	4.3%
Obesity (Diagnosis or Procedure Codes)	506	31.6%
Obesity (Dispensing Code)	*****	*****
Overweight	184	11.5%
Smoking (Diagnosis or Procedure Codes)	128	8.0%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	26	1.6%
Drug Abuse or Dependence	37	2.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	110	6.9%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	16.8	11.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.1	5.7

Table 1h. Aggregated Characteristics of Mavacamten Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mavacamten Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.7	15.0
Mean number of generics dispensed	9.0	5.2
Mean number of unique drug classes dispensed	8.5	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1i. Aggregated Characteristics of Vonoprazan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vonoprazan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	431	N/A
Demographic Characteristics		
Age (years)	58.3	13.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	232	53.8%
≥ 65 years	149	34.6%
Sex		
Female	271	62.9%
Male	160	37.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	21	4.9%
Black or African American	28	6.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	101	23.4%
White	261	60.6%
Hispanic origin		
Yes	31	7.2%
No	135	31.3%
Unknown	265	61.5%
Year		
2022	0	0.0%
2023	45	10.4%
2024	386	89.6%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	68	15.8%
Heart Failure	22	5.1%
Hyperlipidemia	170	39.4%

Table 1i. Aggregated Characteristics of Vonoprazan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vonoprazan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	179	41.5%
Depression	101	23.4%
Ischemic Heart Disease	45	10.4%
Rheumatoid Arthritis/Osteoarthritis	90	20.9%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	47	10.9%
Anemia	112	26.0%
Asthma	39	9.0%
Benign Prostatic Hyperplasia	11	2.6%
Chronic Kidney Disease	44	10.2%
COPD and Bronchiectasis	26	6.0%
Glaucoma	47	10.9%
Osteoporosis	23	5.3%
Liver Disease (Diagnosis Codes Only)	26	6.0%
Liver Disease (Diagnosis and Procedure Codes)	26	6.0%
Obesity (Diagnosis or Procedure Codes)	125	29.0%
Obesity (Dispensing Code)	*****	*****
Overweight	52	12.1%
Smoking (Diagnosis or Procedure Codes)	39	9.0%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	23	5.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	13	3.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	15.9	12.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.8	4.8

Table 1i. Aggregated Characteristics of Vonoprazan Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vonoprazan Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	23.3	19.2
Mean number of generics dispensed	10.8	7.0
Mean number of unique drug classes dispensed	9.7	6.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1j. Aggregated Characteristics of Tirzepatide Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tirzepatide Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	438,820	N/A
Demographic Characteristics		
Age (years)	57.9	10.9
Age		
0-17 years	133	0.0%
18-24 years	3,518	0.8%
25-40 years	46,406	10.6%
41-64 years	235,674	53.7%
≥ 65 years	153,089	34.9%
Sex		
Female	273,416	62.3%
Male	165,404	37.7%
Race ²		
American Indian or Alaska Native	1,273	0.3%
Asian	5,615	1.3%
Black or African American	38,311	8.7%
Multi-racial	6,541	1.5%
Native Hawaiian or Other Pacific Islander	665	0.2%
Unknown	145,308	33.1%
White	241,107	54.9%
Hispanic origin		
Yes	14,323	3.3%
No	247,404	56.4%
Unknown	177,093	40.4%
Year		
2022	71,864	16.4%
2023	291,519	66.4%
2024	75,437	17.2%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	1,455	0.3%
Alzheimer's Disease and related conditions	3,656	0.8%
Atrial Fibrillation	20,369	4.6%
Diabetes Mellitus	268,182	61.1%
Heart Failure	34,842	7.9%
Hyperlipidemia	192,355	43.8%

Table 1j. Aggregated Characteristics of Tirzepatide Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tirzepatide Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	218,945	49.9%
Depression	96,940	22.1%
Ischemic Heart Disease	66,613	15.2%
Rheumatoid Arthritis/Osteoarthritis	73,656	16.8%
Stroke/TIA	5,583	1.3%
Breast Cancer	7,096	1.6%
Colorectal Cancer	1,607	0.4%
Prostate Cancer	4,384	1.0%
Lung Cancer	957	0.2%
Endometrial Cancer	1,029	0.2%
Acquired Hypothyroidism	56,153	12.8%
Anemia	63,008	14.4%
Asthma	20,588	4.7%
Benign Prostatic Hyperplasia	12,083	2.8%
Chronic Kidney Disease	56,759	12.9%
COPD and Bronchiectasis	22,374	5.1%
Glaucoma	29,979	6.8%
Osteoporosis	6,425	1.5%
Liver Disease (Diagnosis Codes Only)	19,366	4.4%
Liver Disease (Diagnosis and Procedure Codes)	19,366	4.4%
Obesity (Diagnosis or Procedure Codes)	252,315	57.5%
Obesity (Dispensing Code)	17,523	4.0%
Overweight	32,936	7.5%
Smoking (Diagnosis or Procedure Codes)	25,132	5.7%
Smoking (Dispensing Code)	2,585	0.6%
Alcohol Abuse or Dependence	4,724	1.1%
Drug Abuse or Dependence	10,818	2.5%
History of Cardiac Arrest	285	0.1%
History of Coronary Angioplasty or Bypass	17,000	3.9%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	10.7	10.8
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	5.1

Table 1j. Aggregated Characteristics of Tirzepatide Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tirzepatide Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	23.1	18.6
Mean number of generics dispensed	9.8	5.6
Mean number of unique drug classes dispensed	8.8	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1k. Aggregated Characteristics of Tapinarof Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tapinarof Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	14,042	N/A
Demographic Characteristics		
Age (years)	51.9	14.1
Age		
0-17 years	264	1.9%
18-24 years	619	4.4%
25-40 years	2,911	20.7%
41-64 years	6,953	49.5%
≥ 65 years	3,295	23.5%
Sex		
Female	7,303	52.0%
Male	6,739	48.0%
Race ²		
American Indian or Alaska Native	28	0.2%
Asian	654	4.7%
Black or African American	463	3.3%
Multi-racial	344	2.4%
Native Hawaiian or Other Pacific Islander	14	0.1%
Unknown	5,872	41.8%
White	6,667	47.5%
Hispanic origin		
Yes	467	3.3%
No	5,911	42.1%
Unknown	7,664	54.6%
Year		
2022	3,036	21.6%
2023	9,531	67.9%
2024	1,475	10.5%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	26	0.2%
Alzheimer's Disease and related conditions	103	0.7%
Atrial Fibrillation	359	2.6%
Diabetes Mellitus	1,749	12.5%
Heart Failure	416	3.0%
Hyperlipidemia	2,940	20.9%

Table 1k. Aggregated Characteristics of Tapinarof Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tapinarof Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	3,217	22.9%
Depression	2,022	14.4%
Ischemic Heart Disease	1,110	7.9%
Rheumatoid Arthritis/Osteoarthritis	2,008	14.3%
Stroke/TIA	102	0.7%
Breast Cancer	202	1.4%
Colorectal Cancer	44	0.3%
Prostate Cancer	130	0.9%
Lung Cancer	44	0.3%
Endometrial Cancer	16	0.1%
Acquired Hypothyroidism	970	6.9%
Anemia	1,292	9.2%
Asthma	379	2.7%
Benign Prostatic Hyperplasia	314	2.2%
Chronic Kidney Disease	580	4.1%
COPD and Bronchiectasis	386	2.7%
Glaucoma	787	5.6%
Osteoporosis	276	2.0%
Liver Disease (Diagnosis Codes Only)	398	2.8%
Liver Disease (Diagnosis and Procedure Codes)	398	2.8%
Obesity (Diagnosis or Procedure Codes)	2,738	19.5%
Obesity (Dispensing Code)	103	0.7%
Overweight	1,036	7.4%
Smoking (Diagnosis or Procedure Codes)	646	4.6%
Smoking (Dispensing Code)	75	0.5%
Alcohol Abuse or Dependence	237	1.7%
Drug Abuse or Dependence	212	1.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	269	1.9%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	10.0	10.8
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.2	4.6

Table 1k. Aggregated Characteristics of Tapinarof Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tapinarof Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	15.0	15.8
Mean number of generics dispensed	6.8	5.2
Mean number of unique drug classes dispensed	6.2	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1I. Aggregated Characteristics of Vutrisiran Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vutrisiran Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	607	N/A
Demographic Characteristics		
Age (years)	71.7	7.9
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	523	86.2%
Sex		
Female	214	35.3%
Male	393	64.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	226	37.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	70	11.5%
White	297	48.9%
Hispanic origin		
Yes	*****	*****
No	486	80.1%
Unknown	*****	*****
Year		
2022	51	8.4%
2023	535	88.1%
2024	21	3.5%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	25	4.1%
Atrial Fibrillation	176	29.0%
Diabetes Mellitus	138	22.7%
Heart Failure	442	72.8%
Hyperlipidemia	276	45.5%

Table 1I. Aggregated Characteristics of Vutrisiran Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vutrisiran Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	360	59.3%
Depression	100	16.5%
Ischemic Heart Disease	203	33.4%
Rheumatoid Arthritis/Osteoarthritis	138	22.7%
Stroke/TIA	15	2.5%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	36	5.9%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	74	12.2%
Anemia	186	30.6%
Asthma	30	4.9%
Benign Prostatic Hyperplasia	53	8.7%
Chronic Kidney Disease	187	30.8%
COPD and Bronchiectasis	44	7.2%
Glaucoma	99	16.3%
Osteoporosis	28	4.6%
Liver Disease (Diagnosis Codes Only)	40	6.6%
Liver Disease (Diagnosis and Procedure Codes)	40	6.6%
Obesity (Diagnosis or Procedure Codes)	111	18.3%
Obesity (Dispensing Code)	*****	*****
Overweight	59	9.7%
Smoking (Diagnosis or Procedure Codes)	30	4.9%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	13	2.1%
Drug Abuse or Dependence	17	2.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	49	8.1%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	19.9	13.1
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.7	10.4

Table 1I. Aggregated Characteristics of Vutrisiran Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Vutrisiran Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	18.8	13.6
Mean number of generics dispensed	8.5	4.8
Mean number of unique drug classes dispensed	8.1	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1m. Aggregated Characteristics of Deucravacitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Deucravacitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,517	N/A
Demographic Characteristics		
Age (years)	54.5	14.3
Age		
0-17 years	*****	*****
18-24 years	54	3.6%
25-40 years	*****	*****
41-64 years	726	47.9%
≥ 65 years	458	30.2%
Sex		
Female	832	54.8%
Male	685	45.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	70	4.6%
Black or African American	67	4.4%
Multi-racial	23	1.5%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	435	28.7%
White	910	60.0%
Hispanic origin		
Yes	52	3.4%
No	867	57.2%
Unknown	598	39.4%
Year		
2022	137	9.0%
2023	1,187	78.2%
2024	193	12.7%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	13	0.9%
Atrial Fibrillation	50	3.3%
Diabetes Mellitus	287	18.9%
Heart Failure	73	4.8%
Hyperlipidemia	398	26.2%

Table 1m. Aggregated Characteristics of Deucravacitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Deucravacitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	444	29.3%
Depression	293	19.3%
Ischemic Heart Disease	151	10.0%
Rheumatoid Arthritis/Osteoarthritis	310	20.4%
Stroke/TIA	14	0.9%
Breast Cancer	20	1.3%
Colorectal Cancer	*****	*****
Prostate Cancer	14	0.9%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	139	9.2%
Anemia	177	11.7%
Asthma	48	3.2%
Benign Prostatic Hyperplasia	35	2.3%
Chronic Kidney Disease	104	6.9%
COPD and Bronchiectasis	84	5.5%
Glaucoma	91	6.0%
Osteoporosis	34	2.2%
Liver Disease (Diagnosis Codes Only)	47	3.1%
Liver Disease (Diagnosis and Procedure Codes)	47	3.1%
Obesity (Diagnosis or Procedure Codes)	363	23.9%
Obesity (Dispensing Code)	*****	*****
Overweight	112	7.4%
Smoking (Diagnosis or Procedure Codes)	115	7.6%
Smoking (Dispensing Code)	11	0.7%
Alcohol Abuse or Dependence	45	3.0%
Drug Abuse or Dependence	45	3.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	27	1.8%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	10.8	10.0
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.8	5.6

Table 1m. Aggregated Characteristics of Deucravacitinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Deucravacitinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.8	18.5
Mean number of generics dispensed	8.5	5.9
Mean number of unique drug classes dispensed	7.8	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1n. Aggregated Characteristics of Terlipressin Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Terlipressin Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	42	N/A
Demographic Characteristics		
Age (years)	63.0	10.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	24	57.1%
Sex		
Female	22	52.4%
Male	20	47.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	25	59.5%
Hispanic origin		
Yes	*****	*****
No	27	64.3%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	16	38.1%
Heart Failure	12	28.6%
Hyperlipidemia	16	38.1%

Table 1n. Aggregated Characteristics of Terlipressin Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Terlipressin Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	23	54.8%
Depression	16	38.1%
Ischemic Heart Disease	11	26.2%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	*****	*****
Anemia	27	64.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	27	64.3%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	34	81.0%
Liver Disease (Diagnosis and Procedure Codes)	34	81.0%
Obesity (Diagnosis or Procedure Codes)	17	40.5%
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	24	57.1%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	22.7	19.3
Mean number of emergency room encounters	2.2	4.2
Mean number of inpatient hospital encounters	1.6	2.3
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	10.0	14.1

Table 1n. Aggregated Characteristics of Terlipressin Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Terlipressin Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	15.2	13.4
Mean number of generics dispensed	7.2	5.7
Mean number of unique drug classes dispensed	6.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1o. Aggregated Characteristics of Gadopichlenol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Gadopichlenol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	22,748	N/A
Demographic Characteristics		
Age (years)	62.6	13.8
Age		
0-17 years	351	1.5%
18-24 years	327	1.4%
25-40 years	1,880	8.3%
41-64 years	7,429	32.7%
≥ 65 years	12,761	56.1%
Sex		
Female	13,270	58.3%
Male	9,478	41.7%
Race ²		
American Indian or Alaska Native	48	0.2%
Asian	355	1.6%
Black or African American	2,965	13.0%
Multi-racial	368	1.6%
Native Hawaiian or Other Pacific Islander	35	0.2%
Unknown	5,000	22.0%
White	13,977	61.4%
Hispanic origin		
Yes	358	1.6%
No	10,908	48.0%
Unknown	11,482	50.5%
Year		
2022	0	0.0%
2023	13,492	59.3%
2024	9,256	40.7%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	118	0.5%
Alzheimer's Disease and related conditions	633	2.8%
Atrial Fibrillation	1,433	6.3%
Diabetes Mellitus	4,404	19.4%
Heart Failure	1,823	8.0%
Hyperlipidemia	7,934	34.9%

Table 1o. Aggregated Characteristics of Gadopichlenol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Gadopichlenol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	9,795	43.1%
Depression	4,591	20.2%
Ischemic Heart Disease	3,954	17.4%
Rheumatoid Arthritis/Osteoarthritis	4,090	18.0%
Stroke/TIA	849	3.7%
Breast Cancer	1,872	8.2%
Colorectal Cancer	525	2.3%
Prostate Cancer	1,069	4.7%
Lung Cancer	1,049	4.6%
Endometrial Cancer	109	0.5%
Acquired Hypothyroidism	2,589	11.4%
Anemia	4,676	20.6%
Asthma	995	4.4%
Benign Prostatic Hyperplasia	1,613	7.1%
Chronic Kidney Disease	3,150	13.8%
COPD and Bronchiectasis	1,798	7.9%
Glaucoma	2,023	8.9%
Osteoporosis	970	4.3%
Liver Disease (Diagnosis Codes Only)	1,844	8.1%
Liver Disease (Diagnosis and Procedure Codes)	1,845	8.1%
Obesity (Diagnosis or Procedure Codes)	5,107	22.5%
Obesity (Dispensing Code)	126	0.6%
Overweight	2,590	11.4%
Smoking (Diagnosis or Procedure Codes)	2,068	9.1%
Smoking (Dispensing Code)	97	0.4%
Alcohol Abuse or Dependence	688	3.0%
Drug Abuse or Dependence	845	3.7%
History of Cardiac Arrest	24	0.1%
History of Coronary Angioplasty or Bypass	945	4.2%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	15.0	13.1
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.2	6.7

Table 1o. Aggregated Characteristics of Gadopichlenol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Gadopichlenol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	14.9	15.3
Mean number of generics dispensed	7.0	5.8
Mean number of unique drug classes dispensed	6.5	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1p. Aggregated Characteristics of Omidenepag Isopropyl Ophthalmic Solution Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Omidenepag Isopropyl Ophthalmic Solution Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
2024	.	.
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.

Table 1p. Aggregated Characteristics of Omidenepag Isopropyl Ophthalmic Solution Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Omidenepag Isopropyl Ophthalmic Solution Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	.	.
Depression	.	.
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Liver Disease (Diagnosis Codes Only)	.	.
Liver Disease (Diagnosis and Procedure Codes)	.	.
Obesity (Diagnosis or Procedure Codes)	.	.
Obesity (Dispensing Code)	.	.
Overweight	.	.
Smoking (Diagnosis or Procedure Codes)	.	.
Smoking (Dispensing Code)	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.

Table 1p. Aggregated Characteristics of Omidopag Isopropyl Ophthalmic Solution Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Omidopag Isopropyl Ophthalmic Solution Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1q. Aggregated Characteristics of Sodium Phenylbutyrate and Taurursodiol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sodium Phenylbutyrate and Taurursodiol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	2,227	N/A
Demographic Characteristics		
Age (years)	66.5	9.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	682	30.6%
≥ 65 years	1,477	66.3%
Sex		
Female	1,004	45.1%
Male	1,223	54.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	53	2.4%
Black or African American	86	3.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	357	16.0%
White	1,709	76.7%
Hispanic origin		
Yes	58	2.6%
No	1,742	78.2%
Unknown	427	19.2%
Year		
2022	481	21.6%
2023	1,679	75.4%
2024	67	3.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	101	4.5%
Atrial Fibrillation	115	5.2%
Diabetes Mellitus	263	11.8%
Heart Failure	105	4.7%
Hyperlipidemia	699	31.4%

Table 1q. Aggregated Characteristics of Sodium Phenylbutyrate and Taurursodiol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sodium Phenylbutyrate and Taurursodiol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	823	37.0%
Depression	545	24.5%
Ischemic Heart Disease	281	12.6%
Rheumatoid Arthritis/Osteoarthritis	415	18.6%
Stroke/TIA	68	3.1%
Breast Cancer	38	1.7%
Colorectal Cancer	11	0.5%
Prostate Cancer	55	2.5%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	213	9.6%
Anemia	301	13.5%
Asthma	119	5.3%
Benign Prostatic Hyperplasia	141	6.3%
Chronic Kidney Disease	133	6.0%
COPD and Bronchiectasis	128	5.7%
Glaucoma	144	6.5%
Osteoporosis	65	2.9%
Liver Disease (Diagnosis Codes Only)	54	2.4%
Liver Disease (Diagnosis and Procedure Codes)	54	2.4%
Obesity (Diagnosis or Procedure Codes)	232	10.4%
Obesity (Dispensing Code)	*****	*****
Overweight	227	10.2%
Smoking (Diagnosis or Procedure Codes)	103	4.6%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	48	2.2%
Drug Abuse or Dependence	50	2.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	67	3.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	18.0	14.6
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.3	16.6

Table 1q. Aggregated Characteristics of Sodium Phenylbutyrate and Taurursodiol Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sodium Phenylbutyrate and Taurursodiol Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.5	14.2
Mean number of generics dispensed	8.1	4.6
Mean number of unique drug classes dispensed	7.4	4.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1r. Aggregated Characteristics of Futibatinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Futibatinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	82	N/A
Demographic Characteristics		
Age (years)	65.5	9.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	46	56.1%
Sex		
Female	49	59.8%
Male	33	40.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	58	70.7%
Hispanic origin		
Yes	*****	*****
No	62	75.6%
Unknown	*****	*****
Year		
2022	0	0.0%
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	22	26.8%
Heart Failure	*****	*****
Hyperlipidemia	35	42.7%

Table 1r. Aggregated Characteristics of Futibatinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Futibatinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	49	59.8%
Depression	16	19.5%
Ischemic Heart Disease	25	30.5%
Rheumatoid Arthritis/Osteoarthritis	15	18.3%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	16	19.5%
Anemia	42	51.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	16	19.5%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	43	52.4%
Liver Disease (Diagnosis and Procedure Codes)	43	52.4%
Obesity (Diagnosis or Procedure Codes)	25	30.5%
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	32.0	17.0
Mean number of emergency room encounters	1.1	2.0
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.4	14.1

Table 1r. Aggregated Characteristics of Futibatinib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Futibatinib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	24.1	13.7
Mean number of generics dispensed	10.9	5.3
Mean number of unique drug classes dispensed	9.8	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1s. Aggregated Characteristics of Olutasidenib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olutasidenib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	51	N/A
Demographic Characteristics		
Age (years)	74.7	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	21	41.2%
Male	30	58.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	40	78.4%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	11	21.6%
Diabetes Mellitus	11	21.6%
Heart Failure	13	25.5%
Hyperlipidemia	23	45.1%

Table 1s. Aggregated Characteristics of Olutasidenib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olutasidenib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	30	58.8%
Depression	12	23.5%
Ischemic Heart Disease	17	33.3%
Rheumatoid Arthritis/Osteoarthritis	11	21.6%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	12	23.5%
Anemia	45	88.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	13	25.5%
Chronic Kidney Disease	15	29.4%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	11	21.6%
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	47.8	27.5
Mean number of emergency room encounters	0.6	0.8
Mean number of inpatient hospital encounters	1.1	1.4
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	19.5	24.4

Table 1s. Aggregated Characteristics of Olutasidenib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olutasidenib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	28.1	15.3
Mean number of generics dispensed	12.1	5.5
Mean number of unique drug classes dispensed	11.2	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1t. Aggregated Characteristics of Adagrasib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Adagrasib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	351	N/A
Demographic Characteristics		
Age (years)	69.7	8.8
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	255	72.6%
Sex		
Female	215	61.3%
Male	136	38.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	47	13.4%
White	261	74.4%
Hispanic origin		
Yes	*****	*****
No	273	77.8%
Unknown	*****	*****
Year		
2022	*****	*****
2023	312	88.9%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	13	3.7%
Atrial Fibrillation	56	16.0%
Diabetes Mellitus	79	22.5%
Heart Failure	61	17.4%
Hyperlipidemia	163	46.4%

Table 1t. Aggregated Characteristics of Adagrasib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Adagrasib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	197	56.1%
Depression	94	26.8%
Ischemic Heart Disease	124	35.3%
Rheumatoid Arthritis/Osteoarthritis	68	19.4%
Stroke/TIA	29	8.3%
Breast Cancer	25	7.1%
Colorectal Cancer	46	13.1%
Prostate Cancer	11	3.1%
Lung Cancer	300	85.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	78	22.2%
Anemia	186	53.0%
Asthma	21	6.0%
Benign Prostatic Hyperplasia	30	8.5%
Chronic Kidney Disease	87	24.8%
COPD and Bronchiectasis	152	43.3%
Glaucoma	28	8.0%
Osteoporosis	23	6.6%
Liver Disease (Diagnosis Codes Only)	45	12.8%
Liver Disease (Diagnosis and Procedure Codes)	45	12.8%
Obesity (Diagnosis or Procedure Codes)	54	15.4%
Obesity (Dispensing Code)	0	0.0%
Overweight	35	10.0%
Smoking (Diagnosis or Procedure Codes)	95	27.1%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	14	4.0%
Drug Abuse or Dependence	22	6.3%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	28	8.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	30.0	16.5
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.3	12.5

Table 1t. Aggregated Characteristics of Adagrasib Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Adagrasib Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	29.9	19.3
Mean number of generics dispensed	13.0	6.5
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1u. Aggregated Characteristics of Lenacapavir Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lenacapavir Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	193	N/A
Demographic Characteristics		
Age (years)	56.6	12.3
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	115	59.6%
≥ 65 years	51	26.4%
Sex		
Female	43	22.3%
Male	150	77.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	83	43.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	26	13.5%
White	80	41.5%
Hispanic origin		
Yes	18	9.3%
No	152	78.8%
Unknown	23	11.9%
Year		
2022	0	0.0%
2023	182	94.3%
2024	11	5.7%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	33	17.1%
Heart Failure	13	6.7%
Hyperlipidemia	58	30.1%

Table 1u. Aggregated Characteristics of Lenacapavir Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lenacapavir Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	72	37.3%
Depression	60	31.1%
Ischemic Heart Disease	28	14.5%
Rheumatoid Arthritis/Osteoarthritis	23	11.9%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	13	6.7%
Anemia	46	23.8%
Asthma	13	6.7%
Benign Prostatic Hyperplasia	19	9.8%
Chronic Kidney Disease	43	22.3%
COPD and Bronchiectasis	11	5.7%
Glaucoma	12	6.2%
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	13	6.7%
Liver Disease (Diagnosis and Procedure Codes)	13	6.7%
Obesity (Diagnosis or Procedure Codes)	27	14.0%
Obesity (Dispensing Code)	0	0.0%
Overweight	19	9.8%
Smoking (Diagnosis or Procedure Codes)	30	15.5%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	28	14.5%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	11	5.7%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	15.5	20.7
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.0	13.4

Table 1u. Aggregated Characteristics of Lenacapavir Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Lenacapavir Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	40.0	28.7
Mean number of generics dispensed	11.9	7.2
Mean number of unique drug classes dispensed	9.7	6.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1v. Aggregated Characteristics of Hyperpolarized 129-Xe Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Hyperpolarized 129-Xe Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	61	N/A
Demographic Characteristics		
Age (years)	73.8	12.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	36	59.0%
Male	25	41.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	0	0.0%
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	11	18.0%
Diabetes Mellitus	28	45.9%
Heart Failure	28	45.9%
Hyperlipidemia	31	50.8%

Table 1v. Aggregated Characteristics of Hyperpolarized 129-Xe Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Hyperpolarized 129-Xe Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	42	68.9%
Depression	20	32.8%
Ischemic Heart Disease	27	44.3%
Rheumatoid Arthritis/Osteoarthritis	19	31.1%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	19	31.1%
Anemia	24	39.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	23	37.7%
COPD and Bronchiectasis	24	39.3%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	26	42.6%
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	21.1	22.3
Mean number of emergency room encounters	1.2	2.9
Mean number of inpatient hospital encounters	0.7	2.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.9	18.6

Table 1v. Aggregated Characteristics of Hyperpolarized 129-Xe Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Hyperpolarized 129-Xe Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	26.9	17.7
Mean number of generics dispensed	11.2	5.9
Mean number of unique drug classes dispensed	10.4	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1w. Aggregated Characteristics of Tebentafusp-tebn Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tebentafusp-tebn Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	196	N/A
Demographic Characteristics		
Age (years)	68.4	8.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	151	77.0%
Sex		
Female	103	52.6%
Male	93	47.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	168	85.7%
Hispanic origin		
Yes	*****	*****
No	155	79.1%
Unknown	*****	*****
Year		
2022	95	48.5%
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	40	20.4%
Heart Failure	*****	*****
Hyperlipidemia	89	45.4%

Table 1w. Aggregated Characteristics of Tebentafusp-tebn Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tebentafusp-tebn Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	99	50.5%
Depression	51	26.0%
Ischemic Heart Disease	34	17.3%
Rheumatoid Arthritis/Osteoarthritis	35	17.9%
Stroke/TIA	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	11	5.6%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	46	23.5%
Anemia	36	18.4%
Asthma	16	8.2%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	32	16.3%
COPD and Bronchiectasis	14	7.1%
Glaucoma	24	12.2%
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	97	49.5%
Liver Disease (Diagnosis and Procedure Codes)	97	49.5%
Obesity (Diagnosis or Procedure Codes)	35	17.9%
Obesity (Dispensing Code)	*****	*****
Overweight	27	13.8%
Smoking (Diagnosis or Procedure Codes)	16	8.2%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	25.6	12.0
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	6.4	5.9

Table 1w. Aggregated Characteristics of Tebentafusp-tebn Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tebentafusp-tebn Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	16.1	14.7
Mean number of generics dispensed	8.2	5.5
Mean number of unique drug classes dispensed	7.7	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1x. Aggregated Characteristics of Faricimab-svoa Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Faricimab-svoa Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	114,321	N/A
Demographic Characteristics		
Age (years)	78.7	9.1
Age		
0-17 years	*****	*****
18-24 years	11	0.0%
25-40 years	294	0.3%
41-64 years	*****	*****
≥ 65 years	108,039	94.5%
Sex		
Female	67,016	58.6%
Male	47,305	41.4%
Race ²		
American Indian or Alaska Native	388	0.3%
Asian	1,748	1.5%
Black or African American	3,248	2.8%
Multi-racial	151	0.1%
Native Hawaiian or Other Pacific Islander	124	0.1%
Unknown	7,682	6.7%
White	100,980	88.3%
Hispanic origin		
Yes	1,365	1.2%
No	98,372	86.0%
Unknown	14,584	12.8%
Year		
2022	33,814	29.6%
2023	75,936	66.4%
2024	4,571	4.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	784	0.7%
Alzheimer's Disease and related conditions	5,217	4.6%
Atrial Fibrillation	14,952	13.1%
Diabetes Mellitus	39,649	34.7%
Heart Failure	15,815	13.8%
Hyperlipidemia	49,824	43.6%

Table 1x. Aggregated Characteristics of Faricimab-svoa Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Faricimab-svoa Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	64,326	56.3%
Depression	15,816	13.8%
Ischemic Heart Disease	29,005	25.4%
Rheumatoid Arthritis/Osteoarthritis	20,272	17.7%
Stroke/TIA	3,296	2.9%
Breast Cancer	3,427	3.0%
Colorectal Cancer	1,080	0.9%
Prostate Cancer	3,604	3.2%
Lung Cancer	1,167	1.0%
Endometrial Cancer	331	0.3%
Acquired Hypothyroidism	16,180	14.2%
Anemia	23,531	20.6%
Asthma	3,542	3.1%
Benign Prostatic Hyperplasia	6,501	5.7%
Chronic Kidney Disease	22,633	19.8%
COPD and Bronchiectasis	9,371	8.2%
Glaucoma	24,264	21.2%
Osteoporosis	7,248	6.3%
Liver Disease (Diagnosis Codes Only)	2,271	2.0%
Liver Disease (Diagnosis and Procedure Codes)	2,271	2.0%
Obesity (Diagnosis or Procedure Codes)	20,898	18.3%
Obesity (Dispensing Code)	619	0.5%
Overweight	10,456	9.1%
Smoking (Diagnosis or Procedure Codes)	4,990	4.4%
Smoking (Dispensing Code)	156	0.1%
Alcohol Abuse or Dependence	1,169	1.0%
Drug Abuse or Dependence	1,565	1.4%
History of Cardiac Arrest	109	0.1%
History of Coronary Angioplasty or Bypass	8,188	7.2%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	16.0	14.9
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	6.9

Table 1x. Aggregated Characteristics of Faricimab-svoa Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Faricimab-svoa Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	16.1	14.4
Mean number of generics dispensed	7.4	4.8
Mean number of unique drug classes dispensed	7.0	4.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1y. Aggregated Characteristics of Sutimlimab-jome Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sutimlimab-jome Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	170	N/A
Demographic Characteristics		
Age (years)	73.6	11.2
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	146	85.9%
Sex		
Female	113	66.5%
Male	57	33.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	17	10.0%
White	136	80.0%
Hispanic origin		
Yes	*****	*****
No	134	78.8%
Unknown	*****	*****
Year		
2022	*****	*****
2023	99	58.2%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	22	12.9%
Diabetes Mellitus	38	22.4%
Heart Failure	30	17.6%
Hyperlipidemia	62	36.5%

Table 1y. Aggregated Characteristics of Sutimlimab-jome Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sutimlimab-jome Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	93	54.7%
Depression	37	21.8%
Ischemic Heart Disease	53	31.2%
Rheumatoid Arthritis/Osteoarthritis	44	25.9%
Stroke/TIA	*****	*****
Breast Cancer	12	7.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	32	18.8%
Anemia	168	98.8%
Asthma	11	6.5%
Benign Prostatic Hyperplasia	18	10.6%
Chronic Kidney Disease	60	35.3%
COPD and Bronchiectasis	21	12.4%
Glaucoma	24	14.1%
Osteoporosis	17	10.0%
Liver Disease (Diagnosis Codes Only)	16	9.4%
Liver Disease (Diagnosis and Procedure Codes)	16	9.4%
Obesity (Diagnosis or Procedure Codes)	29	17.1%
Obesity (Dispensing Code)	*****	*****
Overweight	19	11.2%
Smoking (Diagnosis or Procedure Codes)	17	10.0%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	11	6.5%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	28.2	17.0
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.8	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	11.4	15.7

Table 1y. Aggregated Characteristics of Sutimlimab-jome Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Sutimlimab-jome Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	17.6	13.3
Mean number of generics dispensed	8.6	5.2
Mean number of unique drug classes dispensed	8.0	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1z. Aggregated Characteristics of Nivolumab and Relatlimab-rmbw Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Nivolumab and Relatlimab-rmbw Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	2,545	N/A
Demographic Characteristics		
Age (years)	72.8	10.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	45	1.8%
41-64 years	*****	*****
≥ 65 years	2,113	83.0%
Sex		
Female	958	37.6%
Male	1,587	62.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	30	1.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	308	12.1%
White	2,182	85.7%
Hispanic origin		
Yes	25	1.0%
No	1,995	78.4%
Unknown	525	20.6%
Year		
2022	775	30.5%
2023	1,657	65.1%
2024	113	4.4%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	34	1.3%
Alzheimer's Disease and related conditions	104	4.1%
Atrial Fibrillation	396	15.6%
Diabetes Mellitus	592	23.3%
Heart Failure	357	14.0%
Hyperlipidemia	1,171	46.0%

Table 1z. Aggregated Characteristics of Nivolumab and Relatlimab-rmbw Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Nivolumab and Relatlimab-rmbw Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	1,495	58.7%
Depression	475	18.7%
Ischemic Heart Disease	758	29.8%
Rheumatoid Arthritis/Osteoarthritis	466	18.3%
Stroke/TIA	176	6.9%
Breast Cancer	100	3.9%
Colorectal Cancer	94	3.7%
Prostate Cancer	154	6.1%
Lung Cancer	189	7.4%
Endometrial Cancer	18	0.7%
Acquired Hypothyroidism	581	22.8%
Anemia	807	31.7%
Asthma	106	4.2%
Benign Prostatic Hyperplasia	305	12.0%
Chronic Kidney Disease	545	21.4%
COPD and Bronchiectasis	239	9.4%
Glaucoma	265	10.4%
Osteoporosis	129	5.1%
Liver Disease (Diagnosis Codes Only)	322	12.7%
Liver Disease (Diagnosis and Procedure Codes)	322	12.7%
Obesity (Diagnosis or Procedure Codes)	497	19.5%
Obesity (Dispensing Code)	11	0.4%
Overweight	320	12.6%
Smoking (Diagnosis or Procedure Codes)	169	6.6%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	60	2.4%
Drug Abuse or Dependence	67	2.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	244	9.6%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	24.7	13.7
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	7.2	9.2

Table 1z. Aggregated Characteristics of Nivolumab and Relatlimab-rmbw Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Nivolumab and Relatlimab-rmbw Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	17.7	14.1
Mean number of generics dispensed	8.5	5.4
Mean number of unique drug classes dispensed	7.9	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1aa. Aggregated Characteristics of Olipudase Alfa-rpcp Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olipudase Alfa-rpcp Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	12	N/A
Demographic Characteristics		
Age (years)	33.6	20.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****

Table 1aa. Aggregated Characteristics of Olipudase Alfa-rpcp Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olipudase Alfa-rpcp Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Code)	0	0.0%
Overweight	0	0.0%
Smoking (Diagnosis or Procedure Codes)	0	0.0%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	27.1	23.5
Mean number of emergency room encounters	1.0	2.1
Mean number of inpatient hospital encounters	0.2	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	12.2	16.5

Table 1aa. Aggregated Characteristics of Olipudase Alfa-rpcp Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Olipudase Alfa-rpcp Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	9.9	11.4
Mean number of generics dispensed	4.2	4.5
Mean number of unique drug classes dispensed	4.0	4.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ab. Aggregated Characteristics of Spesolimab-sbzo Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Spesolimab-sbzo Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	55	N/A
Demographic Characteristics		
Age (years)	62.0	11.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	30	54.5%
Sex		
Female	36	65.5%
Male	19	34.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	40	72.7%
Hispanic origin		
Yes	*****	*****
No	38	69.1%
Unknown	*****	*****
Year		
2022	*****	*****
2023	43	78.2%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	16	29.1%

Table 1ab. Aggregated Characteristics of Spesolimab-sbzo Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Spesolimab-sbzo Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	21	38.2%
Depression	16	29.1%
Ischemic Heart Disease	12	21.8%
Rheumatoid Arthritis/Osteoarthritis	17	30.9%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	11	20.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	15	27.3%
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	14.2	10.2
Mean number of emergency room encounters	0.8	1.5
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.4	8.3

Table 1ab. Aggregated Characteristics of Spesolimab-sbzo Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Spesolimab-sbzo Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	22.6	16.9
Mean number of generics dispensed	10.4	7.1
Mean number of unique drug classes dispensed	9.5	6.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ac. Aggregated Characteristics of Daxibotulinumtoxina-lanm Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*****Data are not presented in this table due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Table 1ad. Aggregated Characteristics of Eflapegrastim-xnst Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Eflapegrastim-xnst Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	3,303	N/A
Demographic Characteristics		
Age (years)	73.2	7.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	191	5.8%
≥ 65 years	3,095	93.7%
Sex		
Female	1,870	56.6%
Male	1,433	43.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	36	1.1%
Black or African American	190	5.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	224	6.8%
White	2,838	85.9%
Hispanic origin		
Yes	67	2.0%
No	3,022	91.5%
Unknown	214	6.5%
Year		
2022	13	0.4%
2023	3,237	98.0%
2024	53	1.6%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	38	1.2%
Alzheimer's Disease and related conditions	100	3.0%
Atrial Fibrillation	413	12.5%
Diabetes Mellitus	846	25.6%
Heart Failure	435	13.2%
Hyperlipidemia	1,855	56.2%

Table 1ad. Aggregated Characteristics of Eflapegrastim-xnst Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Eflapegrastim-xnst Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	2,171	65.7%
Depression	647	19.6%
Ischemic Heart Disease	980	29.7%
Rheumatoid Arthritis/Osteoarthritis	665	20.1%
Stroke/TIA	136	4.1%
Breast Cancer	763	23.1%
Colorectal Cancer	373	11.3%
Prostate Cancer	383	11.6%
Lung Cancer	652	19.7%
Endometrial Cancer	128	3.9%
Acquired Hypothyroidism	641	19.4%
Anemia	1,868	56.6%
Asthma	171	5.2%
Benign Prostatic Hyperplasia	353	10.7%
Chronic Kidney Disease	808	24.5%
COPD and Bronchiectasis	590	17.9%
Glaucoma	339	10.3%
Osteoporosis	228	6.9%
Liver Disease (Diagnosis Codes Only)	467	14.1%
Liver Disease (Diagnosis and Procedure Codes)	467	14.1%
Obesity (Diagnosis or Procedure Codes)	813	24.6%
Obesity (Dispensing Code)	*****	*****
Overweight	490	14.8%
Smoking (Diagnosis or Procedure Codes)	455	13.8%
Smoking (Dispensing Code)	13	0.4%
Alcohol Abuse or Dependence	72	2.2%
Drug Abuse or Dependence	89	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	304	9.2%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	30.1	13.9
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	9.2	9.5

Table 1ad. Aggregated Characteristics of Eflapegrastim-xnst Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Patient Characteristics	Eflapegrastim-xnst Users	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.3	12.8
Mean number of generics dispensed	10.6	5.2
Mean number of unique drug classes dispensed	9.8	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ae. Aggregated Characteristics of Tremelimumab-actl Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tremelimumab-actl Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	972	N/A
Demographic Characteristics		
Age (years)	71.3	8.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	818	84.2%
Sex		
Female	210	21.6%
Male	762	78.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	26	2.7%
Black or African American	113	11.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	124	12.8%
White	697	71.7%
Hispanic origin		
Yes	26	2.7%
No	704	72.4%
Unknown	242	24.9%
Year		
2022	*****	*****
2023	848	87.2%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	14	1.4%
Alzheimer's Disease and related conditions	41	4.2%
Atrial Fibrillation	158	16.3%
Diabetes Mellitus	412	42.4%
Heart Failure	189	19.4%
Hyperlipidemia	499	51.3%

Table 1ae. Aggregated Characteristics of Tremelimumab-actl Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tremelimumab-actl Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	743	76.4%
Depression	147	15.1%
Ischemic Heart Disease	377	38.8%
Rheumatoid Arthritis/Osteoarthritis	184	18.9%
Stroke/TIA	48	4.9%
Breast Cancer	22	2.3%
Colorectal Cancer	32	3.3%
Prostate Cancer	60	6.2%
Lung Cancer	162	16.7%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	165	17.0%
Anemia	524	53.9%
Asthma	51	5.2%
Benign Prostatic Hyperplasia	151	15.5%
Chronic Kidney Disease	286	29.4%
COPD and Bronchiectasis	230	23.7%
Glaucoma	75	7.7%
Osteoporosis	29	3.0%
Liver Disease (Diagnosis Codes Only)	764	78.6%
Liver Disease (Diagnosis and Procedure Codes)	764	78.6%
Obesity (Diagnosis or Procedure Codes)	284	29.2%
Obesity (Dispensing Code)	*****	*****
Overweight	152	15.6%
Smoking (Diagnosis or Procedure Codes)	251	25.8%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	238	24.5%
Drug Abuse or Dependence	66	6.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	127	13.1%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	23.3	13.5
Mean number of emergency room encounters	1.1	1.8
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	7.4	8.9

Table 1ae. Aggregated Characteristics of Tremelimumab-actl Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Tremelimumab-actl Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	21.4	16.5
Mean number of generics dispensed	10.3	6.0
Mean number of unique drug classes dispensed	9.4	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1af. Aggregated Characteristics of Teclistamab-cqyv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teclistamab-cqyv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,233	N/A
Demographic Characteristics		
Age (years)	71.5	8.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,013	82.2%
Sex		
Female	589	47.8%
Male	644	52.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	174	14.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	134	10.9%
White	884	71.7%
Hispanic origin		
Yes	40	3.2%
No	986	80.0%
Unknown	207	16.8%
Year		
2022	62	5.0%
2023	1,121	90.9%
2024	50	4.1%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	15	1.2%
Alzheimer's Disease and related conditions	56	4.5%
Atrial Fibrillation	228	18.5%
Diabetes Mellitus	291	23.6%
Heart Failure	329	26.7%
Hyperlipidemia	481	39.0%

Table 1af. Aggregated Characteristics of Teclistamab-cqyv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teclistamab-cqyv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	769	62.4%
Depression	282	22.9%
Ischemic Heart Disease	304	24.7%
Rheumatoid Arthritis/Osteoarthritis	281	22.8%
Stroke/TIA	52	4.2%
Breast Cancer	50	4.1%
Colorectal Cancer	18	1.5%
Prostate Cancer	49	4.0%
Lung Cancer	15	1.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	204	16.5%
Anemia	951	77.1%
Asthma	93	7.5%
Benign Prostatic Hyperplasia	146	11.8%
Chronic Kidney Disease	554	44.9%
COPD and Bronchiectasis	136	11.0%
Glaucoma	128	10.4%
Osteoporosis	78	6.3%
Liver Disease (Diagnosis Codes Only)	85	6.9%
Liver Disease (Diagnosis and Procedure Codes)	85	6.9%
Obesity (Diagnosis or Procedure Codes)	214	17.4%
Obesity (Dispensing Code)	*****	*****
Overweight	154	12.5%
Smoking (Diagnosis or Procedure Codes)	79	6.4%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	22	1.8%
Drug Abuse or Dependence	58	4.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	83	6.7%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	36.4	18.4
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.9	1.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	12.6	13.2

Table 1af. Aggregated Characteristics of Teclistamab-cqyv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teclistamab-cqyv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	27.7	16.4
Mean number of generics dispensed	12.6	6.2
Mean number of unique drug classes dispensed	11.6	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ag. Aggregated Characteristics of Mirvetuximab Soravtansine-gynx Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mirvetuximab Soravtansine-gynx Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	280	N/A
Demographic Characteristics		
Age (years)	64.3	10.8
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	138	49.3%
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	86	30.7%
White	168	60.0%
Hispanic origin		
Yes	12	4.3%
No	97	34.6%
Unknown	171	61.1%
Year		
2022	*****	*****
2023	224	80.0%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	11	3.9%
Diabetes Mellitus	40	14.3%
Heart Failure	15	5.4%
Hyperlipidemia	72	25.7%

Table 1ag. Aggregated Characteristics of Mirvetuximab Soravtansine-gynx Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mirvetuximab Soravtansine-gynx Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	126	45.0%
Depression	51	18.2%
Ischemic Heart Disease	37	13.2%
Rheumatoid Arthritis/Osteoarthritis	27	9.6%
Stroke/TIA	*****	*****
Breast Cancer	29	10.4%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	19	6.8%
Acquired Hypothyroidism	33	11.8%
Anemia	136	48.6%
Asthma	13	4.6%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	62	22.1%
COPD and Bronchiectasis	12	4.3%
Glaucoma	42	15.0%
Osteoporosis	22	7.9%
Liver Disease (Diagnosis Codes Only)	33	11.8%
Liver Disease (Diagnosis and Procedure Codes)	33	11.8%
Obesity (Diagnosis or Procedure Codes)	47	16.8%
Obesity (Dispensing Code)	0	0.0%
Overweight	13	4.6%
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	29.0	12.7
Mean number of emergency room encounters	0.7	1.5
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	6.7	16.3

Table 1ag. Aggregated Characteristics of Mirvetuximab Soravtansine-gynx Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mirvetuximab Soravtansine-gynx Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	17.8	14.5
Mean number of generics dispensed	8.9	6.4
Mean number of unique drug classes dispensed	8.3	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ah. Aggregated Characteristics of Teplizumab-mzwv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teplizumab-mzwv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	42	N/A
Demographic Characteristics		
Age (years)	26.7	13.3
Age		
0-17 years	16	38.1%
18-24 years	*****	*****
25-40 years	13	31.0%
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	19	45.2%
Male	23	54.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	22	52.4%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	27	64.3%
Year		
2022	0	0.0%
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	26	61.9%
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****

Table 1ah. Aggregated Characteristics of Teplizumab-mzwv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teplizumab-mzwv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	0	0.0%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	0	0.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	8.9	6.7
Mean number of emergency room encounters	0.2	0.4
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.5	4.2

Table 1ah. Aggregated Characteristics of Teplizumab-mzwv Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Teplizumab-mzwv Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	9.3	8.5
Mean number of generics dispensed	4.4	3.2
Mean number of unique drug classes dispensed	3.8	2.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ai. Aggregated Characteristics of Mosunetuzumab-axgb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mosunetuzumab-axgb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	63	N/A
Demographic Characteristics		
Age (years)	70.5	10.7
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	46	73.0%
Sex		
Female	28	44.4%
Male	35	55.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	46	73.0%
Hispanic origin		
Yes	*****	*****
No	37	58.7%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	13	20.6%
Hyperlipidemia	18	28.6%

Table 1ai. Aggregated Characteristics of Mosunetuzumab-axgb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mosunetuzumab-axgb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	25	39.7%
Depression	19	30.2%
Ischemic Heart Disease	14	22.2%
Rheumatoid Arthritis/Osteoarthritis	11	17.5%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	*****	*****
Anemia	26	41.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	21	33.3%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Code)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	*****	*****
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	24.3	15.1
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.4	7.5

Table 1ai. Aggregated Characteristics of Mosunetuzumab-axgb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Mosunetuzumab-axgb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	19.0	16.2
Mean number of generics dispensed	9.6	6.5
Mean number of unique drug classes dispensed	8.8	5.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1aj. Aggregated Characteristics of Anacaulase-bcdb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Anacaulase-bcdb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	127	N/A
Demographic Characteristics		
Age (years)	73.2	12.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	103	81.1%
Sex		
Female	66	52.0%
Male	61	48.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	21	16.5%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	12	9.4%
White	94	74.0%
Hispanic origin		
Yes	*****	*****
No	104	81.9%
Unknown	*****	*****
Year		
2022	*****	*****
2023	66	52.0%
2024	*****	*****
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	34	26.8%
Atrial Fibrillation	37	29.1%
Diabetes Mellitus	62	48.8%
Heart Failure	48	37.8%
Hyperlipidemia	83	65.4%

Table 1aj. Aggregated Characteristics of Anacaulase-bcdb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Anacaulase-bcdb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	103	81.1%
Depression	54	42.5%
Ischemic Heart Disease	57	44.9%
Rheumatoid Arthritis/Osteoarthritis	51	40.2%
Stroke/TIA	21	16.5%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	27	21.3%
Anemia	78	61.4%
Asthma	13	10.2%
Benign Prostatic Hyperplasia	17	13.4%
Chronic Kidney Disease	64	50.4%
COPD and Bronchiectasis	28	22.0%
Glaucoma	15	11.8%
Osteoporosis	*****	*****
Liver Disease (Diagnosis Codes Only)	17	13.4%
Liver Disease (Diagnosis and Procedure Codes)	17	13.4%
Obesity (Diagnosis or Procedure Codes)	45	35.4%
Obesity (Dispensing Code)	*****	*****
Overweight	11	8.7%
Smoking (Diagnosis or Procedure Codes)	18	14.2%
Smoking (Dispensing Code)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	16	12.6%
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	23.7	30.3
Mean number of emergency room encounters	1.3	1.9
Mean number of inpatient hospital encounters	1.4	1.8
Mean number of non-acute institutional encounters	0.7	1.1
Mean number of other ambulatory encounters	28.7	32.4

Table 1aj. Aggregated Characteristics of Anacaulase-bcdb Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Anacaulase-bcdb Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	25.7	21.6
Mean number of generics dispensed	10.9	6.8
Mean number of unique drug classes dispensed	10.1	6.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 1ak. Aggregated Characteristics of Ublituximab-xiiy Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ublituximab-xiiy Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	482	N/A
Demographic Characteristics		
Age (years)	48.5	11.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	142	29.5%
41-64 years	271	56.2%
≥ 65 years	*****	*****
Sex		
Female	358	74.3%
Male	124	25.7%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	42	8.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	149	30.9%
White	277	57.5%
Hispanic origin		
Yes	16	3.3%
No	242	50.2%
Unknown	224	46.5%
Year		
2022	0	0.0%
2023	381	79.0%
2024	101	21.0%
Health Characteristics [-183, -1]		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	31	6.4%
Heart Failure	*****	*****
Hyperlipidemia	73	15.1%

Table 1ak. Aggregated Characteristics of Ublituximab-xiiy Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ublituximab-xiiy Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hypertension	85	17.6%
Depression	141	29.3%
Ischemic Heart Disease	13	2.7%
Rheumatoid Arthritis/Osteoarthritis	61	12.7%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	26	5.4%
Anemia	55	11.4%
Asthma	18	3.7%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	12	2.5%
Glaucoma	23	4.8%
Osteoporosis	12	2.5%
Liver Disease (Diagnosis Codes Only)	*****	*****
Liver Disease (Diagnosis and Procedure Codes)	*****	*****
Obesity (Diagnosis or Procedure Codes)	108	22.4%
Obesity (Dispensing Code)	*****	*****
Overweight	41	8.5%
Smoking (Diagnosis or Procedure Codes)	43	8.9%
Smoking (Dispensing Code)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	12	2.5%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics [-183, -1]		
Mean number of ambulatory encounters	14.5	12.4
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.9	4.3

Table 1ak. Aggregated Characteristics of Ublituximab-xiiy Users in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Ublituximab-xiiy Users		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	14.1	14.7
Mean number of generics dispensed	6.2	5.3
Mean number of unique drug classes dispensed	5.8	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
<i>Daridorexant</i>	31,814	30,915	97.2%	215	0.7%	684	2.1%	0	0.0%
<i>Abrocitinib</i>	2,951	2,888	97.9%	15	0.5%	48	1.6%	0	0.0%
<i>Mitapivat</i>	189	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pacritinib</i>	4,313	4,298	99.7%	15	0.3%	0	0.0%	0	0.0%
<i>Ganaxolone</i>	198	198	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lutetium</i>	13,811	13,811	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Vipivotide</i>									
<i>Tetraxetan</i>									
<i>Oteseconazole</i>	211	61	28.9%	*****	*****	104	49.3%	*****	*****
<i>Mavacamten</i>	11,061	10,358	93.6%	*****	*****	*****	*****	0	0.0%
<i>Vonoprazan</i>	644	610	94.7%	21	3.3%	13	2.0%	0	0.0%
<i>Tirzepatide</i>	2,176,027	1,997,341	91.8%	53,690	2.5%	122,858	5.6%	2,138	0.1%
<i>Tapinarof</i>	27,773	26,739	96.3%	584	2.1%	436	1.6%	14	0.1%
<i>Vutrisiran</i>	1,875	1,558	83.1%	35	1.9%	282	15.0%	0	0.0%
<i>Deucravacitinib</i>	6,072	5,903	97.2%	29	0.5%	140	2.3%	0	0.0%
<i>Terlipressin</i>	45	45	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gadopicolenol</i>	24,310	24,310	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Omidenepag</i>	0	.	.	.	.	.	.	.	.
<i>Isopropyl Ophthalmic Solution</i>									
<i>Sodium Phenylbutyrate and Taurursodiol</i>	10,702	10,581	98.9%	71	0.7%	50	0.5%	0	0.0%
<i>Futibatinib</i>	278	278	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Olutasidenib</i>	193	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Adagrasib</i>	938	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lenacapavir</i>	316	130	41.1%	29	9.2%	32	10.1%	125	39.6%
<i>Hyperpolarized 129-Xe</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
<i>Tebentafusp-tebn</i>	5,618	5,618	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	569,956	569,907	100.0%	*****	*****	*****	*****	*****	*****
<i>Sutimlimab-jome</i>	2,578	2,578	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Nivolumab and Relatlimab-rmbw</i>	12,522	12,522	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Olipudase Alfa-rpcp</i>	143	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Spesolimab-sbzo</i>	95	95	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumt oxina-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	9,684	9,684	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tremelimumab-actl</i>	1,243	1,243	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Teclistamab-cqyv</i>	6,348	6,348	100.0%	0	0.0%	0	0.0%	0	0.0%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
<i>Mirvetuximab</i>	1,250	1,250	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Soravtansine-gynx</i>									
<i>Teplizumab-mzwv</i>	287	287	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mosunetuzuma b-axgb</i>	286	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Anacaulase-bcdb</i>	129	129	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ublituximab-</i>	924	*****	*****	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Daridorexant</i>	31,814	1	30	30	30	90	29.2	10.8
<i>Abrocitinib</i>	2,951	1	30	30	30	90	29.5	9.3
<i>Mitapivat</i>	189	3	28	28	28	56	27.0	4.9
<i>Pacritinib</i>	4,313	1	30	30	30	60	28.8	4.8
<i>Ganaxolone</i>	198	3	24	27	29	30	26.0	4.7
<i>Lutetium Vipivotide</i>	13,811	1	1	1	1	1	1.0	0.0
<i>Oteseconazole</i>	211	2	30	63	84	91	56.1	29.3
<i>Mavacamten</i>	11,061	1	30	30	30	70	28.1	6.7
<i>Vonoprazan</i>	644	1	13	26	30	90	22.5	13.9
<i>Tirzepatide</i>	2,176,027	1	28	28	28	351	30.1	14.9
<i>Tapinarof</i>	27,773	1	30	30	30	120	29.4	10.2
<i>Vutrisiran</i>	1,875	1	1	1	1	90	15.2	31.4
<i>Deucravacitinib</i>	6,072	1	30	30	30	90	29.7	10.8
<i>Terlipressin</i>	45	1	1	1	1	1	1.0	0.0
<i>Gadopiclenol</i>	24,310	1	1	1	1	1	1.0	0.0
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	10,702	1	28	28	28	84	27.2	6.3
<i>Futibatinib</i>	278	1	28	28	28	28	25.2	6.2
<i>Olutasidenib</i>	193	2	30	30	30	90	28.7	6.6
<i>Adagrasib</i>	938	1	30	30	30	45	27.7	6.2
<i>Lenacapavir</i>	316	1	2	56	142	210	75.2	69.7
<i>Hyperpolarized 129-Xe</i>	61	1	1	1	1	1	1.0	0.0
<i>Tebentafusp-tebn</i>	5,618	1	1	1	1	7	1.0	0.1

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Faricimab-svoa</i>	569,956	1	1	1	1	112	1.1	1.2
<i>Sutimlimab-jome</i>	2,578	1	1	1	1	14	1.2	1.7
<i>Nivolumab and Relatlimab-</i>	12,522	1	1	1	1	28	1.2	2.3
<i>Olipudase Alfa-rpcp</i>	143	1	1	1	1	84	7.5	17.1
<i>Spesolimab-sbzo</i>	95	1	1	1	1	7	1.8	2.1
<i>Daxibotulinumtoxina-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	9,684	1	1	1	1	30	1.2	2.1
<i>Tremelimumab-actl</i>	1,243	1	1	1	1	30	1.4	3.3
<i>Teclistamab-cqyv</i>	6,348	1	1	1	1	28	1.0	0.5
<i>Mirvetuximab</i>	1,250	1	1	1	1	1	1.0	0.0
<i>Teplizumab-mzwv</i>	287	1	1	1	1	14	1.1	1.1
<i>Mosunetuzumab-axgb</i>	286	1	1	1	1	36	1.6	3.7
<i>Anacaulase-bcdb</i>	129	1	1	1	1	1	1.0	0.0
<i>Ublituximab-xiiy</i>	924	1	1	1	1	168	2.1	9.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Daridorexant	31,814	30,915	100.0%	215	100.0%	684	100.0%	0	NaN
Female	19,906	19,389	62.7%	103	47.9%	414	60.5%	0	NaN
Male	11,908	11,526	37.3%	112	52.1%	270	39.5%	0	NaN
Abrocitinib	2,951	2,888	100.0%	15	100.0%	48	100.0%	0	NaN
Female	1,381	1,354	46.9%	*****	*****	*****	*****	0	NaN
Male	1,570	1,534	53.1%	*****	*****	*****	*****	0	NaN
Mitapivat	189	*****	*****	*****	*****	0	NaN	0	NaN
Female	132	*****	*****	*****	*****	0	NaN	0	NaN
Male	57	57	30.3%	0	0.0%	0	NaN	0	NaN
Pacritinib	4,313	4,298	100.0%	15	100.0%	0	NaN	0	NaN
Female	1,964	*****	*****	*****	*****	0	NaN	0	NaN
Male	2,349	*****	*****	*****	*****	0	NaN	0	NaN
Ganaxolone	198	198	100.0%	0	NaN	0	NaN	0	NaN
Female	182	182	91.9%	0	NaN	0	NaN	0	NaN
Male	16	16	8.1%	0	NaN	0	NaN	0	NaN
Lutetium Vipivotide									
Tetraxetan	13,811	13,811	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Oteseconazole	211	61	100.0%	*****	*****	104	100.0%	*****	*****
Female	211	61	100.0%	*****	*****	104	100.0%	*****	*****
Male	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mavacamten	11,061	10,358	100.0%	*****	*****	*****	*****	0	NaN
Female	7,450	6,960	67.2%	490	69.8%	0	0.0%	0	NaN
Male	3,611	3,398	32.8%	*****	*****	*****	*****	0	NaN
Vonoprazan	644	610	100.0%	21	100.0%	13	100.0%	0	NaN
Female	398	378	62.0%	*****	*****	*****	*****	0	NaN
Male	246	232	38.0%	*****	*****	*****	*****	0	NaN
Tirzepatide	2,176,027	1,997,341	100.0%	53,690	100.0%	122,858	100.0%	2,138	100.0%
Female	1,373,423	1,268,104	63.5%	32,246	60.1%	71,839	58.5%	1,234	57.7%
Male	802,604	729,237	36.5%	21,444	39.9%	51,019	41.5%	904	42.3%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Tapinarof	27,773	26,739	100.0%	584	100.0%	436	100.0%	14	100.0%
Female	14,187	13,668	51.1%	294	50.3%	*****	*****	*****	*****
Male	13,586	13,071	48.9%	290	49.7%	*****	*****	*****	*****
Vutrisiran	1,875	1,558	100.0%	35	100.0%	282	100.0%	0	NaN
Female	681	527	33.8%	15	42.9%	139	49.3%	0	NaN
Male	1,194	1,031	66.2%	20	57.1%	143	50.7%	0	NaN
Deucravacitinib	6,072	5,903	100.0%	29	100.0%	140	100.0%	0	NaN
Female	3,160	3,066	51.9%	13	44.8%	81	57.9%	0	NaN
Male	2,912	2,837	48.1%	16	55.2%	59	42.1%	0	NaN
Terlipressin	45	45	100.0%	0	NaN	0	NaN	0	NaN
Female	23	23	51.1%	0	NaN	0	NaN	0	NaN
Male	22	22	48.9%	0	NaN	0	NaN	0	NaN
Gadopiclenol	24,310	24,310	100.0%	0	NaN	0	NaN	0	NaN
Female	14,202	14,202	58.4%	0	NaN	0	NaN	0	NaN
Male	10,108	10,108	41.6%	0	NaN	0	NaN	0	NaN
Omidenepag									
Isopropyl Ophthalmic	0	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.
Sodium									
Phenylbutyrate and									
Taurursodiol	10,702	10,581	100.0%	71	100.0%	50	100.0%	0	NaN
Female	4,464	4,405	41.6%	33	46.5%	26	52.0%	0	NaN
Male	6,238	6,176	58.4%	38	53.5%	24	48.0%	0	NaN
Futibatinib	278	278	100.0%	0	NaN	0	NaN	0	NaN
Female	164	164	59.0%	0	NaN	0	NaN	0	NaN
Male	114	114	41.0%	0	NaN	0	NaN	0	NaN
Olutasidenib	193	*****	*****	0	NaN	*****	*****	0	NaN
Female	80	80	41.7%	0	NaN	0	0.0%	0	NaN
Male	113	*****	*****	0	NaN	*****	*****	0	NaN
Adagrasib	938	*****	*****	*****	*****	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Female	593	*****	*****	*****	*****	0	NaN	0	NaN
Male	345	*****	*****	*****	*****	0	NaN	0	NaN
Lenacapavir	316	130	100.0%	29	100.0%	32	100.0%	125	100.0%
Female	67	23	17.7%	*****	*****	*****	*****	33	26.4%
Male	249	107	82.3%	*****	*****	*****	*****	92	73.6%
Hyperpolarized 129-	61	61	100.0%	0	NaN	0	NaN	0	NaN
Female	36	36	59.0%	0	NaN	0	NaN	0	NaN
Male	25	25	41.0%	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	5,618	5,618	100.0%	0	NaN	0	NaN	0	NaN
Female	3,014	3,014	53.6%	0	NaN	0	NaN	0	NaN
Male	2,604	2,604	46.4%	0	NaN	0	NaN	0	NaN
Faricimab-svoa	569,956	569,907	100.0%	*****	*****	*****	*****	*****	*****
Female	335,438	335,418	58.9%	*****	*****	0	0.0%	*****	*****
Male	234,518	234,489	41.1%	*****	*****	*****	*****	*****	*****
Sutimlimab-jome	2,578	2,578	100.0%	0	NaN	0	NaN	0	NaN
Female	1,828	1,828	70.9%	0	NaN	0	NaN	0	NaN
Male	750	750	29.1%	0	NaN	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	12,522	12,522	100.0%	0	NaN	0	NaN	0	NaN
Female	4,582	4,582	36.6%	0	NaN	0	NaN	0	NaN
Male	7,940	7,940	63.4%	0	NaN	0	NaN	0	NaN
Olipudase Alfa-rpcp	143	*****	*****	*****	*****	*****	*****	0	NaN
Female	109	*****	*****	*****	*****	*****	*****	0	NaN
Male	34	34	24.8%	0	0.0%	0	0.0%	0	NaN
Spesolimab-sbzo	95	95	100.0%	0	NaN	0	NaN	0	NaN
Female	61	61	64.2%	0	NaN	0	NaN	0	NaN
Male	34	34	35.8%	0	NaN	0	NaN	0	NaN
Daxibotulinumtoxina- lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Eflapegrastim-xnst	9,684	9,684	100.0%	0	NaN	0	NaN	0	NaN
Female	5,252	5,252	54.2%	0	NaN	0	NaN	0	NaN
Male	4,432	4,432	45.8%	0	NaN	0	NaN	0	NaN
Tremelimumab-actl	1,243	1,243	100.0%	0	NaN	0	NaN	0	NaN
Female	344	344	27.7%	0	NaN	0	NaN	0	NaN
Male	899	899	72.3%	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	6,348	6,348	100.0%	0	NaN	0	NaN	0	NaN
Female	3,035	3,035	47.8%	0	NaN	0	NaN	0	NaN
Male	3,313	3,313	52.2%	0	NaN	0	NaN	0	NaN
Mirvetuximab									
Soravtansine-gynx	1,250	1,250	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	287	287	100.0%	0	NaN	0	NaN	0	NaN
Female	132	132	46.0%	0	NaN	0	NaN	0	NaN
Male	155	155	54.0%	0	NaN	0	NaN	0	NaN
Mosunetuzumab-	286	*****	*****	*****	*****	0	NaN	0	NaN
Female	127	127	44.6%	0	0.0%	0	NaN	0	NaN
Male	159	*****	*****	*****	*****	0	NaN	0	NaN
Anacaulase-bcdb	129	129	100.0%	0	NaN	0	NaN	0	NaN
Female	67	67	51.9%	0	NaN	0	NaN	0	NaN
Male	62	62	48.1%	0	NaN	0	NaN	0	NaN
Ublituximab-xiiy	924	*****	*****	*****	*****	*****	*****	*****	*****
Female	682	*****	*****	*****	*****	*****	*****	*****	*****
Male	242	*****	*****	0	0.0%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	31,814	1	30	30	30	90	29.2	10.8
Female	19,906	1	30	30	30	90	29.2	10.6
Male	11,908	1	30	30	30	90	29.2	11.1
Abrocitinib	2,951	1	30	30	30	90	29.5	9.3
Female	1,381	1	30	30	30	90	29.2	8.7
Male	1,570	1	30	30	30	90	29.8	9.7
Mitapivat	189	3	28	28	28	56	27.0	4.9
Female	132	3	28	28	28	56	27.2	4.8
Male	57	3	28	28	28	28	26.5	5.1
Pacritinib	4,313	1	30	30	30	60	28.8	4.8
Female	1,964	1	30	30	30	60	28.9	4.8
Male	2,349	1	30	30	30	45	28.7	4.8
Ganaxolone	198	3	24	27	29	30	26.0	4.7
Female	182	3	24	27	29	30	26.3	4.1
Male	16	4	18	27	28	30	22.3	8.3
Lutetium Vipivotide								
Tetraxetan	13,811	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Oteseconazole	211	2	30	63	84	91	56.1	29.3
Female	211	2	30	63	84	91	56.1	29.3
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	11,061	1	30	30	30	70	28.1	6.7
Female	7,450	1	30	30	30	60	28.2	6.6
Male	3,611	1	30	30	30	70	28.0	6.8
Vonoprazan	644	1	13	26	30	90	22.5	13.9
Female	398	1	13	26	30	90	22.2	13.3
Male	246	1	13	25	30	90	22.8	14.9
Tirzepatide	2,176,027	1	28	28	28	351	30.1	14.9
Female	1,373,423	1	28	28	28	300	29.9	14.4
Male	802,604	1	28	28	28	351	30.6	15.6
Tapinarof	27,773	1	30	30	30	120	29.4	10.2

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	14,187	1	30	30	30	120	29.4	10.2
Male	13,586	1	30	30	30	120	29.3	10.3
Vutrisiran	1,875	1	1	1	1	90	15.2	31.4
Female	681	1	1	1	1	90	20.1	35.2
Male	1,194	1	1	1	1	90	12.4	28.6
Deucravacitinib	6,072	1	30	30	30	90	29.7	10.8
Female	3,160	1	30	30	30	90	29.9	11.2
Male	2,912	1	30	30	30	90	29.5	10.3
Terlipressin	45	1	1	1	1	1	1.0	0.0
Female	23	1	1	1	1	1	1.0	0.0
Male	22	1	1	1	1	1	1.0	0.0
Gadopichlenol	24,310	1	1	1	1	1	1.0	0.0
Female	14,202	1	1	1	1	1	1.0	0.0
Male	10,108	1	1	1	1	1	1.0	0.0
Omidenedapag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	10,702	1	28	28	28	84	27.2	6.3
Female	4,464	1	28	28	28	84	27.3	6.6
Male	6,238	1	28	28	28	84	27.2	6.0
Futibatinib	278	1	28	28	28	28	25.2	6.2
Female	164	2	28	28	28	28	25.8	5.5
Male	114	1	22	28	28	28	24.3	7.0
Olutasidenib	193	2	30	30	30	90	28.7	6.6
Female	80	2	30	30	30	30	28.4	4.9
Male	113	2	30	30	30	90	29.0	7.5
Adagrasib	938	1	30	30	30	45	27.7	6.2
Female	593	1	30	30	30	45	27.7	6.2
Male	345	1	30	30	30	45	27.6	6.4
Lenacapavir	316	1	2	56	142	210	75.2	69.7

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	67	1	11	88	165	210	89.0	72.7
Male	249	1	2	49	132	210	71.5	68.5
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
Female	36	1	1	1	1	1	1.0	0.0
Male	25	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	5,618	1	1	1	1	7	1.0	0.1
Female	3,014	1	1	1	1	7	1.0	0.2
Male	2,604	1	1	1	1	1	1.0	0.0
Faricimab-svoa	569,956	1	1	1	1	112	1.1	1.2
Female	335,438	1	1	1	1	93	1.1	1.2
Male	234,518	1	1	1	1	112	1.1	1.3
Sutimlimab-jome	2,578	1	1	1	1	14	1.2	1.7
Female	1,828	1	1	1	1	14	1.2	1.4
Male	750	1	1	1	1	14	1.4	2.3
Nivolumab and Relatlimab-rmbw	12,522	1	1	1	1	28	1.2	2.3
Female	4,582	1	1	1	1	28	1.2	2.5
Male	7,940	1	1	1	1	28	1.2	2.2
Olipudase Alfa-rpcp	143	1	1	1	1	84	7.5	17.1
Female	109	1	1	1	1	84	9.5	19.2
Male	34	1	1	1	1	1	1.0	0.0
Spesolimab-sbzo	95	1	1	1	1	7	1.8	2.1
Female	61	1	1	1	1	7	1.8	2.0
Male	34	1	1	1	1	7	1.9	2.2
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,684	1	1	1	1	30	1.2	2.1
Female	5,252	1	1	1	1	30	1.2	2.0
Male	4,432	1	1	1	1	28	1.2	2.1
Tremelimumab-actl	1,243	1	1	1	1	30	1.4	3.3
Female	344	1	1	1	1	30	1.7	4.3

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	899	1	1	1	1	30	1.3	2.9
Teclistamab-cqyv	6,348	1	1	1	1	28	1.0	0.5
Female	3,035	1	1	1	1	28	1.0	0.6
Male	3,313	1	1	1	1	7	1.0	0.1
Mirvetuximab Soravtansine-gynx	1,250	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	287	1	1	1	1	14	1.1	1.1
Female	132	1	1	1	1	14	1.1	1.1
Male	155	1	1	1	1	14	1.1	1.0
Mosunetuzumab-axgb	286	1	1	1	1	36	1.6	3.7
Female	127	1	1	1	1	1	1.0	0.0
Male	159	1	1	1	1	36	2.1	4.9
Anacaulase-bcdb	129	1	1	1	1	1	1.0	0.0
Female	67	1	1	1	1	1	1.0	0.0
Male	62	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	924	1	1	1	1	168	2.1	9.4
Female	682	1	1	1	1	168	2.1	9.1
Male	242	1	1	1	1	134	2.2	10.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Daridorexant	31,814	30,915	100.0%	215	100.0%	684	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	3,550	3,475	11.2%	*****	*****	*****	*****	0	NaN
41-64 years	16,819	16,420	53.1%	94	43.7%	305	44.6%	0	NaN
≥ 65 years	11,017	10,603	34.3%	94	43.7%	320	46.8%	0	NaN
Abrocitinib	2,951	2,888	100.0%	15	100.0%	48	100.0%	0	NaN
0-17 years	91	87	3.0%	*****	*****	*****	*****	0	NaN
18-24 years	377	375	13.0%	*****	*****	*****	*****	0	NaN
25-40 years	676	671	23.2%	*****	*****	*****	*****	0	NaN
41-64 years	1,126	1,112	38.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	681	643	22.3%	*****	*****	*****	*****	0	NaN
Mitapivat	189	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	15	15	8.0%	0	0.0%	0	NaN	0	NaN
25-40 years	72	72	38.3%	0	0.0%	0	NaN	0	NaN
41-64 years	73	73	38.8%	0	0.0%	0	NaN	0	NaN
≥ 65 years	29	*****	*****	*****	*****	0	NaN	0	NaN
Pacritinib	4,313	4,298	100.0%	15	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	18	18	0.4%	0	0.0%	0	NaN	0	NaN
41-64 years	334	334	7.8%	0	0.0%	0	NaN	0	NaN
≥ 65 years	3,961	3,946	91.8%	15	100.0%	0	NaN	0	NaN
Ganaxolone	198	198	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	135	135	68.2%	0	NaN	0	NaN	0	NaN
18-24 years	45	45	22.7%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
Lutetium Vipivotide									
Tetraxetan	13,811	13,811	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	794	794	5.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	13,017	13,017	94.3%	0	NaN	0	NaN	0	NaN
Oteseconazole	211	61	100.0%	*****	*****	104	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	124	41	67.2%	*****	*****	51	49.0%	*****	*****
≥ 65 years	49	*****	*****	*****	*****	36	34.6%	*****	*****
Mavacamten	11,061	10,358	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	15	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	51	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	410	397	3.8%	13	1.9%	0	0.0%	0	NaN
41-64 years	2,517	2,373	22.9%	144	20.5%	0	0.0%	0	NaN
≥ 65 years	8,068	7,524	72.6%	*****	*****	*****	*****	0	NaN
Vonoprazan	644	610	100.0%	21	100.0%	13	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	59	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	339	325	53.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	232	214	35.1%	*****	*****	*****	*****	0	NaN
Tirzepatide	2,176,027	1,997,341	100.0%	53,690	100.0%	122,858	100.0%	2,138	100.0%
0-17 years	679	*****	*****	*****	*****	24	0.0%	0	0.0%
18-24 years	14,990	*****	*****	*****	*****	416	0.3%	12	0.6%
25-40 years	225,662	212,629	10.6%	4,301	8.0%	8,550	7.0%	182	8.5%
41-64 years	1,229,351	1,132,545	56.7%	28,465	53.0%	67,037	54.6%	1,304	61.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
≥ 65 years	705,345	637,200	31.9%	20,674	38.5%	46,831	38.1%	640	29.9%
Tapinarof	27,773	26,739	100.0%	584	100.0%	436	100.0%	14	100.0%
0-17 years	508	494	1.8%	*****	*****	*****	*****	0	0.0%
18-24 years	1,122	1,093	4.1%	13	2.2%	*****	*****	*****	*****
25-40 years	5,354	5,219	19.5%	*****	*****	73	16.7%	*****	*****
41-64 years	14,417	13,866	51.9%	319	54.6%	*****	*****	*****	*****
≥ 65 years	6,372	6,067	22.7%	179	30.7%	*****	*****	*****	*****
Vutrisiran	1,875	1,558	100.0%	35	100.0%	282	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	27	9.6%	0	NaN
≥ 65 years	1,624	1,344	86.3%	*****	*****	*****	*****	0	NaN
Deucravacitinib	6,072	5,903	100.0%	29	100.0%	140	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	973	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	3,044	2,993	50.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,843	1,734	29.4%	*****	*****	*****	*****	0	NaN
Terlipressin	45	45	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	24	24	53.3%	0	NaN	0	NaN	0	NaN
Gadopichlenol	24,310	24,310	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	373	373	1.5%	0	NaN	0	NaN	0	NaN
18-24 years	337	337	1.4%	0	NaN	0	NaN	0	NaN
25-40 years	2,033	2,033	8.4%	0	NaN	0	NaN	0	NaN
41-64 years	8,057	8,057	33.1%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
≥ 65 years	13,510	13,510	55.6%	0	NaN	0	NaN	0	NaN
Omidenepag									
Isopropyl Ophthalmic	0	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.
Sodium									
Phenylbutyrate and									
Taurursodiol	10,702	10,581	100.0%	71	100.0%	50	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	297	2.8%	*****	*****	0	0.0%	0	NaN
41-64 years	3,738	*****	*****	*****	*****	15	30.0%	0	NaN
≥ 65 years	6,660	6,599	62.4%	26	36.6%	35	70.0%	0	NaN
Futibatinib	278	278	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	16	16	5.8%	0	NaN	0	NaN	0	NaN
41-64 years	120	120	43.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	142	142	51.1%	0	NaN	0	NaN	0	NaN
Olutasidenib	193	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN
41-64 years	17	17	8.9%	0	NaN	0	0.0%	0	NaN
≥ 65 years	176	*****	*****	0	NaN	*****	*****	0	NaN
Adagrasib	938	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	690	*****	*****	*****	*****	0	NaN	0	NaN
Lenacapavir	316	130	100.0%	29	100.0%	32	100.0%	125	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	*****	*****
25-40 years	*****	24	18.5%	*****	*****	*****	*****	*****	*****
41-64 years	193	81	62.3%	16	55.2%	21	65.6%	75	60.0%
≥ 65 years	78	25	19.2%	*****	*****	*****	*****	35	28.0%
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	5,618	5,618	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	121	121	2.2%	0	NaN	0	NaN	0	NaN
41-64 years	1,229	1,229	21.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	4,268	4,268	76.0%	0	NaN	0	NaN	0	NaN
Faricimab-svoa	569,956	569,907	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	11	11	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	20	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	971	971	0.2%	0	0.0%	0	0.0%	0	0.0%
41-64 years	24,975	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	543,979	*****	*****	*****	*****	*****	*****	*****	*****
Sutimlimab-jome	2,578	2,578	100.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	150	150	5.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	2,380	2,380	92.3%	0	NaN	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	12,522	12,522	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	160	160	1.3%	0	NaN	0	NaN	0	NaN
41-64 years	1,967	1,967	15.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	10,373	10,373	82.8%	0	NaN	0	NaN	0	NaN
Olipudase Alfa-rpcp	143	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	48	48	35.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	65	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
Spesolimab-sbzo	95	95	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	11	11	11.6%	0	NaN	0	NaN	0	NaN
41-64 years	30	30	31.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	54	54	56.8%	0	NaN	0	NaN	0	NaN
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,684	9,684	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	39	39	0.4%	0	NaN	0	NaN	0	NaN
41-64 years	519	519	5.4%	0	NaN	0	NaN	0	NaN
≥ 65 years	9,113	9,113	94.1%	0	NaN	0	NaN	0	NaN
Tremelimumab-actl	1,243	1,243	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	1,032	1,032	83.0%	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	6,348	6,348	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	15	15	0.2%	0	NaN	0	NaN	0	NaN
41-64 years	1,525	1,525	24.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	4,808	4,808	75.7%	0	NaN	0	NaN	0	NaN
Mirvetuximab									
Soravtansine-gynx	1,250	1,250	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	576	576	46.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	648	648	51.8%	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	287	287	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	144	144	50.2%	0	NaN	0	NaN	0	NaN
18-24 years	23	23	8.0%	0	NaN	0	NaN	0	NaN
25-40 years	66	66	23.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total	Number of Dispensings	Percent of Total
41-64 years	54	54	18.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Mosunetuzumab-	286	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	190	190	66.7%	0	0.0%	0	NaN	0	NaN
Anacaulase-bcdb	129	129	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	104	104	80.6%	0	NaN	0	NaN	0	NaN
Ublituximab-xiiy	924	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	20	2.2%	0	0.0%	0	0.0%	0	0.0%
25-40 years	291	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	511	*****	*****	0	0.0%	*****	*****	*****	*****
≥ 65 years	102	*****	*****	0	0.0%	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	31,814	1	30	30	30	90	29.2	10.8
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	2	30	30	30	90	29.4	10.5
25-40 years	3,550	1	30	30	30	90	28.5	9.8
41-64 years	16,819	1	30	30	30	90	29.2	9.9
≥ 65 years	11,017	1	30	30	30	90	29.5	12.2
Abrocitinib	2,951	1	30	30	30	90	29.5	9.3
0-17 years	91	1	30	30	30	90	29.0	11.5
18-24 years	377	1	30	30	30	63	29.0	4.9
25-40 years	676	1	30	30	30	90	28.8	6.6
41-64 years	1,126	1	30	30	30	90	29.0	8.2
≥ 65 years	681	2	30	30	30	90	31.3	13.5
Mitapivat	189	3	28	28	28	56	27.0	4.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	15	16	28	28	28	28	27.0	3.1
25-40 years	72	3	28	28	28	28	26.8	4.7
41-64 years	73	10	28	28	28	28	27.4	2.6
≥ 65 years	29	3	28	28	28	56	26.6	9.1
Pacritinib	4,313	1	30	30	30	60	28.8	4.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	6	30	30	30	30	27.7	6.9
41-64 years	334	1	30	30	30	30	28.6	5.0
≥ 65 years	3,961	1	30	30	30	60	28.8	4.7
Ganaxolone	198	3	24	27	29	30	26.0	4.7
0-17 years	135	3	23	27	29	30	25.4	4.8
18-24 years	45	6	27	27	30	30	27.3	5.0
25-40 years	*****	25	27	27	29	29	27.5	1.4
41-64 years	*****	24	27	27	27	28	26.9	1.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Vipivotide								
Tetraxetan	13,811	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	794	1	1	1	1	1	1.0	0.0
≥ 65 years	13,017	1	1	1	1	1	1.0	0.0
Oteseconazole	211	2	30	63	84	91	56.1	29.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	31	31	58	90	90	59.5	31.3
25-40 years	*****	2	30	31	84	90	49.6	31.4
41-64 years	124	3	30	31	84	91	51.1	28.4
≥ 65 years	49	3	74	84	84	91	72.7	23.7
Mavacamten	11,061	1	30	30	30	70	28.1	6.7
0-17 years	15	3	30	30	30	35	28.5	7.2
18-24 years	51	1	30	30	30	35	28.2	6.2
25-40 years	410	1	30	30	30	60	28.7	5.4
41-64 years	2,517	1	30	30	30	60	27.9	6.9
≥ 65 years	8,068	1	30	30	30	70	28.2	6.7
Vonoprazan	644	1	13	26	30	90	22.5	13.9
0-17 years	*****	8	19	30	30	30	24.5	11.0
18-24 years	*****	7	13	18	30	30	19.6	8.7
25-40 years	59	1	10	20	30	90	20.8	16.2
41-64 years	339	1	14	25	30	90	21.7	12.2
≥ 65 years	232	1	13	30	30	90	24.1	15.7
Tirzepatide	2,176,027	1	28	28	28	351	30.1	14.9
0-17 years	679	1	28	28	28	90	28.6	12.0
18-24 years	14,990	1	28	28	28	118	28.1	11.6
25-40 years	225,662	1	28	28	28	224	28.9	12.9
41-64 years	1,229,351	1	28	28	28	351	30.0	14.7
≥ 65 years	705,345	1	28	28	28	228	30.8	15.7

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tapinarof	27,773	1	30	30	30	120	29.4	10.2
0-17 years	508	2	30	30	30	90	28.6	6.7
18-24 years	1,122	1	30	30	30	120	29.0	9.6
25-40 years	5,354	1	30	30	30	120	29.1	9.4
41-64 years	14,417	1	30	30	30	120	29.4	10.2
≥ 65 years	6,372	1	30	30	30	120	29.5	11.3
Vutrisiran	1,875	1	1	1	1	90	15.2	31.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	6	90	90	90	55.4	47.4
41-64 years	*****	1	1	1	1	90	12.2	28.4
≥ 65 years	1,624	1	1	1	1	90	15.5	31.7
Deucravacitinib	6,072	1	30	30	30	90	29.7	10.8
0-17 years	*****	26	26	28	30	30	28.0	2.8
18-24 years	*****	1	30	30	30	30	28.3	5.5
25-40 years	973	1	30	30	30	90	28.4	7.9
41-64 years	3,044	1	30	30	30	90	29.1	9.4
≥ 65 years	1,843	1	30	30	30	90	31.7	14.0
Terlipressin	45	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	24	1	1	1	1	1	1.0	0.0
Gadopicleonol	24,310	1	1	1	1	1	1.0	0.0
0-17 years	373	1	1	1	1	1	1.0	0.0
18-24 years	337	1	1	1	1	1	1.0	0.0
25-40 years	2,033	1	1	1	1	1	1.0	0.0
41-64 years	8,057	1	1	1	1	1	1.0	0.0
≥ 65 years	13,510	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

		Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Omidenepag Isopropyl								
Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate								
and Taurursodiol	10,702	1	28	28	28	84	27.2	6.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	28	28	28.0	0.0
25-40 years	*****	1	28	28	28	56	27.1	5.0
41-64 years	3,738	1	28	28	28	84	27.3	6.4
≥ 65 years	6,660	1	28	28	28	84	27.2	6.3
Futibatinib	278	1	28	28	28	28	25.2	6.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	3	28	28	28	28	26.0	6.4
41-64 years	120	1	21	28	28	28	23.8	7.3
≥ 65 years	142	2	28	28	28	28	26.3	4.9
Olutasidenib	193	2	30	30	30	90	28.7	6.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	17	29	30	30	30	30	29.9	0.2
≥ 65 years	176	2	30	30	30	90	28.6	6.9
Adagrasib	938	1	30	30	30	45	27.7	6.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	27	27	29	30	30	28.5	2.1
41-64 years	*****	3	30	30	30	45	28.2	5.6

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	690	1	30	30	30	45	27.5	6.5
Lenacapavir	316	1	2	56	142	210	75.2	69.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	32	32	127	210	210	123.0	89.1
25-40 years	*****	1	2	21	128	182	59.4	68.6
41-64 years	193	1	2	55	135	210	73.7	69.0
≥ 65 years	78	1	8	84	160	195	85.6	70.1
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	5,618	1	1	1	1	7	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	121	1	1	1	1	1	1.0	0.0
41-64 years	1,229	1	1	1	1	1	1.0	0.0
≥ 65 years	4,268	1	1	1	1	7	1.0	0.1
Faricimab-svoa	569,956	1	1	1	1	112	1.1	1.2
0-17 years	11	1	1	1	1	1	1.0	0.0
18-24 years	20	1	1	1	1	1	1.0	0.0
25-40 years	971	1	1	1	1	16	1.0	0.5
41-64 years	24,975	1	1	1	1	56	1.1	1.6
≥ 65 years	543,979	1	1	1	1	112	1.0	1.2
Sutimlimab-jome	2,578	1	1	1	1	14	1.2	1.7
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	150	1	1	1	1	1	1.0	0.0
≥ 65 years	2,380	1	1	1	1	14	1.3	1.8

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Nivolumab and Relatlimab-rmbw	12,522	1	1	1	1	28	1.2	2.3
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	160	1	1	1	1	1	1.0	0.0
41-64 years	1,967	1	1	1	1	28	1.1	1.5
≥ 65 years	10,373	1	1	1	1	28	1.2	2.5
Olipudase Alfa-rpcp	143	1	1	1	1	84	7.5	17.1
0-17 years	48	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	84	15.7	31.7
41-64 years	65	1	1	1	28	56	9.2	13.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	95	1	1	1	1	7	1.8	2.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	11	1	1	1	1	7	1.5	1.8
41-64 years	30	1	1	1	1	7	1.4	1.5
≥ 65 years	54	1	1	1	1	7	2.1	2.4
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,684	1	1	1	1	30	1.2	2.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	39	1	1	1	1	21	2.5	5.4
41-64 years	519	1	1	1	1	21	1.4	2.8
≥ 65 years	9,113	1	1	1	1	30	1.2	2.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tremelimumab-actl	1,243	1	1	1	1	30	1.4	3.3
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.1	1.9
≥ 65 years	1,032	1	1	1	1	30	1.5	3.5
Teclistamab-cqyv	6,348	1	1	1	1	28	1.0	0.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	15	1	1	1	1	1	1.0	0.0
41-64 years	1,525	1	1	1	1	1	1.0	0.0
≥ 65 years	4,808	1	1	1	1	28	1.0	0.5
Mirvetuximab								
Soravtansine-gynx	1,250	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	576	1	1	1	1	1	1.0	0.0
≥ 65 years	648	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	287	1	1	1	1	14	1.1	1.1
0-17 years	144	1	1	1	1	1	1.0	0.0
18-24 years	23	1	1	1	1	1	1.0	0.0
25-40 years	66	1	1	1	1	14	1.2	1.6
41-64 years	54	1	1	1	1	14	1.2	1.8
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	286	1	1	1	1	36	1.6	3.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	36	2.9	6.3
≥ 65 years	190	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Anacaulase-bcdb	129	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	104	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	924	1	1	1	1	168	2.1	9.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	1	1	1	1	1.0	0.0
25-40 years	291	1	1	1	1	168	2.7	12.2
41-64 years	511	1	1	1	1	134	1.8	8.2
≥ 65 years	102	1	1	1	1	63	2.1	6.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Daridorexant</i>	10,520	5,087	48.4%	2,501	23.8%	2,668	25.4%	264	2.5%	0	0.0%
<i>Abrocitinib</i>	609	142	23.3%	150	24.6%	275	45.2%	42	6.9%	0	0.0%
<i>Mitapivat</i>	26	*****	*****	*****	*****	12	46.2%	*****	*****	0	0.0%
<i>Pacritinib</i>	879	226	25.7%	250	28.4%	330	37.5%	73	8.3%	0	0.0%
<i>Ganaxolone</i>	23	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Lutetium Vipivotide</i>											
<i>Tetraxetan</i>	4,303	4,303	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Oteseconazole</i>	161	35	21.7%	109	67.7%	17	10.6%	0	0.0%	0	0.0%
<i>Mavacamten</i>	1,600	202	12.6%	313	19.6%	843	52.7%	242	15.1%	0	0.0%
<i>Vonoprazan</i>	431	275	63.8%	130	30.2%	26	6.0%	0	0.0%	0	0.0%
<i>Tirzepatide</i>	438,820	84,727	19.3%	114,100	26.0%	204,518	46.6%	35,475	8.1%	0	0.0%
<i>Tapinarof</i>	14,042	7,588	54.0%	4,557	32.5%	1,869	13.3%	28	0.2%	0	0.0%
<i>Vutrisiran</i>	607	515	84.8%	*****	*****	53	8.7%	*****	*****	0	0.0%
<i>Deucravacitinib</i>	1,517	395	26.0%	433	28.5%	649	42.8%	40	2.6%	0	0.0%
<i>Terlipressin</i>	42	42	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gadopiclenol</i>	22,748	22,748	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and</i>											
<i>Taurursodiol</i>	2,227	555	24.9%	620	27.8%	941	42.3%	111	5.0%	0	0.0%
<i>Futibatinib</i>	82	21	25.6%	38	46.3%	23	28.0%	0	0.0%	0	0.0%
<i>Olutasidenib</i>	51	*****	*****	23	45.1%	16	31.4%	*****	*****	0	0.0%
<i>Adagrasib</i>	351	153	43.6%	108	30.8%	90	25.6%	0	0.0%	0	0.0%
<i>Lenacapavir</i>	193	*****	*****	37	19.2%	112	58.0%	*****	*****	0	0.0%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Hyperpolarized</i>											
<i>129-Xe</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tebentafusp-</i>											
<i>tebn</i>	196	124	63.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	114,321	114,099	99.8%	*****	*****	131	0.1%	*****	*****	0	0.0%
<i>Sutimlimab-</i>											
<i>jome</i>	170	147	86.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Nivolumab and</i>											
<i>Relatlimab-</i>											
<i>rmbw</i>	2,545	2,527	99.3%	*****	*****	11	0.4%	*****	*****	0	0.0%
<i>Olipudase Alfa-</i>											
<i>rpcp</i>	12	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
<i>Spesolimab-</i>											
<i>sbzo</i>	55	55	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumt</i>											
<i>oxina-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-</i>											
<i>xnst</i>	3,303	3,283	99.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tremelimumab-</i>											
<i>actl</i>	972	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Teclistamab-</i>											
<i>cqyv</i>	1,233	1,214	98.5%	19	1.5%	0	0.0%	0	0.0%	0	0.0%
<i>Mirvetuximab</i>											
<i>Soravtansine-</i>											
<i>gynx</i>	280	280	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Teplizumab-</i>											
<i>mzvv</i>	42	42	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mosunetuzuma</i>											
<i>b-axgb</i>	63	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Anacaulase-</i>										
<i>bcd</i>	127	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ublituximab-</i>	482	97.7%	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Daridorexant</i>	10,520	1	30	42	117	687	88.4	95.7
<i>Abrocitinib</i>	609	1	37	106	210	682	143.0	122.7
<i>Mitapivat</i>	26	16	56	153	280	584	196.4	162.0
<i>Pacritinib</i>	879	1	30	90	181	721	141.3	139.0
<i>Ganaxolone</i>	23	17	102	158	357	542	223.6	171.6
<i>Lutetium Vipivotide</i>	4,303	1	2	3	5	10	3.2	1.7
<i>Oteseconazole</i>	161	3	33	84	84	351	73.6	42.2
<i>Mavacamten</i>	1,600	1	67	161	291	710	194.4	147.6
<i>Vonoprazan</i>	431	1	13	25	47	180	33.6	29.9
<i>Tirzepatide</i>	438,820	1	46	112	224	718	149.4	126.8
<i>Tapinarof</i>	14,042	1	30	30	60	540	58.1	51.0
<i>Vutrisiran</i>	607	1	2	3	4	550	46.9	117.8
<i>Deucravacitinib</i>	1,517	1	30	90	179	501	118.9	99.6
<i>Terlipressin</i>	42	1	1	1	1	3	1.1	0.3
<i>Gadopiclenol</i>	22,748	1	1	1	1	6	1.1	0.3
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	2,227	2	31	84	196	486	130.8	112.5
<i>Futibatinib</i>	82	6	28	56	109	351	85.4	67.8
<i>Olutasidenib</i>	51	13	47	65	135	374	108.7	95.5
<i>Adagrasib</i>	351	1	30	54	99	330	74.0	64.8
<i>Lenacapavir</i>	193	1	33	118	182	373	123.1	93.5
<i>Hyperpolarized 129-Xe</i>	61	1	1	1	1	1	1.0	0.0
<i>Tebentafusp-tebn</i>	196	1	10	22	44	105	28.7	23.8
<i>Faricimab-svoa</i>	114,321	1	2	4	7	478	5.2	7.8
<i>Sutimlimab-jome</i>	170	1	4	12	24	350	18.6	36.2
<i>Nivolumab and Relatlimab-rmbw</i>	2,545	1	2	3	7	393	5.9	14.2
<i>Olipudase Alfa-rpcp</i>	12	1	3	7	24	549	87.2	184.5
<i>Spesolimab-sbzo</i>	55	1	1	2	2	21	3.1	4.0

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>DaxibotulinumtoxinA-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	3,303	1	1	2	4	140	3.5	7.0
<i>Tremelimumab-actl</i>	972	1	1	1	1	112	1.8	5.2
<i>Teclistamab-cqyv</i>	1,233	1	1	2	8	57	5.2	6.9
<i>Mirvetuximab Soravtansine-gynx</i>	280	1	2	4	6	16	4.5	3.3
<i>Teplizumab-mzwv</i>	42	1	4	5	14	14	7.5	5.1
<i>Mosunetuzumab-axgb</i>	63	1	1	2	8	183	7.3	22.9
<i>Anacaulase-bcdb</i>	127	1	1	1	1	2	1.0	0.1
<i>Ublituximab-xiiy</i>	482	1	1	2	2	229	4.0	15.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Daridorexant	10,520	5,087	100.0%	2,501	100.0%	2,668	100.0%	264	100.0%	0	NaN
Female	6,568	3,182	62.6%	1,538	61.5%	1,681	63.0%	167	63.3%	0	NaN
Male	3,952	1,905	37.4%	963	38.5%	987	37.0%	97	36.7%	0	NaN
Abrocitinib	609	142	100.0%	150	100.0%	275	100.0%	42	100.0%	0	NaN
Female	315	84	59.2%	85	56.7%	128	46.5%	18	42.9%	0	NaN
Male	294	58	40.8%	65	43.3%	147	53.5%	24	57.1%	0	NaN
Mitapivat	26	*****	*****	*****	*****	12	100.0%	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Pacritinib	879	226	100.0%	250	100.0%	330	100.0%	73	100.0%	0	NaN
Female	396	111	49.1%	112	44.8%	136	41.2%	37	50.7%	0	NaN
Male	483	115	50.9%	138	55.2%	194	58.8%	36	49.3%	0	NaN
Ganaxolone	23	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Lutetium											
Vipivotide											
Tetraxetan	4,303	4,303	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole	161	35	100.0%	109	100.0%	17	100.0%	0	NaN	0	NaN
Female	161	35	100.0%	109	100.0%	17	100.0%	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Mavacamten	1,600	202	100.0%	313	100.0%	843	100.0%	242	100.0%	0	NaN
Female	1,072	134	66.3%	199	63.6%	573	68.0%	166	68.6%	0	NaN
Male	528	68	33.7%	114	36.4%	270	32.0%	76	31.4%	0	NaN
Vonoprazan	431	275	100.0%	130	100.0%	26	100.0%	0	NaN	0	NaN
Female	271	172	62.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	160	103	37.5%	*****	*****	*****	*****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Tirzepatide	438,820	84,727	100.0%	114,100	100.0%	204,518	100.0%	35,475	100.0%	0	NaN
Female	273,416	52,383	61.8%	71,243	62.4%	127,425	62.3%	22,365	63.0%	0	NaN
Male	165,404	32,344	38.2%	42,857	37.6%	77,093	37.7%	13,110	37.0%	0	NaN
Tapinarof	14,042	7,588	100.0%	4,557	100.0%	1,869	100.0%	28	100.0%	0	NaN
Female	7,303	4,078	53.7%	2,285	50.1%	925	49.5%	15	53.6%	0	NaN
Male	6,739	3,510	46.3%	2,272	49.9%	944	50.5%	13	46.4%	0	NaN
Vutrisiran	607	515	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
Female	214	173	33.6%	*****	*****	23	43.4%	*****	*****	0	NaN
Male	393	342	66.4%	*****	*****	30	56.6%	*****	*****	0	NaN
Deucravacitinib	1,517	395	100.0%	433	100.0%	649	100.0%	40	100.0%	0	NaN
Female	832	242	61.3%	244	56.4%	324	49.9%	22	55.0%	0	NaN
Male	685	153	38.7%	189	43.6%	325	50.1%	18	45.0%	0	NaN
Terlipressin	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	22	22	52.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	20	20	47.6%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopiclenol	22,748	22,748	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	13,270	13,270	58.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	9,478	9,478	41.7%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl Ophthalmic Solution											
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol											
Female	2,227	555	100.0%	620	100.0%	941	100.0%	111	100.0%	0	NaN
Male	1,004	286	51.5%	282	45.5%	397	42.2%	39	35.1%	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	1,223	269	48.5%	338	54.5%	544	57.8%	72	64.9%	0	NaN
Futibatinib	82	21	100.0%	38	100.0%	23	100.0%	0	NaN	0	NaN
Female	49	*****	*****	25	65.8%	*****	*****	0	NaN	0	NaN
Male	33	*****	*****	13	34.2%	*****	*****	0	NaN	0	NaN
Olutasidenib	51	*****	*****	23	100.0%	16	100.0%	*****	*****	0	NaN
Female	21	*****	*****	11	47.8%	*****	*****	0	0.0%	0	NaN
Male	30	*****	*****	12	52.2%	*****	*****	*****	*****	0	NaN
Adagrasib	351	153	100.0%	108	100.0%	90	100.0%	0	NaN	0	NaN
Female	215	90	58.8%	65	60.2%	60	66.7%	0	NaN	0	NaN
Male	136	63	41.2%	43	39.8%	30	33.3%	0	NaN	0	NaN
Lenacapavir	193	*****	*****	37	100.0%	112	100.0%	*****	*****	0	NaN
Female	43	*****	*****	*****	*****	28	25.0%	0	0.0%	0	NaN
Male	150	*****	*****	*****	*****	84	75.0%	*****	*****	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	36	36	59.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	25	25	41.0%	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp- tebn	196	124	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	103	65	52.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	93	59	47.6%	*****	*****	*****	*****	0	NaN	0	NaN
Faricimab-svoa	114,321	114,099	100.0%	*****	*****	131	100.0%	*****	*****	0	NaN
Female	67,016	66,889	58.6%	*****	*****	77	58.8%	*****	*****	0	NaN
Male	47,305	47,210	41.4%	*****	*****	54	41.2%	*****	*****	0	NaN
Sutimlimab- jome	170	147	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	113	96	65.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	57	51	34.7%	*****	*****	*****	*****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Nivolumab and Relatlimab-rmbw											
	2,545	2,527	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	958	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,587	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Olipudase Alfa-rpcp											
	12	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
Spesolimab-											
	55	55	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	36	36	65.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	19	19	34.5%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinumt oxina-lanm											
	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst											
	3,303	3,283	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,870	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,433	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab-actl											
	972	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	210	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	762	762	78.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
Teclistamab-cqyv											
	1,233	1,214	100.0%	19	100.0%	0	NaN	0	NaN	0	NaN
Female	589	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	644	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Mirvetuximab											
Soravtansine-											
gynx	280	280	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-											
mzvv	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	19	19	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	23	23	54.8%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzuma											
b-axgb	63	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	28	28	45.2%	0	NaN	0	0.0%	0	NaN	0	NaN
Male	35	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Anacaulase-											
127	127	127	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	66	66	52.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	61	61	48.0%	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-											
482	471	100.0%	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	358	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	124	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	10,520	1	30	42	117	687	88.4	95.7
Female	6,568	1	30	41	119	687	88.6	96.1
Male	3,952	1	30	44	115	640	88.0	95.0
Abrocitinib	609	1	37	106	210	682	143.0	122.7
Female	315	1	30	90	180	682	128.0	117.3
Male	294	4	60	121	240	600	159.0	126.6
Mitapivat	26	16	56	153	280	584	196.4	162.0
Female	*****	16	56	165	280	584	211.5	178.5
Male	*****	19	81	140	280	367	167.8	129.8
Pacritinib	879	1	30	90	181	721	141.3	139.0
Female	396	8	30	90	182	721	143.5	147.7
Male	483	1	38	90	181	684	139.5	131.6
Ganaxolone	23	17	102	158	357	542	223.6	171.6
Female	*****	19	133	230	424	542	265.9	169.8
Male	*****	17	40	57	115	128	71.4	48.1
Lutetium Vipivotide								
Tetraxetan	4,303	1	2	3	5	10	3.2	1.7
Female	*****	1	1	2	3	3	2.0	1.4
Male	*****	1	2	3	5	10	3.2	1.7
Oteseconazole	161	3	33	84	84	351	73.6	42.2
Female	161	3	33	84	84	351	73.6	42.2
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	1,600	1	67	161	291	710	194.4	147.6
Female	1,072	1	69	167	287	710	196.0	145.9
Male	528	1	64	150	298	642	191.3	150.9
Vonoprazan	431	1	13	25	47	180	33.6	29.9
Female	271	1	12	28	44	145	32.6	28.7
Male	160	1	14	24	56	180	35.1	31.9
Tirzepatide	438,820	1	46	112	224	718	149.4	126.8
Female	273,416	1	47	112	225	718	150.1	127.2
Male	165,404	1	46	112	224	694	148.3	126.2

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tapinarof	14,042	1	30	30	60	540	58.1	51.0
Female	7,303	1	30	30	60	540	57.1	50.8
Male	6,739	1	30	30	60	450	59.1	51.1
Vutrisiran	607	1	2	3	4	550	46.9	117.8
Female	214	1	2	4	5	550	63.9	139.3
Male	393	1	2	3	4	549	37.6	103.2
Deucravacitinib	1,517	1	30	90	179	501	118.9	99.6
Female	832	1	30	84	168	501	113.4	99.6
Male	685	1	42	92	180	476	125.6	99.2
Terlipressin	42	1	1	1	1	3	1.1	0.3
Female	22	1	1	1	1	2	1.0	0.2
Male	20	1	1	1	1	3	1.1	0.4
Gadopichlenol	22,748	1	1	1	1	6	1.1	0.3
Female	13,270	1	1	1	1	6	1.1	0.3
Male	9,478	1	1	1	1	6	1.1	0.3
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	2,227	2	31	84	196	486	130.8	112.5
Female	1,004	2	28	84	170	448	121.3	108.5
Male	1,223	2	42	94	220	486	138.6	115.1
Futibatinib	82	6	28	56	109	351	85.4	67.8
Female	49	10	49	64	91	351	86.5	68.6
Male	33	6	28	56	109	280	83.8	67.6
Olutasidenib	51	13	47	65	135	374	108.7	95.5
Female	21	27	48	82	135	300	108.1	86.7
Male	30	13	30	64	116	374	109.1	102.7
Adagrasib	351	1	30	54	99	330	74.0	64.8
Female	215	1	30	57	120	330	76.5	66.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	136	1	30	44	90	257	70.1	61.9
Lenacapavir	193	1	33	118	182	373	123.1	93.5
Female	43	1	32	136	197	337	138.7	104.5
Male	150	1	35	113	180	373	118.6	90.0
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
Female	36	1	1	1	1	1	1.0	0.0
Male	25	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	196	1	10	22	44	105	28.7	23.8
Female	103	1	10	21	44	105	29.4	24.9
Male	93	1	10	22	43	96	28.0	22.6
Faricimab-svoa	114,321	1	2	4	7	478	5.2	7.8
Female	67,016	1	2	4	7	477	5.3	7.8
Male	47,305	1	2	4	7	478	5.2	7.8
Sutimlimab-jome	170	1	4	12	24	350	18.6	36.2
Female	113	1	5	15	26	308	18.8	30.0
Male	57	1	3	7	20	350	18.1	46.4
Nivolumab and Relatlimab-rmbw	2,545	1	2	3	7	393	5.9	14.2
Female	958	1	2	3	7	393	5.9	17.7
Male	1,587	1	2	4	7	183	5.9	11.7
Olipudase Alfa-rpcp	12	1	3	7	24	549	87.2	184.5
Female	*****	2	7	18	403	549	144.6	230.4
Male	*****	1	2	3	6	22	6.8	8.7
Spesolimab-sbzo	55	1	1	2	2	21	3.1	4.0
Female	36	1	1	2	2	21	3.0	4.3
Male	19	1	1	2	4	14	3.3	3.3
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	1	1	2	4	140	3.5	7.0
Female	1,870	1	1	2	4	126	3.4	6.8

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,433	1	1	3	4	140	3.7	7.3
Tremelimumab-actl	972	1	1	1	1	112	1.8	5.2
Female	210	1	1	1	2	112	2.8	9.3
Male	762	1	1	1	1	30	1.5	3.2
Teclistamab-cqyv	1,233	1	1	2	8	57	5.2	6.9
Female	589	1	1	2	8	57	5.3	6.8
Male	644	1	1	2	8	55	5.2	6.9
Mirvetuximab Soravtansine-gynx	280	1	2	4	6	16	4.5	3.3
Female	*****	1	2	4	6	16	4.5	3.3
Male	*****	4	4	4	4	4	4.0	NaN
Teplizumab-mzwv	42	1	4	5	14	14	7.5	5.1
Female	19	1	4	5	14	14	7.6	5.0
Male	23	1	3	5	14	14	7.3	5.2
Mosunetuzumab-axgb	63	1	1	2	8	183	7.3	22.9
Female	28	1	1	2	8	15	4.5	4.3
Male	35	1	1	2	9	183	9.5	30.5
Anacaulase-bcdb	127	1	1	1	1	2	1.0	0.1
Female	66	1	1	1	1	2	1.0	0.1
Male	61	1	1	1	1	2	1.0	0.1
Ublituximab-xiiy	482	1	1	2	2	229	4.0	15.7
Female	358	1	1	2	2	229	4.0	15.5
Male	124	1	1	2	2	134	4.2	16.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Daridorexant	10,520	5,087	100.0%	2,501	100.0%	2,668	100.0%	264	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	31	1.2%	*****	*****	0	NaN
25-40 years	1,049	417	8.2%	*****	*****	323	12.1%	*****	*****	0	NaN
41-64 years	4,943	2,092	41.1%	1,244	49.7%	1,446	54.2%	161	61.0%	0	NaN
≥ 65 years	4,382	2,516	49.5%	926	37.0%	868	32.5%	72	27.3%	0	NaN
Abrocitinib	609	142	100.0%	150	100.0%	275	100.0%	42	100.0%	0	NaN
0-17 years	25	*****	*****	*****	*****	11	4.0%	0	0.0%	0	NaN
18-24 years	76	*****	*****	21	14.0%	31	11.3%	*****	*****	0	NaN
25-40 years	138	30	21.1%	*****	*****	62	22.5%	*****	*****	0	NaN
41-64 years	221	46	32.4%	55	36.7%	109	39.6%	11	26.2%	0	NaN
≥ 65 years	149	42	29.6%	31	20.7%	62	22.5%	14	33.3%	0	NaN
Mitapivat	26	*****	*****	*****	*****	12	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
Pacritinib	879	226	100.0%	250	100.0%	330	100.0%	73	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
41-64 years	*****	23	10.2%	21	8.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	804	203	89.8%	229	91.6%	306	92.7%	66	90.4%	0	NaN
Ganaxolone	23	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Lutetium											
Vipivotide											
Tetraxetan	4,303	4,303	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	294	294	6.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,009	4,009	93.2%	0	NaN	0	NaN	0	NaN	0	NaN
Otseconazole	161	35	100.0%	109	100.0%	17	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	90	*****	*****	57	52.3%	*****	*****	0	NaN	0	NaN
≥ 65 years	44	*****	*****	32	29.4%	*****	*****	0	NaN	0	NaN
Mavacamten	1,600	202	100.0%	313	100.0%	843	100.0%	242	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	366	*****	*****	*****	*****	166	19.7%	68	28.1%	0	NaN
≥ 65 years	1,176	151	74.8%	217	69.3%	647	76.7%	161	66.5%	0	NaN
Vonoprazan	431	275	100.0%	130	100.0%	26	100.0%	0	NaN	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	13	10.0%	*****	*****	0	NaN	0	NaN
41-64 years	232	156	56.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	149	87	31.6%	48	36.9%	14	53.8%	0	NaN	0	NaN
Tirzepatide	438,820	84,727	100.0%	114,100	100.0%	204,518	100.0%	35,475	100.0%	0	NaN
0-17 years	133	*****	*****	41	0.0%	61	0.0%	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	3,518	*****	*****	1,126	1.0%	1,346	0.7%	*****	*****	0	NaN
25-40 years	46,406	9,874	11.7%	12,912	11.3%	20,280	9.9%	3,340	9.4%	0	NaN
41-64 years	235,674	42,797	50.5%	59,319	52.0%	111,464	54.5%	22,094	62.3%	0	NaN
≥ 65 years	153,089	31,147	36.8%	40,702	35.7%	71,367	34.9%	9,873	27.8%	0	NaN
Tapinarof	14,042	7,588	100.0%	4,557	100.0%	1,869	100.0%	28	100.0%	0	NaN
0-17 years	264	138	1.8%	100	2.2%	26	1.4%	0	0.0%	0	NaN
18-24 years	619	367	4.8%	188	4.1%	*****	*****	*****	*****	0	NaN
25-40 years	2,911	1,695	22.3%	886	19.4%	*****	*****	*****	*****	0	NaN
41-64 years	6,953	3,534	46.6%	2,353	51.6%	1,055	56.4%	11	39.3%	0	NaN
≥ 65 years	3,295	1,854	24.4%	1,030	22.6%	*****	*****	*****	*****	0	NaN
Vutrisiran	607	515	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	523	443	86.0%	*****	*****	*****	*****	*****	*****	0	NaN
Deucravacitinib	1,517	395	100.0%	433	100.0%	649	100.0%	40	100.0%	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	54	19	4.8%	13	3.0%	22	3.4%	0	0.0%	0	NaN
25-40 years	*****	77	19.5%	*****	*****	100	15.4%	*****	*****	0	NaN
41-64 years	726	175	44.3%	*****	*****	337	51.9%	*****	*****	0	NaN
≥ 65 years	458	124	31.4%	123	28.4%	190	29.3%	21	52.5%	0	NaN
Terlipressin	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	24	24	57.1%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopiclenol	22,748	22,748	100.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	351	351	1.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	327	327	1.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	1,880	1,880	8.3%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	7,429	7,429	32.7%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	12,761	12,761	56.1%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl Ophthalmic Solution											
	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Sodium Phenylbutyrate and											
	2,227	555	100.0%	620	100.0%	941	100.0%	111	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	17	3.1%	21	3.4%	*****	*****	*****	*****	0	NaN
41-64 years	682	133	24.0%	184	29.7%	306	32.5%	59	53.2%	0	NaN
≥ 65 years	1,477	405	73.0%	415	66.9%	*****	*****	*****	*****	0	NaN
Futibatinib	82	21	100.0%	38	100.0%	23	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	46	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olutasidenib	51	*****	*****	23	100.0%	16	100.0%	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Adagrasib	351	153	100.0%	108	100.0%	90	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	41	26.8%	*****	*****	23	25.6%	0	NaN	0	NaN
≥ 65 years	255	112	73.2%	76	70.4%	67	74.4%	0	NaN	0	NaN
Lenacapavir	193	*****	*****	37	100.0%	112	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	115	26	60.5%	*****	*****	67	59.8%	*****	*****	0	NaN
≥ 65 years	51	*****	*****	*****	*****	33	29.5%	0	0.0%	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp- tebn	196	124	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	*****	31	25.0%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	151	93	75.0%	*****	*****	*****	*****	0	NaN	0	NaN
Faricimab-svoa	114,321	114,099	100.0%	*****	*****	131	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	11	11	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	294	294	0.3%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	5,954	5.2%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	108,039	107,834	94.5%	*****	*****	*****	*****	*****	*****	0	NaN
Sutimlimab-jome	170	147	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	146	125	85.0%	*****	*****	*****	*****	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	2,545	2,527	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	45	45	1.8%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
≥ 65 years	2,113	2,096	82.9%	*****	*****	*****	*****	*****	*****	0	NaN
Olipudase Alfa-rpcp	12	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
Spesolimab-	55	55	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	30	30	54.5%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinumt											
oxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-											
xnst	3,303	3,283	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	191	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	3,095	3,078	93.8%	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab-											
actl	972	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	818	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Teclistamab-	1,233	1,214	100.0%	19	100.0%	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	1,013	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Mirvetuximab											
Soravtansine-											
gynx	280	280	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	138	138	49.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-											
mzwv	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	16	16	38.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	13	13	31.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzuma											
b-axgb	63	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
≥ 65 years	46	46	74.2%	0	NaN	0	0.0%	0	NaN	0	NaN
Anacaulase-											
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	103	103	81.1%	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-	482	471	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	142	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	271	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	10,520	1	30	42	117	687	88.4	95.7
0-17 years	*****	30	30	60	60	60	50.0	17.3
18-24 years	*****	4	30	60	90	582	87.0	94.9
25-40 years	1,049	1	30	60	122	592	96.3	96.5
41-64 years	4,943	1	30	60	128	687	99.5	103.1
≥ 65 years	4,382	1	30	30	90	651	74.1	84.3
Abrocitinib	609	1	37	106	210	682	143.0	122.7
0-17 years	25	14	38	80	153	270	105.6	77.3
18-24 years	76	1	35	90	240	480	143.6	121.5
25-40 years	138	4	46	119	180	566	141.3	125.1
41-64 years	221	1	45	120	223	682	147.9	122.4
≥ 65 years	149	5	30	93	210	502	143.2	128.0
Mitapivat	26	16	56	153	280	584	196.4	162.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	81	81	128	196	196	135.0	57.8
25-40 years	*****	16	56	168	319	472	192.9	150.5
41-64 years	*****	19	56	165	280	584	222.3	218.2
≥ 65 years	*****	89	104	158	282	367	192.8	124.6
Pacritinib	879	1	30	90	181	721	141.3	139.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	132	132	249	366	366	249.0	165.5
41-64 years	*****	1	30	90	149	618	130.6	144.4
≥ 65 years	804	2	30	90	186	721	142.0	138.5
Ganaxolone	23	17	102	158	357	542	223.6	171.6
0-17 years	*****	17	54	144	387	542	214.1	186.0
18-24 years	*****	115	182	303	433	508	307.3	166.5
25-40 years	*****	220	220	220	220	220	220.0	NaN
41-64 years	*****	133	133	135	136	136	134.5	2.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Vipivotide								
Tetraxetan	4,303	1	2	3	5	10	3.2	1.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	294	1	1	2	4	10	2.7	1.6
≥ 65 years	4,009	1	2	3	5	9	3.2	1.7
Oteseconazole	161	3	33	84	84	351	73.6	42.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	84	87	90	92	93	89.3	3.8
25-40 years	*****	6	34	80	84	168	69.0	33.9
41-64 years	90	4	30	84	84	252	70.4	39.4
≥ 65 years	44	3	63	84	87	351	81.0	52.0
Mavacamten	1,600	1	67	161	291	710	194.4	147.6
0-17 years	*****	428	428	428	428	428	428.0	NaN
18-24 years	*****	14	31	143	270	632	205.4	211.8
25-40 years	*****	9	87	201	341	642	235.6	172.7
41-64 years	366	2	62	139	290	627	191.5	157.0
≥ 65 years	1,176	1	68	167	288	710	193.3	142.7
Vonoprazan	431	1	13	25	47	180	33.6	29.9
0-17 years	*****	98	98	98	98	98	98.0	NaN
18-24 years	*****	14	14	25	42	43	28.0	12.6
25-40 years	*****	1	10	18	45	108	29.2	27.2
41-64 years	232	1	14	24	44	130	31.7	27.6
≥ 65 years	149	1	13	30	52	180	37.5	33.8
Tirzepatide	438,820	1	46	112	224	718	149.4	126.8
0-17 years	133	1	53	112	218	533	146.1	123.6
18-24 years	3,518	1	30	79	173	633	119.9	112.7
25-40 years	46,406	1	40	96	214	677	140.7	124.1
41-64 years	235,674	1	50	114	238	717	156.6	130.9
≥ 65 years	153,089	1	45	106	213	718	141.7	120.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tapinarof	14,042	1	30	30	60	540	58.1	51.0
0-17 years	264	4	30	30	60	316	55.1	42.3
18-24 years	619	1	30	30	60	390	52.6	44.4
25-40 years	2,911	1	30	30	60	450	53.5	45.9
41-64 years	6,953	1	30	30	76	540	61.0	52.8
≥ 65 years	3,295	1	30	30	60	480	57.1	52.7
Vutrisiran	607	1	2	3	4	550	46.9	117.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	139	276	276	138.5	194.5
41-64 years	*****	1	2	3	5	446	36.6	98.1
≥ 65 years	523	1	2	4	4	550	48.1	120.4
Deucravacitinib	1,517	1	30	90	179	501	118.9	99.6
0-17 years	*****	56	56	56	56	56	56.0	NaN
18-24 years	54	2	30	83	174	330	110.2	94.5
25-40 years	*****	1	30	74	137	450	99.4	84.1
41-64 years	726	1	34	90	180	476	121.8	97.6
≥ 65 years	458	1	30	90	180	501	127.4	110.1
Terlipressin	42	1	1	1	1	3	1.1	0.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	3	1.2	0.5
≥ 65 years	24	1	1	1	1	1	1.0	0.0
Gadopicleonol	22,748	1	1	1	1	6	1.1	0.3
0-17 years	351	1	1	1	1	3	1.1	0.3
18-24 years	327	1	1	1	1	2	1.0	0.2
25-40 years	1,880	1	1	1	1	4	1.1	0.3
41-64 years	7,429	1	1	1	1	6	1.1	0.3
≥ 65 years	12,761	1	1	1	1	6	1.1	0.3

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Omidenepag Isopropyl								
Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate								
and Taurursodiol	2,227	2	31	84	196	486	130.8	112.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	112	112	112	112	112	112.0	NaN
25-40 years	*****	5	28	84	180	392	121.3	103.9
41-64 years	682	3	56	112	231	476	149.7	121.7
≥ 65 years	1,477	2	28	84	182	486	122.5	107.3
Futibatinib	82	6	28	56	109	351	85.4	67.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	21	26	100	182	196	104.0	90.9
41-64 years	*****	6	56	74	111	280	89.3	66.4
≥ 65 years	46	14	28	56	84	351	81.1	68.0
Olutasidenib	51	13	47	65	135	374	108.7	95.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	60	89	240	84.8	79.2
≥ 65 years	*****	13	48	82	135	374	111.9	97.8
Adagrasib	351	1	30	54	99	330	74.0	64.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	57	57	57	57	57	57.0	NaN
41-64 years	*****	4	30	55	90	274	72.9	60.9

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	255	1	30	53	111	330	74.5	66.5
Lenacapavir	193	1	33	118	182	373	123.1	93.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	32	32	185	337	337	184.5	215.7
25-40 years	*****	1	13	53	185	314	99.7	98.5
41-64 years	115	1	33	113	185	373	123.6	94.4
≥ 65 years	51	1	59	136	170	330	130.8	84.7
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	196	1	10	22	44	105	28.7	23.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	56	56	61	65	65	60.5	6.4
41-64 years	*****	1	9	21	38	105	28.6	26.8
≥ 65 years	151	1	10	22	44	99	28.3	22.8
Faricimab-svoa	114,321	1	2	4	7	478	5.2	7.8
0-17 years	*****	1	1	1	1	6	1.8	2.0
18-24 years	11	1	1	1	3	5	1.8	1.3
25-40 years	294	1	1	2	4	20	3.4	2.9
41-64 years	*****	1	2	3	6	356	4.5	8.1
≥ 65 years	108,039	1	2	4	7	478	5.3	7.8
Sutimlimab-jome	170	1	4	12	24	350	18.6	36.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	4	21	36	11.8	16.2
41-64 years	*****	1	2	4	9	38	7.9	9.9
≥ 65 years	146	1	5	15	26	350	20.3	38.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Nivolumab and Relatlimab-rmbw	2,545	1	2	3	7	393	5.9	14.2
0-17 years	*****	3	3	3	3	3	3.0	NaN
18-24 years	*****	1	1	1	7	9	3.8	3.9
25-40 years	45	1	1	2	6	16	3.6	3.3
41-64 years	*****	1	2	4	7	149	5.6	8.7
≥ 65 years	2,113	1	2	4	7	393	6.0	15.2
Olipudase Alfa-rpcp	12	1	3	7	24	549	87.2	184.5
0-17 years	*****	22	22	24	26	26	24.0	2.8
18-24 years	*****	3	3	3	3	3	3.0	NaN
25-40 years	*****	2	6	7	7	403	85.0	177.8
41-64 years	*****	1	2	10	284	549	142.5	271.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	55	1	1	2	2	21	3.1	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	2	2	2	7	2.7	2.2
41-64 years	*****	1	1	1	2	14	2.2	3.0
≥ 65 years	30	1	1	2	3	21	3.8	4.7
Daxibotulinumtoxina-	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	1	1	2	4	140	3.5	7.0
0-17 years	*****	3	3	3	3	3	3.0	NaN
18-24 years	*****	4	4	5	6	6	5.0	1.4
25-40 years	*****	1	1	2	6	63	7.1	16.3
41-64 years	191	1	1	2	4	105	3.7	8.4
≥ 65 years	3,095	1	1	2	4	140	3.5	6.9

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tremelimumab-actl	972	1	1	1	1	112	1.8	5.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.6	2.5
≥ 65 years	818	1	1	1	1	112	1.9	5.6
Teclistamab-cqyv	1,233	1	1	2	8	57	5.2	6.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	5	9	9	5.0	4.0
41-64 years	*****	1	1	4	10	55	7.0	8.4
≥ 65 years	1,013	1	1	1	7	57	4.8	6.4
Mirvetuximab								
Soravtansine-gynx	280	1	2	4	6	16	4.5	3.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	2	2	5	6	6	4.2	1.8
41-64 years	138	1	2	3	6	14	4.2	3.0
≥ 65 years	*****	1	2	4	7	16	4.8	3.5
Teplizumab-mzwv	42	1	4	5	14	14	7.5	5.1
0-17 years	16	1	5	10	14	14	9.0	5.3
18-24 years	*****	1	1	2	5	14	4.6	5.5
25-40 years	13	1	5	5	5	14	6.1	3.8
41-64 years	*****	1	4	9	14	14	8.4	5.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	63	1	1	2	8	183	7.3	22.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	2	2	2	1.5	0.7
41-64 years	*****	1	2	7	10	183	17.9	45.9
≥ 65 years	46	1	1	2	6	14	4.1	4.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Anacaulase-bcdb	127	1	1	1	1	2	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	2	1.0	0.2
≥ 65 years	103	1	1	1	1	2	1.0	0.1
Ublituximab-xiiy	482	1	1	2	2	229	4.0	15.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	2	2	2	3	2.0	0.7
25-40 years	142	1	2	2	3	229	5.5	22.3
41-64 years	271	1	1	2	2	134	3.4	12.3
≥ 65 years	*****	1	1	2	2	77	3.6	10.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Daridorexant</i>	19,770	14,436	73.0%	3,848	19.5%	1,405	7.1%	81	0.4%	0	0.0%
<i>Abrocitinib</i>	1,312	716	54.6%	386	29.4%	193	14.7%	17	1.3%	0	0.0%
<i>Mitapivat</i>	55	28	50.9%	13	23.6%	*****	*****	*****	*****	0	0.0%
<i>Pacritinib</i>	1,992	1,150	57.7%	550	27.6%	271	13.6%	21	1.1%	0	0.0%
<i>Ganaxolone</i>	63	29	46.0%	18	28.6%	*****	*****	*****	*****	0	0.0%
<i>Lutetium Vipivotide</i>											
<i>Tetraxetan</i>	13,804	13,804	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Oteseconazole</i>	*****	41	24.0%	118	69.0%	*****	*****	0	0.0%	0	0.0%
<i>Mavacamten</i>	3,381	1,454	43.0%	956	28.3%	852	25.2%	119	3.5%	0	0.0%
<i>Vonoprazan</i>	491	365	74.3%	110	22.4%	16	3.3%	0	0.0%	0	0.0%
<i>Tirzepatide</i>	886,682	450,473	50.8%	244,657	27.6%	174,946	19.7%	16,606	1.9%	0	0.0%
<i>Tapinarof</i>	21,395	17,484	81.7%	3,094	14.5%	806	3.8%	11	0.1%	0	0.0%
<i>Vutrisiran</i>	1,695	1,522	89.8%	104	6.1%	55	3.2%	14	0.8%	0	0.0%
<i>Deucravacitinib</i>	3,086	1,829	59.3%	838	27.2%	*****	*****	*****	*****	0	0.0%
<i>Terlipressin</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gadopiclenol</i>	24,270	24,270	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Omidenepag</i>											
<i>Isopropyl Ophthalmic Sodium</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Phenylbutyrate and Taurursodiol</i>	4,525	2,607	57.6%	1,125	24.9%	751	16.6%	42	0.9%	0	0.0%
<i>Futibatinib</i>	171	114	66.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Olutasidenib</i>	84	44	52.4%	25	29.8%	15	17.9%	0	0.0%	0	0.0%
<i>Adagrasib</i>	587	403	68.7%	140	23.9%	44	7.5%	0	0.0%	0	0.0%
<i>Lenacapavir</i>	251	88	35.1%	47	18.7%	116	46.2%	0	0.0%	0	0.0%
<i>Hyperpolarized 129-</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tebentafusp-tebn</i>	5,612	5,612	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	567,077	566,887	100.0%	161	0.0%	29	0.0%	0	0.0%	0	0.0%
<i>Sutimlimab-jome</i>	2,516	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Nivolumab and</i>											
<i>Relatlimab-rmbw</i>	12,443	12,425	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Olipudase Alfa-rpcp</i>	102	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Spesolimab-sbzo</i>	94	94	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumtoxina-</i>											
<i>lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	9,613	9,599	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tremelimumab-actl</i>	1,235	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Teclistamab-cqyv</i>	6,335	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Mirvetuximab</i>											
<i>Soravtansine-gynx</i>	1,250	1,250	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Teplizumab-mzwv</i>	58	58	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mosunetuzumab-</i>	278	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Anacaulase-bcdb</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ublituximab-xiiy</i>	913	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Daridorexant</i>	19,770	1	30	30	48	577	47.0	49.8
<i>Abrocitinib</i>	1,312	1	30	30	80	600	66.4	71.6
<i>Mitapivat</i>	55	16	28	28	100	584	92.8	116.3
<i>Pacritinib</i>	1,992	1	30	30	60	721	62.4	68.1
<i>Ganaxolone</i>	63	3	27	48	101	508	81.6	96.2
<i>Lutetium Vipivotide</i>	13,804	1	1	1	1	2	1.0	0.0
<i>Oteseconazole</i>	*****	3	31	84	84	264	69.3	36.5
<i>Mavacamten</i>	3,381	1	30	52	117	642	92.0	102.6
<i>Vonoprazan</i>	491	1	14	26	31	180	29.5	25.1
<i>Tirzepatide</i>	886,682	1	28	30	84	718	74.0	84.0
<i>Tapinarof</i>	21,395	1	30	30	30	540	38.1	30.8
<i>Vutrisiran</i>	1,695	1	1	1	1	549	16.8	59.6
<i>Deucravacitinib</i>	3,086	1	30	30	60	470	58.5	58.0
<i>Terlipressin</i>	*****	1	1	1	1	1	1.0	0.0
<i>Gadopiclenol</i>	24,270	1	1	1	1	3	1.0	0.0
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	4,525	1	28	28	69	486	64.4	71.2
<i>Futibatinib</i>	171	1	28	28	56	226	41.0	31.6
<i>Olutasidenib</i>	84	13	30	30	61	322	66.0	64.6
<i>Adagrasib</i>	587	1	30	30	60	305	44.3	35.4
<i>Lenacapavir</i>	251	1	11	84	167	340	94.6	86.5
<i>Hyperpolarized 129-Xe</i>	61	1	1	1	1	1	1.0	0.0
<i>Tebentafusp-tebn</i>	5,612	1	1	1	1	14	1.0	0.2
<i>Faricimab-svoa</i>	567,077	1	1	1	1	248	1.1	1.7
<i>Sutimlimab-jome</i>	2,516	1	1	1	1	308	1.3	6.5
<i>Nivolumab and Relatlimab-rmbw</i>	12,443	1	1	1	1	224	1.2	4.5
<i>Olipudase Alfa-rpcp</i>	102	1	1	1	1	319	10.3	42.3
<i>Spesolimab-sbzo</i>	94	1	1	1	1	7	1.8	2.1
<i>DaxibotulinumtoxinA-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Eflapegrastim-xnst</i>	9,613	1	1	1	1	140	1.2	3.0
<i>Tremelimumab-actl</i>	1,235	1	1	1	1	56	1.4	3.6
<i>Teclistamab-cqyv</i>	6,335	1	1	1	1	35	1.0	0.7
<i>Mirvetuximab Soravtansine-gynx</i>	1,250	1	1	1	1	1	1.0	0.0
<i>Teplizumab-mzwv</i>	58	1	1	5	8	14	5.4	4.9
<i>Mosunetuzumab-axgb</i>	278	1	1	1	1	126	1.7	8.2
<i>Anacaulase-bcdb</i>	*****	1	1	1	1	1	1.0	0.0
<i>Ublituximab-xiiy</i>	913	1	1	1	1	198	2.1	10.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Daridorexant	19,770	14,436	100.0%	3,848	100.0%	1,405	100.0%	81	100.0%	0	NaN
Female	12,289	8,935	61.9%	2,423	63.0%	875	62.3%	56	69.1%	0	NaN
Male	7,481	5,501	38.1%	1,425	37.0%	530	37.7%	25	30.9%	0	NaN
Abrocitinib	1,312	716	100.0%	386	100.0%	193	100.0%	17	100.0%	0	NaN
Female	620	346	48.3%	178	46.1%	*****	*****	*****	*****	0	NaN
Male	692	370	51.7%	208	53.9%	*****	*****	*****	*****	0	NaN
Mitapivat	55	28	100.0%	13	100.0%	*****	*****	*****	*****	0	NaN
Female	30	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	25	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pacritinib	1,992	1,150	100.0%	550	100.0%	271	100.0%	21	100.0%	0	NaN
Female	924	552	48.0%	242	44.0%	*****	*****	*****	*****	0	NaN
Male	1,068	598	52.0%	308	56.0%	*****	*****	*****	*****	0	NaN
Ganaxolone	63	29	100.0%	18	100.0%	*****	*****	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Lutetium Vipivotide											
Tetraxetan	13,804	13,804	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole	*****	41	100.0%	118	100.0%	*****	*****	0	NaN	0	NaN
Female	*****	41	100.0%	118	100.0%	*****	*****	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Mavacamten	3,381	1,454	100.0%	956	100.0%	852	100.0%	119	100.0%	0	NaN
Female	2,268	968	66.6%	644	67.4%	575	67.5%	81	68.1%	0	NaN
Male	1,113	486	33.4%	312	32.6%	277	32.5%	38	31.9%	0	NaN
Vonoprazan	491	365	100.0%	110	100.0%	16	100.0%	0	NaN	0	NaN
Female	302	223	61.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	189	142	38.9%	*****	*****	*****	*****	0	NaN	0	NaN
Tirzepatide	886,682	450,473	100.0%	244,657	100.0%	174,946	100.0%	16,606	100.0%	0	NaN
Female	555,293	283,710	63.0%	152,346	62.3%	108,502	62.0%	10,735	64.6%	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	331,389	166,763	37.0%	92,311	37.7%	66,444	38.0%	5,871	35.4%	0	NaN
Tapinarof	21,395	17,484	100.0%	3,094	100.0%	806	100.0%	11	100.0%	0	NaN
Female	10,991	9,035	51.7%	1,545	49.9%	*****	*****	*****	*****	0	NaN
Male	10,404	8,449	48.3%	1,549	50.1%	*****	*****	*****	*****	0	NaN
Vutrisiran	1,695	1,522	100.0%	104	100.0%	55	100.0%	14	100.0%	0	NaN
Female	595	519	34.1%	42	40.4%	*****	*****	*****	*****	0	NaN
Male	1,100	1,003	65.9%	62	59.6%	*****	*****	*****	*****	0	NaN
Deucravacitinib	3,086	1,829	100.0%	838	100.0%	*****	*****	*****	*****	0	NaN
Female	1,626	978	53.5%	428	51.1%	*****	*****	*****	*****	0	NaN
Male	1,460	851	46.5%	410	48.9%	*****	*****	*****	*****	0	NaN
Terlipressin	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Gadopiclenol	24,270	24,270	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	14,183	14,183	58.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	10,087	10,087	41.6%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl											
Ophthalmic Solution	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
Sodium											
Phenylbutyrate and	4,525	2,607	100.0%	1,125	100.0%	751	100.0%	42	100.0%	0	NaN
Female	2,019	1,202	46.1%	506	45.0%	295	39.3%	16	38.1%	0	NaN
Male	2,506	1,405	53.9%	619	55.0%	456	60.7%	26	61.9%	0	NaN
Futibatinib	171	114	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	99	65	57.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	72	49	43.0%	*****	*****	*****	*****	0	NaN	0	NaN
Olutasidenib	84	44	100.0%	25	100.0%	15	100.0%	0	NaN	0	NaN
Female	40	23	52.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	44	21	47.7%	*****	*****	*****	*****	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Adagrasib	587	403	100.0%	140	100.0%	44	100.0%	0	NaN	0	NaN
Female	362	249	61.8%	82	58.6%	31	70.5%	0	NaN	0	NaN
Male	225	154	38.2%	58	41.4%	13	29.5%	0	NaN	0	NaN
Lenacapavir	251	88	100.0%	47	100.0%	116	100.0%	0	NaN	0	NaN
Female	53	*****	*****	*****	*****	31	26.7%	0	NaN	0	NaN
Male	198	*****	*****	*****	*****	85	73.3%	0	NaN	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	36	36	59.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	25	25	41.0%	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	5,612	5,612	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	3,012	3,012	53.7%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,600	2,600	46.3%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-svoa	567,077	566,887	100.0%	161	100.0%	29	100.0%	0	NaN	0	NaN
Female	333,619	333,504	58.8%	101	62.7%	14	48.3%	0	NaN	0	NaN
Male	233,458	233,383	41.2%	60	37.3%	15	51.7%	0	NaN	0	NaN
Sutimlimab-jome	2,516	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,812	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	704	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	12,443	12,425	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	4,552	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	7,891	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa-rpcp	102	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	68	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	34	34	35.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
Spesolimab-sbzo	94	94	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	61	61	64.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	33	33	35.1%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinumtoxina- lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,613	9,599	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	5,211	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	4,402	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab-actl	1,235	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	341	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	894	894	72.5%	0	0.0%	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	6,335	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	3,026	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	3,309	3,309	52.3%	0	0.0%	0	NaN	0	NaN	0	NaN
Mirvetuximab											
Soravtansine-gynx	1,250	1,250	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	58	58	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	28	28	48.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	30	30	51.7%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Mosunetuzumab-axgb	278	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	125	125	45.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
Male	153	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Anacaulase-bcdb	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-xiiy	913	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	673	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	240	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	19,770	1	30	30	48	577	47.0	49.8
Female	12,289	1	30	30	51	577	47.4	50.4
Male	7,481	1	30	30	45	542	46.5	48.9
Abrocitinib	1,312	1	30	30	80	600	66.4	71.6
Female	620	1	30	30	72	592	65.0	70.2
Male	692	1	30	30	88	600	67.6	72.8
Mitapivat	55	16	28	28	100	584	92.8	116.3
Female	30	16	28	56	168	584	119.9	139.6
Male	25	19	28	28	56	339	60.4	70.0
Pacritinib	1,992	1	30	30	60	721	62.4	68.1
Female	924	1	30	30	60	721	61.5	69.7
Male	1,068	1	30	30	60	635	63.1	66.8
Ganaxolone	63	3	27	48	101	508	81.6	96.2
Female	*****	3	27	43	81	508	82.5	99.5
Male	*****	17	40	57	115	128	71.4	48.1
Lutetium Vipivotide								
Tetraxetan	13,804	1	1	1	1	2	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	2	1.0	0.0
Oteseconazole	*****	3	31	84	84	264	69.3	36.5
Female	*****	3	31	84	84	264	69.3	36.5
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	3,381	1	30	52	117	642	92.0	102.6
Female	2,268	1	30	55	119	602	92.6	102.2
Male	1,113	1	30	46	112	642	90.7	103.4
Vonoprazan	491	1	14	26	31	180	29.5	25.1
Female	302	1	12	26	31	130	29.3	25.1
Male	189	1	14	27	30	180	29.7	25.2
Tirzepatide	886,682	1	28	30	84	718	74.0	84.0
Female	555,293	1	28	30	84	718	73.9	84.4
Male	331,389	1	28	30	84	694	74.0	83.2
Tapinarof	21,395	1	30	30	30	540	38.1	30.8

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	10,991	1	30	30	30	540	38.0	30.9
Male	10,404	1	30	30	30	399	38.3	30.7
Vutrisiran	1,695	1	1	1	1	549	16.8	59.6
Female	595	1	1	1	1	520	23.0	73.0
Male	1,100	1	1	1	1	549	13.4	50.6
Deucravacitinib	3,086	1	30	30	60	470	58.5	58.0
Female	1,626	1	30	30	60	438	58.0	57.6
Male	1,460	1	30	30	60	470	58.9	58.5
Terlipressin	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Gadopiclenol	24,270	1	1	1	1	3	1.0	0.0
Female	14,183	1	1	1	1	3	1.0	0.0
Male	10,087	1	1	1	1	2	1.0	0.0
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	4,525	1	28	28	69	486	64.4	71.2
Female	2,019	1	28	28	56	434	60.3	66.1
Male	2,506	1	28	28	84	486	67.6	75.0
Futibatinib	171	1	28	28	56	226	41.0	31.6
Female	99	7	28	28	56	226	42.8	35.9
Male	72	1	28	28	53	165	38.4	24.6
Olutasidenib	84	13	30	30	61	322	66.0	64.6
Female	40	15	30	30	60	297	56.8	57.7
Male	44	13	30	49	101	322	74.4	69.9
Adagrasib	587	1	30	30	60	305	44.3	35.4
Female	362	1	30	30	60	305	45.4	38.3
Male	225	1	30	30	58	180	42.4	30.1
Lenacapavir	251	1	11	84	167	340	94.6	86.5

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	53	1	21	123	170	337	112.5	92.6
Male	198	1	8	77	159	340	89.8	84.4
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
Female	36	1	1	1	1	1	1.0	0.0
Male	25	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	5,612	1	1	1	1	14	1.0	0.2
Female	3,012	1	1	1	1	14	1.0	0.2
Male	2,600	1	1	1	1	2	1.0	0.0
Faricimab-svoa	567,077	1	1	1	1	248	1.1	1.7
Female	333,619	1	1	1	1	248	1.1	1.7
Male	233,458	1	1	1	1	210	1.1	1.7
Sutimlimab-jome	2,516	1	1	1	1	308	1.3	6.5
Female	1,812	1	1	1	1	56	1.2	2.5
Male	704	1	1	1	1	308	1.5	11.6
Nivolumab and Relatlimab-rmbw	12,443	1	1	1	1	224	1.2	4.5
Female	4,552	1	1	1	1	224	1.2	5.5
Male	7,891	1	1	1	1	168	1.2	3.9
Olipudase Alfa-rpcp	102	1	1	1	1	319	10.3	42.3
Female	68	1	1	1	1	319	14.9	51.3
Male	34	1	1	1	1	1	1.0	0.0
Spesolimab-sbzo	94	1	1	1	1	7	1.8	2.1
Female	61	1	1	1	1	7	1.8	2.0
Male	33	1	1	1	1	7	1.9	2.2
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,613	1	1	1	1	140	1.2	3.0
Female	5,211	1	1	1	1	126	1.2	2.9
Male	4,402	1	1	1	1	140	1.2	3.1
Tremelimumab-actl	1,235	1	1	1	1	56	1.4	3.6
Female	341	1	1	1	1	56	1.7	5.1

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	894	1	1	1	1	30	1.3	2.9
Teclistamab-cqyv	6,335	1	1	1	1	35	1.0	0.7
Female	3,026	1	1	1	1	35	1.0	0.9
Male	3,309	1	1	1	1	7	1.0	0.2
Mirvetuximab Soravtansine-gynx	1,250	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	58	1	1	5	8	14	5.4	4.9
Female	28	1	1	5	7	14	5.2	4.5
Male	30	1	1	5	14	14	5.6	5.4
Mosunetuzumab-axgb	278	1	1	1	1	126	1.7	8.2
Female	125	1	1	1	1	2	1.0	0.1
Male	153	1	1	1	1	126	2.2	11.0
Anacaulase-bcdb	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	913	1	1	1	1	198	2.1	10.1
Female	673	1	1	1	1	198	2.1	10.0
Male	240	1	1	1	1	134	2.2	10.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Daridorexant	19,770	14,436	100.0%	3,848	100.0%	1,405	100.0%	81	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	17	1.2%	*****	*****	0	NaN
25-40 years	2,131	1,505	10.4%	465	12.1%	*****	*****	*****	*****	0	NaN
41-64 years	10,107	7,230	50.1%	2,066	53.7%	763	54.3%	48	59.3%	0	NaN
≥ 65 years	7,251	5,496	38.1%	1,259	32.7%	*****	*****	*****	*****	0	NaN
Abrocitinib	1,312	716	100.0%	386	100.0%	193	100.0%	17	100.0%	0	NaN
0-17 years	48	25	3.5%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	182	107	14.9%	56	14.5%	*****	*****	*****	*****	0	NaN
25-40 years	324	184	25.7%	*****	*****	43	22.3%	*****	*****	0	NaN
41-64 years	463	238	33.2%	140	36.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	295	162	22.6%	*****	*****	47	24.4%	*****	*****	0	NaN
Mitapivat	55	28	100.0%	13	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	17	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	17	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pacritinib	1,992	1,150	100.0%	550	100.0%	271	100.0%	21	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	87	7.6%	*****	*****	23	8.5%	*****	*****	0	NaN
≥ 65 years	1,837	1,063	92.4%	509	92.5%	*****	*****	*****	*****	0	NaN
Ganaxolone	63	29	100.0%	18	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	52	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Lutetium Vipivotide											
Tetraxetan	13,804	13,804	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	793	793	5.7%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	13,011	13,011	94.3%	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole	*****	41	100.0%	118	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	95	*****	*****	60	50.8%	*****	*****	0	NaN	0	NaN
≥ 65 years	47	*****	*****	37	31.4%	*****	*****	0	NaN	0	NaN
Mavacamten	3,381	1,454	100.0%	956	100.0%	852	100.0%	119	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	137	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	837	412	28.3%	228	23.8%	*****	*****	*****	*****	0	NaN
≥ 65 years	2,393	966	66.4%	689	72.1%	661	77.6%	77	64.7%	0	NaN
Vonoprazan	491	365	100.0%	110	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	11	10.0%	0	0.0%	0	NaN	0	NaN
41-64 years	258	197	54.0%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	176	126	34.5%	*****	*****	*****	*****	0	NaN	0	NaN
Tirzepatide	886,682	450,473	100.0%	244,657	100.0%	174,946	100.0%	16,606	100.0%	0	NaN
0-17 years	264	139	0.0%	68	0.0%	*****	*****	*****	*****	0	NaN
18-24 years	7,039	4,109	0.9%	1,876	0.8%	*****	*****	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	93,266	50,041	11.1%	25,148	10.3%	16,313	9.3%	1,764	10.6%	0	NaN
41-64 years	479,025	239,995	53.3%	130,339	53.3%	97,726	55.9%	10,965	66.0%	0	NaN
≥ 65 years	307,088	156,189	34.7%	87,226	35.7%	59,875	34.2%	3,798	22.9%	0	NaN
Tapinarof	21,395	17,484	100.0%	3,094	100.0%	806	100.0%	11	100.0%	0	NaN
0-17 years	389	325	1.9%	51	1.6%	13	1.6%	0	0.0%	0	NaN
18-24 years	906	766	4.4%	114	3.7%	26	3.2%	0	0.0%	0	NaN
25-40 years	4,222	3,523	20.1%	559	18.1%	140	17.4%	0	0.0%	0	NaN
41-64 years	10,904	8,791	50.3%	1,661	53.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	4,974	4,079	23.3%	709	22.9%	*****	*****	*****	*****	0	NaN
Vutrisiran	1,695	1,522	100.0%	104	100.0%	55	100.0%	14	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,463	1,312	86.2%	*****	*****	*****	*****	14	100.0%	0	NaN
Deucravacitinib	3,086	1,829	100.0%	838	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	77	4.2%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	552	360	19.7%	137	16.3%	*****	*****	*****	*****	0	NaN
41-64 years	1,526	904	49.4%	418	49.9%	*****	*****	*****	*****	0	NaN
≥ 65 years	886	488	26.7%	248	29.6%	*****	*****	*****	*****	0	NaN
Terlipressin	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	24	24	53.3%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopichlenol	24,270	24,270	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	373	373	1.5%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	335	335	1.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	2,026	2,026	8.3%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	8,042	8,042	33.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	13,494	13,494	55.6%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag											
Isopropyl Ophthalmic											
Solution	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Sodium											
Phenylbutyrate and											
Taurursodiol	4,525	2,607	100.0%	1,125	100.0%	751	100.0%	42	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	19	2.5%	0	0.0%	0	NaN
41-64 years	1,495	852	32.7%	370	32.9%	251	33.4%	22	52.4%	0	NaN
≥ 65 years	2,884	1,659	63.6%	724	64.4%	481	64.0%	20	47.6%	0	NaN
Futibatinib	171	114	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	95	68	59.6%	*****	*****	*****	*****	0	NaN	0	NaN
Olutasidenib	84	44	100.0%	25	100.0%	15	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	13	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	71	*****	*****	*****	*****	15	100.0%	0	NaN	0	NaN
Adagrasib	587	403	100.0%	140	100.0%	44	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	118	29.3%	36	25.7%	*****	*****	0	NaN	0	NaN
≥ 65 years	422	*****	*****	104	74.3%	*****	*****	0	NaN	0	NaN
Lenacapavir	251	88	100.0%	47	100.0%	116	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	152	*****	*****	*****	*****	69	59.5%	0	NaN	0	NaN
≥ 65 years	65	16	18.2%	15	31.9%	34	29.3%	0	NaN	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	5,612	5,612	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	121	121	2.2%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,229	1,229	21.9%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,262	4,262	75.9%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-svoa	567,077	566,887	100.0%	161	100.0%	29	100.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	11	11	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	20	20	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	965	965	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	24,865	24,852	4.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	541,216	541,039	95.4%	*****	*****	*****	*****	0	NaN	0	NaN
Sutimlimab-jome	2,516	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	47	47	1.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	149	149	5.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	12,443	12,425	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	19	19	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	160	160	1.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	10,304	10,287	82.8%	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa-rpcp	102	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	48	48	50.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Spesolimab-sbzo	94	94	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	54	54	57.4%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinumtoxin											
a-lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,613	9,599	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	38	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	512	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	9,050	9,039	94.2%	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab-actl	1,235	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,025	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	6,335	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	14	14	0.2%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	1,523	1,523	24.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	4,798	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Mirvetuximab											
Soravtansine-gynx	1,250	1,250	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	576	576	46.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	648	648	51.8%	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	58	58	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	21	21	36.2%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	20	20	34.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzumab-axgb	278	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	190	190	68.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
Anacaulase-bcdb	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	104	104	80.6%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ublituximab-xiiy	913	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	20	20	2.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	283	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	509	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	101	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	19,770	1	30	30	48	577	47.0	49.8
0-17 years	*****	30	30	30	45	60	37.5	15.0
18-24 years	*****	2	30	30	52	420	44.9	43.2
25-40 years	2,131	1	30	30	60	577	47.4	50.3
41-64 years	10,107	1	30	30	60	542	48.6	52.4
≥ 65 years	7,251	1	30	30	30	526	44.8	46.0
Abrocitinib	1,312	1	30	30	80	600	66.4	71.6
0-17 years	48	1	30	30	60	213	55.0	44.3
18-24 years	182	1	30	30	60	420	60.0	63.7
25-40 years	324	1	30	30	60	510	60.2	63.3
41-64 years	463	1	30	30	90	600	70.6	75.4
≥ 65 years	295	5	30	30	90	502	72.3	80.9
Mitapivat	55	16	28	28	100	584	92.8	116.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	28	42	70	100	50.6	28.8
25-40 years	17	16	28	56	151	392	113.5	117.0
41-64 years	17	19	28	28	165	584	117.7	152.6
≥ 65 years	*****	28	28	28	56	339	59.3	85.2
Pacritinib	1,992	1	30	30	60	721	62.4	68.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	96	141	153	156	124.5	44.2
41-64 years	*****	1	30	30	86	420	63.2	64.5
≥ 65 years	1,837	1	30	30	60	721	62.2	68.4
Ganaxolone	63	3	27	48	101	508	81.6	96.2
0-17 years	52	3	26	39	69	319	65.9	68.8
18-24 years	*****	115	182	303	433	508	307.3	166.5
25-40 years	*****	220	220	220	220	220	220.0	NaN
41-64 years	*****	24	27	28	54	109	44.8	33.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Vipivotide								
Tetraxetan	13,804	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	793	1	1	1	1	2	1.0	0.0
≥ 65 years	13,011	1	1	1	1	2	1.0	0.0
Oteseconazole	*****	3	31	84	84	264	69.3	36.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	84	87	90	92	93	89.3	3.8
25-40 years	*****	6	30	80	84	90	63.5	27.5
41-64 years	95	3	30	84	84	252	66.7	38.7
≥ 65 years	47	3	66	84	84	264	75.8	36.8
Mavacamten	3,381	1	30	52	117	642	92.0	102.6
0-17 years	*****	428	428	428	428	428	428.0	NaN
18-24 years	*****	14	30	31	95	632	110.6	171.7
25-40 years	137	1	30	30	90	642	86.0	105.7
41-64 years	837	1	30	33	90	602	83.8	104.6
≥ 65 years	2,393	1	30	60	120	585	95.0	100.9
Vonoprazan	491	1	14	26	31	180	29.5	25.1
0-17 years	*****	30	30	30	38	38	32.7	4.6
18-24 years	*****	14	14	25	42	43	28.0	12.6
25-40 years	*****	1	10	21	30	90	26.1	22.9
41-64 years	258	1	14	25	30	130	28.5	24.0
≥ 65 years	176	1	13	30	33	180	31.7	27.8
Tirzepatide	886,682	1	28	30	84	718	74.0	84.0
0-17 years	264	1	28	28	84	472	73.6	85.8
18-24 years	7,039	1	28	28	58	550	59.9	69.2
25-40 years	93,266	1	28	28	84	672	70.0	82.1
41-64 years	479,025	1	28	30	84	717	77.1	88.5

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	307,088	1	28	30	84	718	70.7	77.1
Tapinarof	21,395	1	30	30	30	540	38.1	30.8
0-17 years	389	4	30	30	30	316	37.4	29.2
18-24 years	906	1	30	30	30	284	36.0	25.4
25-40 years	4,222	1	30	30	30	276	36.9	27.1
41-64 years	10,904	1	30	30	30	540	38.9	32.2
≥ 65 years	4,974	1	30	30	30	406	37.8	31.7
Vutrisiran	1,695	1	1	1	1	549	16.8	59.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	46	90	93	96	69.3	45.6
41-64 years	*****	1	1	1	1	325	13.2	48.2
≥ 65 years	1,463	1	1	1	1	549	17.2	61.2
Deucravacitinib	3,086	1	30	30	60	470	58.5	58.0
0-17 years	*****	56	56	56	56	56	56.0	NaN
18-24 years	*****	1	30	30	60	307	49.2	44.1
25-40 years	552	1	30	30	60	420	50.1	47.0
41-64 years	1,526	1	30	30	60	418	58.0	56.0
≥ 65 years	886	1	30	30	80	470	65.8	67.7
Terlipressin	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	24	1	1	1	1	1	1.0	0.0
Gadopiclenol	24,270	1	1	1	1	3	1.0	0.0
0-17 years	373	1	1	1	1	1	1.0	0.0
18-24 years	335	1	1	1	1	2	1.0	0.1
25-40 years	2,026	1	1	1	1	3	1.0	0.1
41-64 years	8,042	1	1	1	1	2	1.0	0.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	13,494	1	1	1	1	2	1.0	0.0
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	4,525	1	28	28	69	486	64.4	71.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	56	56	37.3	16.2
25-40 years	*****	4	28	28	56	364	56.8	65.4
41-64 years	1,495	1	28	28	77	431	68.3	78.1
≥ 65 years	2,884	1	28	28	67	486	62.7	67.6
Futibatinib	171	1	28	28	56	226	41.0	31.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	21	28	31	112	140	59.4	47.5
41-64 years	*****	1	28	28	56	222	41.4	34.2
≥ 65 years	95	6	28	28	56	226	39.3	28.1
Olutasidenib	84	13	30	30	61	322	66.0	64.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	13	30	30	30	30	90	39.2	18.8
≥ 65 years	71	13	30	44	90	322	70.9	68.8
Adagrasib	587	1	30	30	60	305	44.3	35.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	*****	27	27	29	30	30	28.5	2.1
41-64 years	*****	4	30	30	45	236	42.5	32.7
≥ 65 years	422	1	30	30	60	305	45.0	36.4
Lenacapavir	251	1	11	84	167	340	94.6	86.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	32	32	185	337	337	184.5	215.7
25-40 years	*****	1	3	32	155	274	77.9	84.3
41-64 years	152	1	5	80	161	340	93.5	89.6
≥ 65 years	65	1	34	103	168	279	102.6	75.4
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	5,612	1	1	1	1	14	1.0	0.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	121	1	1	1	1	1	1.0	0.0
41-64 years	1,229	1	1	1	1	1	1.0	0.0
≥ 65 years	4,262	1	1	1	1	14	1.0	0.2
Faricimab-svoa	567,077	1	1	1	1	248	1.1	1.7
0-17 years	11	1	1	1	1	1	1.0	0.0
18-24 years	20	1	1	1	1	1	1.0	0.0
25-40 years	965	1	1	1	1	16	1.0	0.5
41-64 years	24,865	1	1	1	1	112	1.1	1.9
≥ 65 years	541,216	1	1	1	1	248	1.1	1.7
Sutimlimab-jome	2,516	1	1	1	1	308	1.3	6.5
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	47	1	1	1	1	1	1.0	0.0
41-64 years	149	1	1	1	1	2	1.0	0.1
≥ 65 years	*****	1	1	1	1	308	1.3	6.8
Nivolumab and Relatlimab-rmbw	12,443	1	1	1	1	224	1.2	4.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	19	1	1	1	1	1	1.0	0.0
25-40 years	160	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	84	1.1	2.2
≥ 65 years	10,304	1	1	1	1	224	1.2	4.9
Olipudase Alfa-rpcp	102	1	1	1	1	319	10.3	42.3
0-17 years	48	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	319	17.7	66.4
41-64 years	27	1	1	1	1	241	21.1	52.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	94	1	1	1	1	7	1.8	2.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	7	1.6	1.9
41-64 years	*****	1	1	1	1	7	1.4	1.5
≥ 65 years	54	1	1	1	1	7	2.1	2.4
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	9,613	1	1	1	1	140	1.2	3.0
0-17 years	*****	1	1	1	1	1	1.0	0.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	38	1	1	1	1	42	2.6	7.3
41-64 years	512	1	1	1	1	63	1.4	3.8
≥ 65 years	9,050	1	1	1	1	140	1.2	2.9
Tremelimumab-actl	1,235	1	1	1	1	56	1.4	3.6
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.1	1.9
≥ 65 years	1,025	1	1	1	1	56	1.5	3.9
Teclistamab-cqyv	6,335	1	1	1	1	35	1.0	0.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	14	1	1	1	1	2	1.1	0.3
41-64 years	1,523	1	1	1	1	2	1.0	0.0
≥ 65 years	4,798	1	1	1	1	35	1.0	0.8
Mirvetuximab								
Soravtansine-gynx	1,250	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	576	1	1	1	1	1	1.0	0.0
≥ 65 years	648	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	58	1	1	5	8	14	5.4	4.9
0-17 years	21	1	1	5	14	14	6.9	5.6
18-24 years	*****	1	1	1	5	14	3.8	5.2
25-40 years	20	1	1	4	5	14	4.0	3.9
41-64 years	*****	1	1	5	9	14	6.1	4.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	278	1	1	1	1	126	1.7	8.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	126	3.2	14.8
≥ 65 years	190	1	1	1	1	1	1.0	0.0
Anacaulase-bcdb	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	104	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	913	1	1	1	1	198	2.1	10.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	1	1	1	1	1.0	0.0
25-40 years	283	1	1	1	1	198	2.7	13.7
41-64 years	509	1	1	1	1	134	1.8	8.2
≥ 65 years	101	1	1	1	1	77	2.1	7.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Daridorexant</i>	10,520	7,937	75.4%	1,781	16.9%	732	7.0%	70	0.7%	0	0.0%
<i>Abrocitinib</i>	609	312	51.2%	181	29.7%	104	17.1%	12	2.0%	0	0.0%
<i>Mitapivat</i>	26	11	42.3%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Pacritinib</i>	879	501	57.0%	233	26.5%	131	14.9%	14	1.6%	0	0.0%
<i>Ganaxolone</i>	23	*****	*****	*****	*****	12	52.2%	*****	*****	0	0.0%
<i>Lutetium Vipivotide</i>											
<i>Tetraxetan</i>	4,303	4,303	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Oteseconazole</i>	161	37	23.0%	112	69.6%	12	7.5%	0	0.0%	0	0.0%
<i>Mavacamten</i>	1,600	728	45.5%	399	24.9%	401	25.1%	72	4.5%	0	0.0%
<i>Vonoprazan</i>	431	320	74.2%	95	22.0%	16	3.7%	0	0.0%	0	0.0%
<i>Tirzepatide</i>	438,820	205,473	46.8%	121,267	27.6%	99,257	22.6%	12,823	2.9%	0	0.0%
<i>Tapinarof</i>	14,042	11,354	80.9%	2,106	15.0%	*****	*****	*****	*****	0	0.0%
<i>Vutrisiran</i>	607	518	85.3%	42	6.9%	35	5.8%	12	2.0%	0	0.0%
<i>Deucravacitinib</i>	1,517	876	57.7%	382	25.2%	*****	*****	*****	*****	0	0.0%
<i>Terlipressin</i>	42	42	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gadopicolenol</i>	22,748	22,748	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Omidenepag</i>											
<i>Isopropyl Ophthalmic Sodium</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Phenylbutyrate and Futibatinib</i>	2,227	1,154	51.8%	584	26.2%	452	20.3%	37	1.7%	0	0.0%
<i>Olutasidenib</i>	82	49	59.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Adagrasib</i>	51	26	51.0%	14	27.5%	11	21.6%	0	0.0%	0	0.0%
<i>Adagrasib</i>	351	246	70.1%	77	21.9%	28	8.0%	0	0.0%	0	0.0%
<i>Lenacapavir</i>	193	61	31.6%	35	18.1%	97	50.3%	0	0.0%	0	0.0%
<i>Hyperpolarized 129-Tebentafusp-tebn</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	196	196	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	114,321	114,261	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Sutimlimab-jome</i>	170	170	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Nivolumab and Relatlimab-rmbw</i>	2,545	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Olipudase Alfa-rpcp</i>	12	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Spesolimab-sbzo</i>	55	55	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumtoxina-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	3,303	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tremelimumab-actl</i>	972	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Teclistamab-cqyv</i>	1,233	1,233	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mirvetuximab</i>											
<i>Soravtansine-gynx</i>	280	280	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Teplizumab-mzwv</i>	42	42	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mosunetuzumab-</i>	63	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Anacaulase-bcdb</i>	127	127	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ublituximab-xiiy</i>	482	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Daridorexant</i>	10,520	1	30	30	30	542	47.6	54.7
<i>Abrocitinib</i>	609	1	30	30	90	600	73.5	81.2
<i>Mitapivat</i>	26	16	28	56	140	584	107.4	132.3
<i>Pacritinib</i>	879	1	30	30	60	721	68.4	81.9
<i>Ganaxolone</i>	23	17	28	109	239	508	142.0	132.2
<i>Lutetium Vipivotide</i>	4,303	1	1	1	1	1	1.0	0.0
<i>Oteseconazole</i>	161	3	31	84	84	264	70.3	36.6
<i>Mavacamten</i>	1,600	1	30	37	120	642	97.7	112.7
<i>Vonoprazan</i>	431	1	13	25	31	180	29.5	26.0
<i>Tirzepatide</i>	438,820	1	28	44	96	718	84.3	95.3
<i>Tapinarof</i>	14,042	1	30	30	30	540	39.1	32.0
<i>Vutrisiran</i>	607	1	1	1	1	549	29.6	85.7
<i>Deucravacitinib</i>	1,517	1	30	30	81	470	65.2	67.7
<i>Terlipressin</i>	42	1	1	1	1	1	1.0	0.0
<i>Gadopiclenol</i>	22,748	1	1	1	1	3	1.0	0.0
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	2,227	2	28	28	84	486	75.5	83.3
<i>Futibatinib</i>	82	6	28	28	56	226	47.3	39.4
<i>Olutasidenib</i>	51	13	30	30	90	322	73.4	72.5
<i>Adagrasib</i>	351	1	30	30	60	305	44.5	37.1
<i>Lenacapavir</i>	193	1	13	92	170	340	103.4	90.5
<i>Hyperpolarized 129-Xe</i>	61	1	1	1	1	1	1.0	0.0
<i>Tebentafusp-tebn</i>	196	1	1	1	1	14	1.1	0.9
<i>Faricimab-svoa</i>	114,321	1	1	1	1	210	1.1	2.1
<i>Sutimlimab-jome</i>	170	1	1	1	1	15	1.2	1.5
<i>Nivolumab and Relatlimab-rmbw</i>	2,545	1	1	1	1	224	1.5	7.2
<i>Olipudase Alfa-rpcp</i>	12	1	1	1	1	84	10.2	24.5
<i>Spesolimab-sbzo</i>	55	1	1	1	1	7	1.9	2.1
<i>DaxibotulinumtoxinA-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Eflapegrastim-xnst</i>	3,303	1	1	1	1	140	1.3	4.2
<i>Tremelimumab-actl</i>	972	1	1	1	1	42	1.4	3.5
<i>Teclistamab-cqyv</i>	1,233	1	1	1	1	3	1.0	0.1
<i>Mirvetuximab Soravtansine- gynx</i>	280	1	1	1	1	1	1.0	0.0
<i>Teplizumab-mzwv</i>	42	1	1	5	14	14	6.4	5.2
<i>Mosunetuzumab-axgb</i>	63	1	1	1	1	57	1.9	7.1
<i>Anacaulase-bcdb</i>	127	1	1	1	1	1	1.0	0.0
<i>Ublituximab-xiiy</i>	482	1	1	1	1	198	2.3	12.2

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Se

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Daridorexant	10,520	7,937	100.0%	1,781	100.0%	732	100.0%	70	100.0%	0	NaN
Female	6,568	4,943	62.3%	1,111	62.4%	468	63.9%	46	65.7%	0	NaN
Male	3,952	2,994	37.7%	670	37.6%	264	36.1%	24	34.3%	0	NaN
Abrocitinib	609	312	100.0%	181	100.0%	104	100.0%	12	100.0%	0	NaN
Female	315	162	51.9%	94	51.9%	*****	*****	*****	*****	0	NaN
Male	294	150	48.1%	87	48.1%	*****	*****	*****	*****	0	NaN
Mitapivat	26	11	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pacritinib	879	501	100.0%	233	100.0%	131	100.0%	14	100.0%	0	NaN
Female	396	241	48.1%	96	41.2%	*****	*****	*****	*****	0	NaN
Male	483	260	51.9%	137	58.8%	*****	*****	*****	*****	0	NaN
Ganaxolone	23	*****	*****	*****	*****	12	100.0%	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Lutetium Vipivotide											
Tetraxetan	4,303	4,303	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole	161	37	100.0%	112	100.0%	12	100.0%	0	NaN	0	NaN
Female	161	37	100.0%	112	100.0%	12	100.0%	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Mavacamten	1,600	728	100.0%	399	100.0%	401	100.0%	72	100.0%	0	NaN
Female	1,072	493	67.7%	276	69.2%	258	64.3%	45	62.5%	0	NaN
Male	528	235	32.3%	123	30.8%	143	35.7%	27	37.5%	0	NaN
Vonoprazan	431	320	100.0%	95	100.0%	16	100.0%	0	NaN	0	NaN
Female	271	197	61.6%	*****	*****	*****	*****	0	NaN	0	NaN
Male	160	123	38.4%	*****	*****	*****	*****	0	NaN	0	NaN
Tirzepatide	438,820	205,473	100.0%	121,267	100.0%	99,257	100.0%	12,823	100.0%	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Se

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	273,416	127,570	62.1%	75,524	62.3%	62,036	62.5%	8,286	64.6%	0	NaN
Male	165,404	77,903	37.9%	45,743	37.7%	37,221	37.5%	4,537	35.4%	0	NaN
Tapinarof	14,042	11,354	100.0%	2,106	100.0%	*****	*****	*****	*****	0	NaN
Female	7,303	5,963	52.5%	1,049	49.8%	*****	*****	*****	*****	0	NaN
Male	6,739	5,391	47.5%	1,057	50.2%	*****	*****	*****	*****	0	NaN
Vutrisiran	607	518	100.0%	42	100.0%	35	100.0%	12	100.0%	0	NaN
Female	214	175	33.8%	16	38.1%	*****	*****	*****	*****	0	NaN
Male	393	343	66.2%	26	61.9%	*****	*****	*****	*****	0	NaN
Deucravacitinib	1,517	876	100.0%	382	100.0%	*****	*****	*****	*****	0	NaN
Female	832	488	55.7%	204	53.4%	*****	*****	*****	*****	0	NaN
Male	685	388	44.3%	178	46.6%	*****	*****	*****	*****	0	NaN
Terlipressin	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	22	22	52.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	20	20	47.6%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopicleonol	22,748	22,748	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	13,270	13,270	58.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	9,478	9,478	41.7%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag											
Isopropyl											
Ophthalmic											
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
Sodium											
Phenylbutyrate											
and Taurursodiol											
	2,227	1,154	100.0%	584	100.0%	452	100.0%	37	100.0%	0	NaN
Female	1,004	552	47.8%	268	45.9%	171	37.8%	13	35.1%	0	NaN
Male	1,223	602	52.2%	316	54.1%	281	62.2%	24	64.9%	0	NaN
Futibatinib	82	49	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	49	27	55.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	33	22	44.9%	*****	*****	*****	*****	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Se

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Olutasidenib	51	26	100.0%	14	100.0%	11	100.0%	0	NaN	0	NaN
Female	21	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	30	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Adagrasib	351	246	100.0%	77	100.0%	28	100.0%	0	NaN	0	NaN
Female	215	149	60.6%	*****	*****	*****	*****	0	NaN	0	NaN
Male	136	97	39.4%	*****	*****	*****	*****	0	NaN	0	NaN
Lenacapavir	193	61	100.0%	35	100.0%	97	100.0%	0	NaN	0	NaN
Female	43	*****	*****	*****	*****	26	26.8%	0	NaN	0	NaN
Male	150	*****	*****	*****	*****	71	73.2%	0	NaN	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	36	36	59.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	25	25	41.0%	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	196	196	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	103	103	52.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	93	93	47.4%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-svoa	114,321	114,261	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	67,016	66,983	58.6%	*****	*****	*****	*****	0	NaN	0	NaN
Male	47,305	47,278	41.4%	*****	*****	*****	*****	0	NaN	0	NaN
Sutimlimab-jome	170	170	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	113	113	66.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	57	57	33.5%	0	NaN	0	NaN	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	2,545	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	958	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,587	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa- rpcp	12	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Se

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Spesolimab-sbzo	55	55	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	36	36	65.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	19	19	34.5%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinumtoxi na-lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,870	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,433	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab- actl	972	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	210	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	762	762	78.5%	0	0.0%	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	1,233	1,233	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	589	589	47.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	644	644	52.2%	0	NaN	0	NaN	0	NaN	0	NaN
Mirvetuximab Soravtansine-gynx	280	280	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	19	19	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	23	23	54.8%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzumab- axgb	63	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	28	28	45.2%	0	0.0%	0	NaN	0	NaN	0	NaN
Male	35	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Anacaulase-bcdb	127	127	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	66	66	52.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Se

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	61	61	48.0%	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-xiiy	482	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	358	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	124	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	10,520	1	30	30	30	542	47.6	54.7
Female	6,568	1	30	30	30	527	48.1	55.3
Male	3,952	1	30	30	30	542	46.8	53.6
Abrocitinib	609	1	30	30	90	600	73.5	81.2
Female	315	1	30	30	90	480	71.0	74.8
Male	294	4	30	30	90	600	76.1	87.7
Mitapivat	26	16	28	56	140	584	107.4	132.3
Female	*****	16	28	56	196	584	132.4	155.5
Male	*****	19	28	28	84	140	60.2	49.8
Pacritinib	879	1	30	30	60	721	68.4	81.9
Female	396	8	30	30	60	721	67.5	87.4
Male	483	1	30	30	90	635	69.0	77.2
Ganaxolone	23	17	28	109	239	508	142.0	132.2
Female	*****	19	28	134	249	508	161.6	142.2
Male	*****	17	40	57	115	128	71.4	48.1
Lutetium Vipivotide								
Tetraxetan	4,303	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Oteseconazole	161	3	31	84	84	264	70.3	36.6
Female	161	3	31	84	84	264	70.3	36.6
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	1,600	1	30	37	120	642	97.7	112.7
Female	1,072	1	30	35	116	602	95.4	110.2
Male	528	1	30	45	128	642	102.2	117.6
Vonoprazan	431	1	13	25	31	180	29.5	26.0
Female	271	1	12	28	32	130	29.7	25.7
Male	160	1	14	24	30	180	29.2	26.6
Tirzepatide	438,820	1	28	44	96	718	84.3	95.3
Female	273,416	1	28	45	100	718	84.9	96.3
Male	165,404	1	28	43	93	694	83.2	93.7
Tapinarof	14,042	1	30	30	30	540	39.1	32.0

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	7,303	1	30	30	30	540	38.8	31.9
Male	6,739	1	30	30	30	399	39.4	32.1
Vutrisiran	607	1	1	1	1	549	29.6	85.7
Female	214	1	1	1	1	520	40.2	101.6
Male	393	1	1	1	1	549	23.9	75.2
Deucravacitinib	1,517	1	30	30	81	470	65.2	67.7
Female	832	1	30	30	76	437	64.0	65.5
Male	685	1	30	30	84	470	66.6	70.4
Terlipressin	42	1	1	1	1	1	1.0	0.0
Female	22	1	1	1	1	1	1.0	0.0
Male	20	1	1	1	1	1	1.0	0.0
Gadopichlenol	22,748	1	1	1	1	3	1.0	0.0
Female	13,270	1	1	1	1	3	1.0	0.0
Male	9,478	1	1	1	1	2	1.0	0.0
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	2,227	2	28	28	84	486	75.5	83.3
Female	1,004	2	28	28	83	434	68.6	76.0
Male	1,223	2	28	34	88	486	81.1	88.5
Futibatinib	82	6	28	28	56	226	47.3	39.4
Female	49	7	28	28	56	226	51.6	44.7
Male	33	6	28	28	56	165	41.0	29.4
Olutasidenib	51	13	30	30	90	322	73.4	72.5
Female	21	27	30	30	60	297	66.7	73.3
Male	30	13	30	60	112	322	78.0	72.8
Adagrasib	351	1	30	30	60	305	44.5	37.1
Female	215	1	30	30	60	305	46.4	40.6
Male	136	1	30	30	55	180	41.4	30.7
Lenacapavir	193	1	13	92	170	340	103.4	90.5

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	43	1	23	130	180	337	120.7	95.1
Male	150	1	8	89	170	340	98.4	88.8
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
Female	36	1	1	1	1	1	1.0	0.0
Male	25	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	196	1	1	1	1	14	1.1	0.9
Female	103	1	1	1	1	14	1.1	1.3
Male	93	1	1	1	1	2	1.0	0.1
Faricimab-svoa	114,321	1	1	1	1	210	1.1	2.1
Female	67,016	1	1	1	1	140	1.1	1.8
Male	47,305	1	1	1	1	210	1.1	2.4
Sutimlimab-jome	170	1	1	1	1	15	1.2	1.5
Female	113	1	1	1	1	15	1.2	1.8
Male	57	1	1	1	1	1	1.0	0.0
Nivolumab and Relatlimab-rmbw	2,545	1	1	1	1	224	1.5	7.2
Female	958	1	1	1	1	224	1.4	7.6
Male	1,587	1	1	1	1	168	1.5	6.9
Olipudase Alfa-rpcp	12	1	1	1	1	84	10.2	24.5
Female	*****	1	1	1	28	84	16.7	31.3
Male	*****	1	1	1	1	1	1.0	0.0
Spesolimab-sbzo	55	1	1	1	1	7	1.9	2.1
Female	36	1	1	1	1	7	1.7	1.9
Male	19	1	1	1	1	7	2.3	2.5
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	1	1	1	1	140	1.3	4.2
Female	1,870	1	1	1	1	126	1.3	3.9
Male	1,433	1	1	1	1	140	1.3	4.5
Tremelimumab-actl	972	1	1	1	1	42	1.4	3.5

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	210	1	1	1	1	42	1.7	4.7
Male	762	1	1	1	1	30	1.4	3.1
Teclistamab-cqyv	1,233	1	1	1	1	3	1.0	0.1
Female	589	1	1	1	1	2	1.0	0.1
Male	644	1	1	1	1	3	1.0	0.1
Mirvetuximab								
Soravtansine-gynx	280	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	NaN
Teplizumab-mzwv	42	1	1	5	14	14	6.4	5.2
Female	19	1	1	5	10	14	6.1	4.8
Male	23	1	1	5	14	14	6.7	5.7
Mosunetuzumab-axgb	63	1	1	1	1	57	1.9	7.1
Female	28	1	1	1	1	2	1.0	0.2
Male	35	1	1	1	1	57	2.6	9.5
Anacaulase-bcdb	127	1	1	1	1	1	1.0	0.0
Female	66	1	1	1	1	1	1.0	0.0
Male	61	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	482	1	1	1	1	198	2.3	12.2
Female	358	1	1	1	1	198	2.3	12.2
Male	124	1	1	1	1	134	2.3	12.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Daridorexant	10,520	7,937	100.0%	1,781	100.0%	732	100.0%	70	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	1,049	731	9.2%	224	12.6%	*****	*****	*****	*****	0	NaN
41-64 years	4,943	3,617	45.6%	894	50.2%	390	53.3%	42	60.0%	0	NaN
≥ 65 years	4,382	3,481	43.9%	632	35.5%	*****	*****	*****	*****	0	NaN
Abrocitinib	609	312	100.0%	181	100.0%	104	100.0%	12	100.0%	0	NaN
0-17 years	25	12	3.8%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	76	40	12.8%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	138	69	22.1%	42	23.2%	*****	*****	*****	*****	0	NaN
41-64 years	221	105	33.7%	66	36.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	149	86	27.6%	39	21.5%	*****	*****	*****	*****	0	NaN
Mitapivat	26	11	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
Pacritinib	879	501	100.0%	233	100.0%	131	100.0%	14	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	44	8.8%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	804	457	91.2%	216	92.7%	117	89.3%	14	100.0%	0	NaN
Ganaxolone	23	*****	*****	*****	*****	12	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Lutetium Vipivotide											
Tetraxetan	4,303	4,303	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	294	294	6.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,009	4,009	93.2%	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole											
Oteseconazole	161	37	100.0%	112	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	90	*****	*****	58	51.8%	*****	*****	0	NaN	0	NaN
≥ 65 years	44	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Mavacamten											
Mavacamten	1,600	728	100.0%	399	100.0%	401	100.0%	72	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	*****	*****	11	2.7%	*****	*****	0	NaN
41-64 years	366	173	23.8%	88	22.1%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,176	525	72.1%	300	75.2%	310	77.3%	41	56.9%	0	NaN
Vonoprazan											
Vonoprazan	431	320	100.0%	95	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	0.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	1.3%	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	10.3%	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	232	178	55.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	149	104	32.5%	*****	*****	*****	*****	0	NaN	0	NaN
Tirzepatide											
Tirzepatide	438,820	205,473	100.0%	121,267	100.0%	99,257	100.0%	12,823	100.0%	0	NaN
0-17 years	133	64	0.0%	36	0.0%	*****	*****	*****	*****	0	NaN
18-24 years	3,518	1,838	0.9%	1,013	0.8%	*****	*****	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	46,406	21,892	10.7%	13,133	10.8%	9,938	10.0%	1,443	11.3%	0	NaN
41-64 years	235,674	107,136	52.1%	64,133	52.9%	55,836	56.3%	8,569	66.8%	0	NaN
≥ 65 years	153,089	74,543	36.3%	42,952	35.4%	32,843	33.1%	2,751	21.5%	0	NaN
Tapinarof	14,042	11,354	100.0%	2,106	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	264	215	1.9%	38	1.8%	11	1.9%	0	0.0%	0	NaN
18-24 years	619	519	4.6%	80	3.8%	20	3.5%	0	0.0%	0	NaN
25-40 years	2,911	2,409	21.2%	402	19.1%	100	17.4%	0	0.0%	0	NaN
41-64 years	6,953	5,524	48.7%	1,092	51.9%	*****	*****	*****	*****	0	NaN
≥ 65 years	3,295	2,687	23.7%	494	23.5%	*****	*****	*****	*****	0	NaN
Vutrisiran	607	518	100.0%	42	100.0%	35	100.0%	12	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	523	446	86.1%	*****	*****	*****	*****	12	100.0%	0	NaN
Deucravacitinib	1,517	876	100.0%	382	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	54	36	4.1%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	174	19.9%	71	18.6%	*****	*****	*****	*****	0	NaN
41-64 years	726	416	47.5%	179	46.9%	*****	*****	*****	*****	0	NaN
≥ 65 years	458	250	28.5%	118	30.9%	*****	*****	*****	*****	0	NaN
Terlipressin	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	24	24	57.1%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopichlenol	22,748	22,748	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	351	351	1.5%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	327	327	1.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	1,880	1,880	8.3%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	7,429	7,429	32.7%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	12,761	12,761	56.1%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl											
Ophthalmic Solution	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Sodium											
Phenylbutyrate and											
Taurursodiol	2,227	1,154	100.0%	584	100.0%	452	100.0%	37	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	40	3.5%	17	2.9%	*****	*****	0	0.0%	0	NaN
41-64 years	682	*****	*****	175	30.0%	*****	*****	20	54.1%	0	NaN
≥ 65 years	1,477	778	67.4%	392	67.1%	290	64.2%	17	45.9%	0	NaN
Futibatinib	82	49	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	13	48.1%	*****	*****	0	NaN	0	NaN
≥ 65 years	46	31	63.3%	*****	*****	*****	*****	0	NaN	0	NaN
Olutasidenib	51	26	100.0%	14	100.0%	11	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	14	100.0%	11	100.0%	0	NaN	0	NaN
Adagrasib	351	246	100.0%	77	100.0%	28	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	72	29.3%	19	24.7%	*****	*****	0	NaN	0	NaN
≥ 65 years	255	*****	*****	58	75.3%	*****	*****	0	NaN	0	NaN
Lenacapavir	193	61	100.0%	35	100.0%	97	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	115	38	62.3%	19	54.3%	58	59.8%	0	NaN	0	NaN
≥ 65 years	51	*****	*****	*****	*****	28	28.9%	0	NaN	0	NaN
Hyperpolarized 129-Xe	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Tebentafusp-tebn	196	196	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	151	151	77.0%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-svoa	114,321	114,261	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	11	11	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	294	294	0.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	108,039	107,983	94.5%	*****	*****	*****	*****	0	NaN	0	NaN
Sutimlimab-jome	170	170	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	146	146	85.9%	0	NaN	0	NaN	0	NaN	0	NaN
Nivolumab and Relatlimab-rmbw	2,545	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	381	381	15.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,113	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa-rpcp	12	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Spesolimab-sbzo	55	55	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	30	30	54.5%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
DaxibotulinumtoxinA-lanm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	191	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	3,095	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tremelimumab-actl	972	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	818	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	1,233	1,233	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,013	1,013	82.2%	0	NaN	0	NaN	0	NaN	0	NaN
Mirvetuximab											
Soravtansine-gynx	280	280	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	138	138	49.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-mzwv	42	42	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	16	16	38.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	13	13	31.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzumab-axgb	63	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	46	46	74.2%	0	0.0%	0	NaN	0	NaN	0	NaN
Anacaulase-bcdb	127	127	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	103	103	81.1%	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-xiiy	482	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	142	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	271	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	10,520	1	30	30	30	542	47.6	54.7
0-17 years	*****	30	30	30	60	60	40.0	17.3
18-24 years	*****	4	30	30	33	420	45.7	50.5
25-40 years	1,049	1	30	30	60	521	51.7	59.9
41-64 years	4,943	1	30	30	52	542	50.6	59.5
≥ 65 years	4,382	1	30	30	30	526	43.3	47.0
Abrocitinib	609	1	30	30	90	600	73.5	81.2
0-17 years	25	14	30	31	60	159	54.8	37.8
18-24 years	76	1	30	30	65	420	67.9	77.1
25-40 years	138	4	30	31	90	510	70.5	75.4
41-64 years	221	1	30	38	90	600	80.0	85.8
≥ 65 years	149	5	30	30	90	502	72.6	86.7
Mitapivat	26	16	28	56	140	584	107.4	132.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	56	56	56	46.7	16.2
25-40 years	*****	16	51	70	196	339	122.2	108.6
41-64 years	*****	19	28	56	165	584	146.6	186.5
≥ 65 years	*****	28	28	28	28	28	28.0	0.0
Pacritinib	879	1	30	30	60	721	68.4	81.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	60	96	132	132	96.0	50.9
41-64 years	*****	1	30	30	90	322	63.4	62.6
≥ 65 years	804	2	30	30	60	721	68.7	83.5
Ganaxolone	23	17	28	109	239	508	142.0	132.2
0-17 years	*****	17	26	54	164	319	105.0	100.1
18-24 years	*****	115	182	303	433	508	307.3	166.5
25-40 years	*****	220	220	220	220	220	220.0	NaN
41-64 years	*****	28	28	69	109	109	68.5	57.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Vipivotide								
Tetraxetan	4,303	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	294	1	1	1	1	1	1.0	0.0
≥ 65 years	4,009	1	1	1	1	1	1.0	0.0
Oteseconazole	161	3	31	84	84	264	70.3	36.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	84	87	90	92	93	89.3	3.8
25-40 years	*****	6	30	80	84	90	64.0	27.5
41-64 years	90	4	30	84	84	252	68.6	38.4
≥ 65 years	44	3	63	84	84	264	75.4	38.0
Mavacamten	1,600	1	30	37	120	642	97.7	112.7
0-17 years	*****	428	428	428	428	428	428.0	NaN
18-24 years	*****	14	30	31	270	632	164.3	226.1
25-40 years	*****	9	30	30	103	642	99.0	126.2
41-64 years	366	2	30	35	120	602	102.3	127.3
≥ 65 years	1,176	1	30	44	120	577	95.5	105.8
Vonoprazan	431	1	13	25	31	180	29.5	26.0
0-17 years	*****	30	30	30	30	30	30.0	NaN
18-24 years	*****	14	14	25	42	43	28.0	12.6
25-40 years	*****	1	10	18	30	90	25.1	22.5
41-64 years	232	1	14	24	30	130	28.6	24.8
≥ 65 years	149	1	13	30	35	180	32.3	29.0
Tirzepatide	438,820	1	28	44	96	718	84.3	95.3
0-17 years	133	1	28	38	84	472	83.2	97.0
18-24 years	3,518	1	28	30	84	550	69.1	80.2
25-40 years	46,406	1	28	41	88	672	82.7	95.5
41-64 years	235,674	1	28	50	112	717	89.3	101.1
≥ 65 years	153,089	1	28	35	84	718	77.4	85.5

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tapinarof	14,042	1	30	30	30	540	39.1	32.0
0-17 years	264	4	30	30	30	316	39.3	32.9
18-24 years	619	1	30	30	30	284	36.8	26.8
25-40 years	2,911	1	30	30	30	270	37.4	26.6
41-64 years	6,953	1	30	30	30	540	40.4	34.6
≥ 65 years	3,295	1	30	30	30	406	38.1	31.2
Vutrisiran	607	1	1	1	1	549	29.6	85.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	46	90	90	45.5	62.9
41-64 years	*****	1	1	1	1	325	24.8	71.0
≥ 65 years	523	1	1	1	1	549	30.3	87.9
Deucravacitinib	1,517	1	30	30	81	470	65.2	67.7
0-17 years	*****	56	56	56	56	56	56.0	NaN
18-24 years	54	1	30	30	60	307	51.3	56.3
25-40 years	*****	1	30	30	60	420	54.5	55.3
41-64 years	726	1	30	30	90	418	65.7	65.9
≥ 65 years	458	1	30	30	90	470	72.6	77.2
Terlipressin	42	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	24	1	1	1	1	1	1.0	0.0
Gadopiclenol	22,748	1	1	1	1	3	1.0	0.0
0-17 years	351	1	1	1	1	1	1.0	0.0
18-24 years	327	1	1	1	1	2	1.0	0.1
25-40 years	1,880	1	1	1	1	3	1.0	0.1
41-64 years	7,429	1	1	1	1	2	1.0	0.0
≥ 65 years	12,761	1	1	1	1	2	1.0	0.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Omidenepag Isopropyl								
Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol								
	2,227	2	28	28	84	486	75.5	83.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	28	28	28.0	NaN
25-40 years	*****	5	28	28	56	313	61.5	68.5
41-64 years	682	3	28	39	91	431	84.5	93.8
≥ 65 years	1,477	2	28	28	84	486	72.0	78.4
Futibatinib								
	82	6	28	28	56	226	47.3	39.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	21	25	30	72	112	48.0	42.9
41-64 years	*****	6	28	31	56	222	52.2	44.3
≥ 65 years	46	7	28	28	56	226	43.9	35.9
Olutasidenib								
	51	13	30	30	90	322	73.4	72.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	30	30	30.0	0.0
≥ 65 years	*****	13	30	60	90	322	79.1	75.4
Adagrasib								
	351	1	30	30	60	305	44.5	37.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	NaN
41-64 years	*****	4	30	30	30	236	41.2	31.9

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	255	1	30	30	60	305	45.8	38.9
Lenacapavir	193	1	13	92	170	340	103.4	90.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	32	32	185	337	337	184.5	215.7
25-40 years	*****	1	3	39	170	274	84.3	88.3
41-64 years	115	1	11	92	180	340	104.5	94.3
≥ 65 years	51	1	23	116	170	279	107.1	77.6
Hyperpolarized 129-Xe	61	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Tebentafusp-tebn	196	1	1	1	1	14	1.1	0.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	151	1	1	1	1	14	1.1	1.1
Faricimab-svoa	114,321	1	1	1	1	210	1.1	2.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	11	1	1	1	1	1	1.0	0.0
25-40 years	294	1	1	1	1	2	1.0	0.1
41-64 years	*****	1	1	1	1	56	1.1	1.8
≥ 65 years	108,039	1	1	1	1	210	1.1	2.1
Sutimlimab-jome	170	1	1	1	1	15	1.2	1.5
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	146	1	1	1	1	15	1.2	1.6

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Nivolumab and Relatlimab-rmbw	2,545	1	1	1	1	224	1.5	7.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	381	1	1	1	1	28	1.1	2.0
≥ 65 years	2,113	1	1	1	1	224	1.5	7.8
Olipudase Alfa-rpcp	12	1	1	1	1	84	10.2	24.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	84	17.6	37.1
41-64 years	*****	1	1	1	15	28	7.8	13.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	55	1	1	1	1	7	1.9	2.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	7	2.0	2.4
41-64 years	*****	1	1	1	1	7	1.3	1.4
≥ 65 years	30	1	1	1	1	7	2.2	2.4
Daxibotulinumtoxina-lanm	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Eflapegrastim-xnst	3,303	1	1	1	1	140	1.3	4.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	21	2.4	5.3
41-64 years	191	1	1	1	1	43	1.6	4.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	3,095	1	1	1	1	140	1.3	4.2
Tremelimumab-actl	972	1	1	1	1	42	1.4	3.5
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.2	2.2
≥ 65 years	818	1	1	1	1	42	1.5	3.7
Teclistamab-cqyv	1,233	1	1	1	1	3	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	2	2	1.3	0.6
41-64 years	*****	1	1	1	1	2	1.0	0.1
≥ 65 years	1,013	1	1	1	1	3	1.0	0.1
Mirvetuximab								
Soravtansine-gynx	280	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	138	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	42	1	1	5	14	14	6.4	5.2
0-17 years	16	1	4	8	14	14	8.4	5.5
18-24 years	*****	1	1	1	5	14	4.4	5.6
25-40 years	13	1	1	5	5	14	4.9	4.5
41-64 years	*****	1	3	5	10	14	6.1	5.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	63	1	1	1	1	57	1.9	7.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	57	4.8	14.4

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	46	1	1	1	1	1	1.0	0.0
Anacaulase-bcdb	127	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	103	1	1	1	1	1	1.0	0.0
Ublituximab-xiiy	482	1	1	1	1	198	2.3	12.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	142	1	1	1	1	198	3.0	17.0
41-64 years	271	1	1	1	1	134	1.9	9.6
≥ 65 years	*****	1	1	1	1	77	2.6	10.0

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Daridorexant</i>	9,250	6,499	70.3%	2,067	22.3%	673	7.3%	11	0.1%	0	0.0%
<i>Abrocitinib</i>	703	404	57.5%	205	29.2%	*****	*****	*****	*****	0	0.0%
<i>Mitapivat</i>	29	17	58.6%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Pacritinib</i>	1,113	649	58.3%	317	28.5%	*****	*****	*****	*****	0	0.0%
<i>Ganaxolone</i>	40	22	55.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lutetium Vipivotide</i>											
<i>Tetraxetan</i>	9,501	9,501	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Oteseconazole</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Mavacamten</i>	1,781	726	40.8%	557	31.3%	451	25.3%	47	2.6%	0	0.0%
<i>Vonoprazan</i>	60	45	75.0%	15	25.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tirzepatide</i>	447,862	245,000	54.7%	123,390	27.6%	75,689	16.9%	3,783	0.8%	0	0.0%
<i>Tapinarof</i>	7,353	6,130	83.4%	988	13.4%	*****	*****	*****	*****	0	0.0%
<i>Vutrisiran</i>	1,088	1,004	92.3%	62	5.7%	*****	*****	*****	*****	0	0.0%
<i>Deucravacitinib</i>	1,569	953	60.7%	456	29.1%	*****	*****	*****	*****	0	0.0%
<i>Terlipressin</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gadopicleonol</i>	1,522	1,522	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and</i>											
<i>Taurursodiol</i>	2,298	1,453	63.2%	541	23.5%	*****	*****	*****	*****	0	0.0%
<i>Futibatinib</i>	89	65	73.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Olutasidenib</i>	33	18	54.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Adagrasib</i>	236	157	66.5%	63	26.7%	16	6.8%	0	0.0%	0	0.0%
<i>Lenacapavir</i>	58	27	46.6%	12	20.7%	19	32.8%	0	0.0%	0	0.0%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Hyperpolarized</i>											
<i>129-Xe</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Tebentafusp-</i> <i>tebn</i>	5,416	5,416	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Faricimab-svoa</i>	452,756	452,626	100.0%	109	0.0%	21	0.0%	0	0.0%	0	0.0%
<i>Sutimlimab-</i> <i>jome</i>	2,346	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Nivolumab and</i> <i>Relatlimab-</i> <i>rmbw</i>	9,898	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Olipudase Alfa-</i> <i>rpcp</i>	90	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Spesolimab-</i> <i>sbzo</i>	39	39	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumt</i> <i>oxina-lanm</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Eflapegrastim-</i> <i>xnst</i>	6,310	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Tremelimumab-</i> <i>actl</i>	263	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Teclistamab-</i> <i>cqyv</i>	5,102	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

Mirvetuximab

Soravtansine-

gynx

970

970

100.0%

0

0.0%

0

0.0%

0

0.0%

0

0.0%

Teplizumab-

mzwv

16

16

100.0%

0

0.0%

0

0.0%

0

0.0%

0

0.0%

Mosunetuzuma

b-axgb

215

0

0.0%

0

0.0%

0

0.0%

Anacaulase-

bcdh

0

0.0%

0

0.0%

0

0.0%

0

0.0%

Ublituximab-

431

0

0.0%

0

0.0%

0

0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Daridorexant</i>	9,250	1	30	30	60	577	46.4	43.7
<i>Abrocitinib</i>	703	1	30	30	60	592	60.2	61.4
<i>Mitapivat</i>	29	25	28	28	63	392	79.8	100.6
<i>Pacritinib</i>	1,113	1	30	30	60	445	57.6	54.4
<i>Ganaxolone</i>	40	3	26	29	54	221	46.9	38.3
<i>Lutetium Vipivotide</i>								
<i>Tetraxetan</i>	9,501	1	1	1	1	2	1.0	0.0
<i>Oteseconazole</i>	*****	3	30	53	84	87	52.8	32.6
<i>Mavacamten</i>	1,781	1	30	58	111	585	86.9	92.3
<i>Vonoprazan</i>	60	2	18	30	32	79	29.0	17.8
<i>Tirzepatide</i>	447,862	1	28	28	83	655	63.9	69.6
<i>Tapinarof</i>	7,353	1	30	30	30	413	36.2	28.3
<i>Vutrisiran</i>	1,088	1	1	1	1	435	9.6	36.0
<i>Deucravacitinib</i>	1,569	1	30	30	60	438	51.9	45.9
<i>Terlipressin</i>	*****	1	1	1	1	1	1.0	0.0
<i>Gadopiclenol</i>	1,522	1	1	1	1	2	1.0	0.0
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	2,298	1	28	28	56	391	53.6	55.0
<i>Futibatinib</i>	89	1	28	28	40	140	35.1	20.7
<i>Olutasidenib</i>	33	15	30	30	60	240	54.6	49.0
<i>Adagrasib</i>	236	2	30	30	60	258	43.9	32.7
<i>Lenacapavir</i>	58	1	2	38	116	235	65.5	64.4
<i>Hyperpolarized 129-Xe</i>	0	.	.	.	.	.	.	.
<i>Tebentafusp-tebn</i>	5,416	1	1	1	1	2	1.0	0.0
<i>Faricimab-svoa</i>	452,756	1	1	1	1	248	1.1	1.6
<i>Sutimlimab-jome</i>	2,346	1	1	1	1	308	1.3	6.7
<i>Nivolumab and Relatlimab-rmbw</i>	9,898	1	1	1	1	196	1.1	3.5
<i>Olipudase Alfa-rpcp</i>	90	1	1	1	1	319	10.3	44.2

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Spesolimab-sbzo</i>	39	1	1	1	1	7	1.8	2.0
<i>Daxibotulinumtoxina-</i>	0	.	.	.	.	.	.	.
<i>Eflapegrastim-xnst</i>	6,310	1	1	1	1	63	1.1	2.1
<i>Tremelimumab-actl</i>	263	1	1	1	1	56	1.4	4.0
<i>Teclistamab-cqyv</i>	5,102	1	1	1	1	35	1.0	0.7
<i>Mirvetuximab</i>								
<i>Soravtansine-gynx</i>	970	1	1	1	1	1	1.0	0.0
<i>Teplizumab-mzwv</i>	16	1	1	1	4	9	2.7	2.6
<i>Mosunetuzumab-axgb</i>	215	1	1	1	1	126	1.6	8.5
<i>Anacaulase-bcdb</i>	*****	1	1	1	1	1	1.0	0.0
<i>Ublituximab-xiiy</i>	431	1	1	1	1	90	1.9	7.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Daridorexant	9,250	6,499	100.0%	2,067	100.0%	673	100.0%	11	100.0%	0	NaN
Female	5,721	3,992	61.4%	1,312	63.5%	*****	*****	*****	*****	0	NaN
Male	3,529	2,507	38.6%	755	36.5%	*****	*****	*****	*****	0	NaN
Abrocitinib	703	404	100.0%	205	100.0%	*****	*****	*****	*****	0	NaN
Female	305	184	45.5%	84	41.0%	*****	*****	*****	*****	0	NaN
Male	398	220	54.5%	121	59.0%	*****	*****	*****	*****	0	NaN
Mitapivat	29	17	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	13	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pacritinib	1,113	649	100.0%	317	100.0%	*****	*****	*****	*****	0	NaN
Female	528	311	47.9%	146	46.1%	*****	*****	*****	*****	0	NaN
Male	585	338	52.1%	171	53.9%	*****	*****	*****	*****	0	NaN
Ganaxolone	40	22	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	40	22	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Lutetium Vivotide											
Tetraxetan	9,501	9,501	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Oteseconazole	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Mavacamten	1,781	726	100.0%	557	100.0%	451	100.0%	47	100.0%	0	NaN
Female	1,196	475	65.4%	368	66.1%	317	70.3%	36	76.6%	0	NaN
Male	585	251	34.6%	189	33.9%	134	29.7%	11	23.4%	0	NaN
Vonoprazan	60	45	100.0%	15	100.0%	0	NaN	0	NaN	0	NaN
Female	31	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	29	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tirzepatide	447,862	245,000	100.0%	123,390	100.0%	75,689	100.0%	3,783	100.0%	0	NaN
Female	281,877	156,140	63.7%	76,822	62.3%	46,466	61.4%	2,449	64.7%	0	NaN
Male	165,985	88,860	36.3%	46,568	37.7%	29,223	38.6%	1,334	35.3%	0	NaN
Tapinarof	7,353	6,130	100.0%	988	100.0%	*****	*****	*****	*****	0	NaN
Female	3,688	3,072	50.1%	496	50.2%	*****	*****	*****	*****	0	NaN
Male	3,665	3,058	49.9%	492	49.8%	*****	*****	*****	*****	0	NaN
Vutrisiran	1,088	1,004	100.0%	62	100.0%	*****	*****	*****	*****	0	NaN
Female	381	344	34.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	707	660	65.7%	*****	*****	*****	*****	0	0.0%	0	NaN
Deucravacitin	1,569	953	100.0%	456	100.0%	*****	*****	*****	*****	0	NaN
Female	794	490	51.4%	*****	*****	79	49.7%	*****	*****	0	NaN
Male	775	463	48.6%	*****	*****	*****	*****	0	0.0%	0	NaN
Terlipressin	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Gadopictlenol	1,522	1,522	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	913	913	60.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	609	609	40.0%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl Opthalmic Solution											
	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol											
	2,298	1,453	100.0%	541	100.0%	*****	*****	*****	*****	0	NaN
Female	1,015	650	44.7%	238	44.0%	*****	*****	*****	*****	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	1,283	803	55.3%	303	56.0%	*****	*****	*****	*****	0	NaN
Futibatinib	89	65	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	50	*****	*****	11	47.8%	*****	*****	0	NaN	0	NaN
Male	39	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Olutasidenib	33	18	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	19	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	14	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Adagrasib	236	157	100.0%	63	100.0%	16	100.0%	0	NaN	0	NaN
Female	147	100	63.7%	*****	*****	*****	*****	0	NaN	0	NaN
Male	89	57	36.3%	*****	*****	*****	*****	0	NaN	0	NaN
Lenacapavir	58	27	100.0%	12	100.0%	19	100.0%	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	12	100.0%	*****	*****	0	NaN	0	NaN
Hyperpolarized											
129-Xe	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
Tebentafusp-											
tebn	5,416	5,416	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,909	2,909	53.7%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,507	2,507	46.3%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-svoa	452,756	452,626	100.0%	109	100.0%	21	100.0%	0	NaN	0	NaN
Female	266,603	266,521	58.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	186,153	186,105	41.1%	*****	*****	*****	*****	0	NaN	0	NaN
Sutimlimab-											
jome	2,346	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,699	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	647	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Nivolumab and Relatlimab-rmbw	9,898	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	3,594	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	6,304	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa-rpcp	90	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	61	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	29	29	34.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
Spesolimab-sbzo	39	39	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	25	25	64.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	14	14	35.9%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinum toxina-lanm	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
Eflapegrastim-xnst	6,310	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	3,341	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,969	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Tremelimumab-actl	263	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	131	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	132	132	50.4%	0	0.0%	0	NaN	0	NaN	0	NaN
Teclistamab-cqyv	5,102	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	2,437	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,665	2,665	52.3%	0	0.0%	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

Total Number of Episodes		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Mirvetuximab											
Soravtansine-											
gynx	970	970	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab-											
mzvv	16	16	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzum											
ab-axgb	215	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	97	97	45.3%	0	NaN	0	0.0%	0	NaN	0	NaN
Male	118	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Anacaulase-											
bcdv	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab-	431	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	315	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	116	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	9,250	1	30	30	60	577	46.4	43.7
Female	5,721	1	30	30	60	577	46.5	44.1
Male	3,529	1	30	30	59	490	46.2	43.0
Abrocitinib	703	1	30	30	60	592	60.2	61.4
Female	305	1	30	30	60	592	58.9	64.7
Male	398	1	30	30	61	440	61.2	58.8
Mitapivat	29	25	28	28	63	392	79.8	100.6
Female	13	28	28	52	100	392	103.5	119.8
Male	16	25	28	28	56	339	60.5	80.7
Pacritinib	1,113	1	30	30	60	445	57.6	54.4
Female	528	1	30	30	60	445	57.0	52.3
Male	585	3	30	30	60	425	58.2	56.3
Ganaxolone	40	3	26	29	54	221	46.9	38.3
Female	40	3	26	29	54	221	46.9	38.3
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lutetium Vipivotide								
Tetraxetan	9,501	1	1	1	1	2	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	2	1.0	0.0
Oteseconazole	*****	3	30	53	84	87	52.8	32.6
Female	*****	3	30	53	84	87	52.8	32.6
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	1,781	1	30	58	111	585	86.9	92.3
Female	1,196	1	30	60	120	530	90.1	94.4
Male	585	1	30	46	90	585	80.4	87.5
Vonoprazan	60	2	18	30	32	79	29.0	17.8
Female	31	2	11	25	30	78	25.6	19.2
Male	29	3	25	30	38	79	32.6	15.7
Tirzepatide	447,862	1	28	28	83	655	63.9	69.6
Female	281,877	1	28	28	79	655	63.3	69.5
Male	165,985	1	28	28	84	645	64.9	69.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tapinarof	7,353	1	30	30	30	413	36.2	28.3
Female	3,688	1	30	30	30	413	36.3	28.8
Male	3,665	1	30	30	30	390	36.1	27.8
Vutrisiran	1,088	1	1	1	1	435	9.6	36.0
Female	381	1	1	1	1	435	13.3	47.9
Male	707	1	1	1	1	294	7.6	27.5
Deucravacitinib	1,569	1	30	30	60	438	51.9	45.9
Female	794	1	30	30	60	438	51.8	47.3
Male	775	1	30	30	60	330	52.1	44.4
Terlipressin	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	1	1	1.0	0.0
Gadopiclenol	1,522	1	1	1	1	2	1.0	0.0
Female	913	1	1	1	1	1	1.0	0.0
Male	609	1	1	1	1	2	1.0	0.0
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	2,298	1	28	28	56	391	53.6	55.0
Female	1,015	1	28	28	56	391	52.2	53.3
Male	1,283	1	28	28	56	382	54.8	56.3
Futibatinib	89	1	28	28	40	140	35.1	20.7
Female	50	8	28	28	28	140	34.2	21.6
Male	39	1	28	28	44	85	36.2	19.7
Olutasidenib	33	15	30	30	60	240	54.6	49.0
Female	19	15	30	30	60	150	45.7	31.8
Male	14	18	30	30	90	240	66.6	65.1
Adagrasib	236	2	30	30	60	258	43.9	32.7
Female	147	2	30	30	57	258	44.0	34.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	89	11	30	30	60	180	43.8	29.2
Lenacapavir	58	1	2	38	116	235	65.5	64.4
Female	*****	1	1	77	150	165	77.2	75.4
Male	*****	1	10	38	106	235	63.0	62.5
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tebentafusp-tebn	5,416	1	1	1	1	2	1.0	0.0
Female	2,909	1	1	1	1	2	1.0	0.0
Male	2,507	1	1	1	1	2	1.0	0.0
Faricimab-svoa	452,756	1	1	1	1	248	1.1	1.6
Female	266,603	1	1	1	1	248	1.1	1.6
Male	186,153	1	1	1	1	140	1.0	1.4
Sutimlimab-jome	2,346	1	1	1	1	308	1.3	6.7
Female	1,699	1	1	1	1	56	1.2	2.6
Male	647	1	1	1	1	308	1.5	12.1
Nivolumab and Relatlimab-rmbw	9,898	1	1	1	1	196	1.1	3.5
Female	3,594	1	1	1	1	196	1.2	4.7
Male	6,304	1	1	1	1	112	1.1	2.6
Olipudase Alfa-rpcp	90	1	1	1	1	319	10.3	44.2
Female	61	1	1	1	1	319	14.7	53.3
Male	29	1	1	1	1	1	1.0	0.0
Spesolimab-sbzo	39	1	1	1	1	7	1.8	2.0
Female	25	1	1	1	1	7	2.0	2.2
Male	14	1	1	1	1	7	1.4	1.6
Daxibotulinumtoxina-lanm	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	6,310	1	1	1	1	63	1.1	2.1

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	3,341	1	1	1	1	56	1.1	2.1
Male	2,969	1	1	1	1	63	1.1	2.1
Tremelimumab-actl	263	1	1	1	1	56	1.4	4.0
Female	131	1	1	1	1	56	1.8	5.6
Male	132	1	1	1	1	1	1.0	0.0
Teclistamab-cqyv	5,102	1	1	1	1	35	1.0	0.7
Female	2,437	1	1	1	1	35	1.0	1.0
Male	2,665	1	1	1	1	7	1.0	0.2
Mirvetuximab Soravtansine-gynx	970	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	16	1	1	1	4	9	2.7	2.6
Female	*****	1	1	1	4	9	3.3	3.2
Male	*****	1	1	1	3	4	1.9	1.2
Mosunetuzumab-axgb	215	1	1	1	1	126	1.6	8.5
Female	97	1	1	1	1	2	1.0	0.1
Male	118	1	1	1	1	126	2.1	11.5
Anacaulase-bcdb	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	1	1	1.0	NaN
Ublituximab-xiiy	431	1	1	1	1	90	1.9	7.2
Female	315	1	1	1	1	81	1.9	6.7
Male	116	1	1	1	1	90	2.1	8.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Daridorexant	9,250	6,499	100.0%	2,067	100.0%	673	100.0%	11	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	27	1.3%	11	1.6%	0	0.0%	0	NaN
25-40 years	1,082	774	11.9%	241	11.7%	*****	*****	*****	*****	0	NaN
41-64 years	5,164	3,613	55.6%	1,172	56.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	2,869	2,015	31.0%	627	30.3%	*****	*****	*****	*****	0	NaN
Abrocitinib	703	404	100.0%	205	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	23	13	3.2%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	106	67	16.6%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	186	115	28.5%	52	25.4%	*****	*****	*****	*****	0	NaN
41-64 years	242	133	32.9%	74	36.1%	*****	*****	*****	*****	0	NaN
≥ 65 years	146	76	18.8%	40	19.5%	*****	*****	*****	*****	0	NaN
Mitapivat	29	17	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pacritinib	1,113	649	100.0%	317	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	43	6.6%	24	7.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,033	606	93.4%	293	92.4%	*****	*****	*****	*****	0	NaN
Ganaxolone	40	22	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Lutetium											
Vipivotide											
Tetraxetan	9,501	9,501	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	499	499	5.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	9,002	9,002	94.7%	0	NaN	0	NaN	0	NaN	0	NaN
Otseconazole	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
Mavacamten	1,781	726	100.0%	557	100.0%	451	100.0%	47	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	16	3.5%	*****	*****	0	NaN
41-64 years	471	239	32.9%	140	25.1%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,217	441	60.7%	389	69.8%	351	77.8%	36	76.6%	0	NaN
Vonoprazan	60	45	100.0%	15	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	27	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Tirzepatide	447,862	245,000	100.0%	123,390	100.0%	75,689	100.0%	3,783	100.0%	0	NaN
0-17 years	131	75	0.0%	32	0.0%	*****	*****	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	3,521	2,271	0.9%	863	0.7%	*****	*****	*****	*****	0	NaN
25-40 years	46,860	28,149	11.5%	12,015	9.7%	6,375	8.4%	321	8.5%	0	NaN
41-64 years	243,351	132,859	54.2%	66,206	53.7%	41,890	55.3%	2,396	63.3%	0	NaN
≥ 65 years	153,999	81,646	33.3%	44,274	35.9%	27,032	35.7%	1,047	27.7%	0	NaN
Tapinarof	7,353	6,130	100.0%	988	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	125	110	1.8%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	287	247	4.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	1,311	1,114	18.2%	157	15.9%	40	17.3%	0	0.0%	0	NaN
41-64 years	3,951	3,267	53.3%	569	57.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,679	1,392	22.7%	215	21.8%	*****	*****	*****	*****	0	NaN
Vutrisiran	1,088	1,004	100.0%	62	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	138	13.7%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	940	866	86.3%	56	90.3%	*****	*****	*****	*****	0	NaN
Deucravacitin	1,569	953	100.0%	456	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	67	41	4.3%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	274	186	19.5%	66	14.5%	22	13.8%	0	0.0%	0	NaN
41-64 years	800	488	51.2%	239	52.4%	73	45.9%	0	0.0%	0	NaN
≥ 65 years	428	238	25.0%	*****	*****	*****	*****	*****	*****	0	NaN
Terlipressin	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Gadopiclenol	1,522	1,522	100.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	146	146	9.6%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	613	613	40.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	733	733	48.2%	0	NaN	0	NaN	0	NaN	0	NaN
Omidenepag Isopropyl Ophthalmic Solution											
	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol											
	2,298	1,453	100.0%	541	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	813	517	35.6%	195	36.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,407	881	60.6%	332	61.4%	*****	*****	*****	*****	0	NaN
Futibatinib	89	65	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	49	37	56.9%	12	52.2%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Olutasidenib	33	18	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Adagrasib	236	157	100.0%	63	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	167	110	70.1%	*****	*****	*****	*****	0	NaN	0	NaN
Lenacapavir	58	27	100.0%	12	100.0%	19	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	37	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Tebentafusp-tebn	5,416	5,416	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	119	119	2.2%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,186	1,186	21.9%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,111	4,111	75.9%	0	NaN	0	NaN	0	NaN	0	NaN
Faricimab-	452,756	452,626	100.0%	109	100.0%	21	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	671	671	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	18,894	18,885	4.2%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	433,177	433,056	95.7%	*****	*****	*****	*****	0	NaN	0	NaN
Sutimlimab-											
jome	2,346	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	43	43	1.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	130	130	5.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,173	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nivolumab											
and											
Relatlimab-	9,898	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	14	14	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	115	115	1.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	8,191	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olipudase Alfa-											
rpcp	90	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	46	46	54.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	23	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Spesolimab- sbzo	39	39	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	24	24	61.5%	0	NaN	0	NaN	0	NaN	0	NaN
Daxibotulinum toxina-lanm	0	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
Eflapegrastim- xnst	6,310	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	321	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	5,955	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Tremelimuma b-actl	263	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	56	56	21.4%	0	0.0%	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	207	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Teclistamab- cqyv	5,102	*****	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	11	11	0.2%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	1,306	1,306	25.6%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,785	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Mirvetuximab Soravtansine- gynx	970	970	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	19	19	2.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	438	438	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	513	513	52.9%	0	NaN	0	NaN	0	NaN	0	NaN
Teplizumab- mzwv	16	16	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Mosunetuzum ab-axgb	215	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	144	144	67.3%	0	NaN	0	0.0%	0	NaN	0	NaN
Anacaulase- bcdB	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Ublituximab- xiiy	431	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	238	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	42	42	9.8%	0	0.0%	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	9,250	1	30	30	60	577	46.4	43.7
0-17 years	*****	30	30	30	30	30	30.0	NaN
18-24 years	*****	2	30	30	60	180	44.0	33.9
25-40 years	1,082	1	30	30	53	577	43.3	38.5
41-64 years	5,164	1	30	30	60	490	46.8	44.6
≥ 65 years	2,869	1	30	30	60	413	47.0	44.2
Abrocitinib	703	1	30	30	60	592	60.2	61.4
0-17 years	23	1	30	30	60	213	55.2	51.3
18-24 years	106	6	30	30	60	315	54.3	51.6
25-40 years	186	1	30	30	60	376	52.5	51.5
41-64 years	242	2	30	30	61	592	62.0	63.4
≥ 65 years	146	5	30	30	90	440	72.1	74.8
Mitapivat	29	25	28	28	63	392	79.8	100.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	28	28	84	100	53.0	36.1
25-40 years	*****	28	28	28	151	392	101.0	136.0
41-64 years	*****	28	28	28	112	318	85.3	105.7
≥ 65 years	*****	28	28	28	61	339	73.2	100.9
Pacritinib	1,113	1	30	30	60	445	57.6	54.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	150	150	153	156	156	153.0	4.2
41-64 years	*****	3	30	30	83	420	63.0	66.6
≥ 65 years	1,033	1	30	30	60	445	57.0	53.3
Ganaxolone	40	3	26	29	54	221	46.9	38.3
0-17 years	*****	3	26	29	55	221	48.5	39.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	24	26	27	41	54	33.0	14.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Vipivotide								
Tetraxetan	9,501	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	499	1	1	1	1	2	1.0	0.0
≥ 65 years	9,002	1	1	1	1	2	1.0	0.0
Oteseconazole	*****	3	30	53	84	87	52.8	32.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	57	84	84	57.0	38.2
41-64 years	*****	3	21	30	31	84	33.8	30.2
≥ 65 years	*****	74	74	84	87	87	81.7	6.8
Mavacamten	1,781	1	30	58	111	585	86.9	92.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	37	60	95	48.0	25.9
25-40 years	*****	1	30	38	90	472	78.5	91.8
41-64 years	471	1	30	30	88	515	69.4	79.9
≥ 65 years	1,217	1	30	60	120	585	94.5	96.0
Vonoprazan	60	2	18	30	32	79	29.0	17.8
0-17 years	*****	30	30	34	38	38	34.0	5.7
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	25	30	33	78	33.8	27.4
41-64 years	*****	3	17	30	33	67	28.1	15.0
≥ 65 years	27	2	15	30	30	79	28.6	19.5
Tirzepatide	447,862	1	28	28	83	655	63.9	69.6
0-17 years	131	2	28	28	84	449	63.8	71.9
18-24 years	3,521	1	28	28	56	540	50.8	54.7
25-40 years	46,860	1	28	28	56	645	57.4	63.8
41-64 years	243,351	1	28	28	84	655	65.2	72.4
≥ 65 years	153,999	1	28	28	84	612	63.9	67.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tapinarof	7,353	1	30	30	30	413	36.2	28.3
0-17 years	125	4	30	30	30	167	33.3	18.5
18-24 years	287	1	30	30	30	180	34.1	22.1
25-40 years	1,311	1	30	30	30	276	35.7	28.0
41-64 years	3,951	1	30	30	30	413	36.2	27.0
≥ 65 years	1,679	1	30	30	30	390	37.2	32.5
Vutrisiran	1,088	1	1	1	1	435	9.6	36.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	90	90	93	96	96	93.0	4.2
41-64 years	*****	1	1	1	1	180	6.6	26.7
≥ 65 years	940	1	1	1	1	435	9.9	37.1
Deucravacitinib	1,569	1	30	30	60	438	51.9	45.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	67	1	30	30	60	170	47.5	31.4
25-40 years	274	1	30	30	60	285	45.6	36.3
41-64 years	800	1	30	30	60	330	50.9	44.1
≥ 65 years	428	1	30	30	60	438	58.6	54.9
Terlipressin	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gadopichlenol	1,522	1	1	1	1	2	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	146	1	1	1	1	1	1.0	0.0
41-64 years	613	1	1	1	1	2	1.0	0.0
≥ 65 years	733	1	1	1	1	1	1.0	0.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Omidenepag Isopropyl								
Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate								
and Taurursodiol	2,298	1	28	28	56	391	53.6	55.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	42	56	56	42.0	19.8
25-40 years	*****	4	28	28	56	364	52.7	62.7
41-64 years	813	1	28	28	56	382	54.7	58.6
≥ 65 years	1,407	1	28	28	56	391	53.0	52.4
Futibatinib	89	1	28	28	40	140	35.1	20.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	56	140	140	74.7	58.3
41-64 years	*****	1	28	28	32	85	32.1	18.1
≥ 65 years	49	6	28	28	28	84	35.0	17.1
Olutasidenib	33	15	30	30	60	240	54.6	49.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	60	90	47.0	23.5
≥ 65 years	*****	15	30	30	60	240	56.7	54.0
Adagrasib	236	2	30	30	60	258	43.9	32.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	27	27	27	27	27	27.0	NaN
41-64 years	*****	4	30	30	56	180	44.3	34.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	167	2	30	30	60	258	43.9	32.4
Lenacapavir	58	1	2	38	116	235	65.5	64.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	25	144	165	55.1	69.0
41-64 years	37	1	2	30	101	235	59.6	62.9
≥ 65 years	*****	1	34	79	150	180	86.2	66.5
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tebentafusp-tebn	5,416	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	119	1	1	1	1	1	1.0	0.0
41-64 years	1,186	1	1	1	1	1	1.0	0.0
≥ 65 years	4,111	1	1	1	1	2	1.0	0.0
Faricimab-svoa	452,756	1	1	1	1	248	1.1	1.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	671	1	1	1	1	16	1.0	0.6
41-64 years	18,894	1	1	1	1	112	1.1	1.9
≥ 65 years	433,177	1	1	1	1	248	1.0	1.6
Sutimlimab-jome	2,346	1	1	1	1	308	1.3	6.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	43	1	1	1	1	1	1.0	0.0
41-64 years	130	1	1	1	1	2	1.0	0.1
≥ 65 years	2,173	1	1	1	1	308	1.3	7.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Nivolumab and Relatlimab-rmbw	9,898	1	1	1	1	196	1.1	3.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	14	1	1	1	1	1	1.0	0.0
25-40 years	115	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	84	1.1	2.2
≥ 65 years	8,191	1	1	1	1	196	1.2	3.8
Olipudase Alfa-rpcp	90	1	1	1	1	319	10.3	44.2
0-17 years	46	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	319	17.7	73.0
41-64 years	23	1	1	1	1	241	23.4	56.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	39	1	1	1	1	7	1.8	2.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	7	1.5	1.8
≥ 65 years	24	1	1	1	1	7	2.0	2.3
Daxibotulinumtoxina-lanm	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	6,310	1	1	1	1	63	1.1	2.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	42	2.7	8.4
41-64 years	321	1	1	1	1	63	1.3	3.6
≥ 65 years	5,955	1	1	1	1	56	1.1	1.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tremelimumab-actl	263	1	1	1	1	56	1.4	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	56	1	1	1	1	1	1.0	0.0
≥ 65 years	207	1	1	1	1	56	1.5	4.5
Teclistamab-cqyv	5,102	1	1	1	1	35	1.0	0.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	11	1	1	1	1	1	1.0	0.0
41-64 years	1,306	1	1	1	1	2	1.0	0.0
≥ 65 years	3,785	1	1	1	1	35	1.0	0.8
Mirvetuximab								
Soravtansine-gynx	970	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	1	1	1	1	1	1.0	0.0
41-64 years	438	1	1	1	1	1	1.0	0.0
≥ 65 years	513	1	1	1	1	1	1.0	0.0
Teplizumab-mzwv	16	1	1	1	4	9	2.7	2.6
0-17 years	*****	1	1	1	2	4	1.8	1.3
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	4	4	2.1	1.5
41-64 years	*****	1	1	8	9	9	6.0	4.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	215	1	1	1	1	126	1.6	8.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	126	2.8	14.9
≥ 65 years	144	1	1	1	1	1	1.0	0.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Anacaulase-bcdb	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Ublituximab-xiiy	431	1	1	1	1	90	1.9	7.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	81	2.5	9.5
41-64 years	238	1	1	1	1	90	1.7	6.4
≥ 65 years	42	1	1	1	1	17	1.4	2.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Daridorexant</i>	9,250	1	3	6	18	591	19.1	38.1
<i>Abrocitinib</i>	703	1	4	9	19	288	18.6	31.3
<i>Mitapivat</i>	29	1	3	7	21	62	12.9	14.3
<i>Pacritinib</i>	1,113	1	3	6	17	418	17.3	36.1
<i>Ganaxolone</i>	40	1	1	3	7	14	4.3	3.7
<i>Lutetium Vipivotide</i>								
<i>Tetraxetan</i>	9,501	2	41	41	44	283	44.9	12.8
<i>Oteseconazole</i>	*****	19	27	106	234	337	143.2	120.7
<i>Mavacamten</i>	1,781	1	2	4	8	356	8.9	21.4
<i>Vonoprazan</i>	60	1	4	7	22	65	13.8	14.3
<i>Tirzepatide</i>	447,862	1	3	7	17	654	17.0	33.7
<i>Tapinarof</i>	7,353	1	11	31	68	594	54.2	66.7
<i>Vutrisiran</i>	1,088	1	83	90	91	287	84.9	29.0
<i>Deucravacitinib</i>	1,569	1	3	6	15	195	13.5	20.1
<i>Terlipressin</i>	*****	3	3	9	25	25	12.3	11.4
<i>Gadopiclemol</i>	1,522	1	20	55	96	330	66.3	55.9
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	2,298	1	3	7	19	314	15.9	26.7
<i>Futibatinib</i>	89	1	3	6	11	68	10.5	13.2
<i>Olutasidenib</i>	33	1	2	3	15	47	8.8	11.9
<i>Adagrasib</i>	236	1	4	9	20	167	16.0	20.8
<i>Lenacapavir</i>	58	1	5	19	148	305	66.1	79.1
<i>Hyperpolarized 129-Xe</i>	0	.	.	.	.	.	.	.
<i>Tebentafusp-tebn</i>	5,416	1	6	6	6	321	6.9	7.5
<i>Faricimab-svoa</i>	452,756	1	31	41	55	596	46.5	26.1
<i>Sutimlimab-jome</i>	2,346	1	13	13	13	265	14.8	10.3
<i>Nivolumab and Relatlimab-rmbw</i>	9,898	1	27	27	27	356	29.9	12.6
<i>Olipudase Alfa-rpcp</i>	90	2	13	13	13	88	16.3	11.8
<i>Spesolimab-sbzo</i>	39	5	12	20	65	219	43.7	51.8

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Ianm</i>	0	.	.	.	.	.	.	.
<i>Eflapegrastim-xnst</i>	6,310	1	20	20	27	210	22.7	12.6
<i>Tremelimumab-actl</i>	263	1	20	20	27	267	29.0	24.3
<i>Teclistamab-cqyv</i>	5,102	1	6	6	13	247	11.2	16.2
<i>Mirvetuximab</i>								
<i>Soravtansine-gynx</i>	970	6	20	20	22	378	24.4	16.6
<i>Teplizumab-mzwv</i>	16	1	1	3	5	13	3.9	3.5
<i>Mosunetuzumab-axgb</i>	215	4	6	20	20	160	17.9	14.3
<i>Anacaulase-bcdb</i>	*****	4	4	8	12	12	8.0	5.7
<i>Ublituximab-xiiy</i>	431	2	13	13	24	196	48.0	63.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	9,250	1	3	6	18	591	19.1	38.1
Female	5,721	1	3	6	18	591	18.4	37.4
Male	3,529	1	3	7	19	414	20.2	39.1
Abrocitinib	703	1	4	9	19	288	18.6	31.3
Female	305	1	4	10	19	286	18.9	31.0
Male	398	1	3	7	19	288	18.4	31.5
Mitapivat	29	1	3	7	21	62	12.9	14.3
Female	13	1	2	5	21	62	14.8	18.0
Male	16	1	4	7	19	34	11.4	10.9
Pacritinib	1,113	1	3	6	17	418	17.3	36.1
Female	528	1	3	7	19	401	18.8	39.8
Male	585	1	2	6	16	418	16.0	32.4
Ganaxolone	40	1	1	3	7	14	4.3	3.7
Female	40	1	1	3	7	14	4.3	3.7
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lutetium Vipivotide								
Tetraxetan	9,501	2	41	41	44	283	44.9	12.8
Female	2	55	55	83	111	111	83.0	39.6
Male	9,499	2	41	41	44	283	44.9	12.7
Oteseconazole	*****	19	27	106	234	337	143.2	120.7
Female	*****	19	27	106	234	337	143.2	120.7
Male	*****	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	1,781	1	2	4	8	356	8.9	21.4
Female	1,196	1	2	4	8	356	8.8	22.1
Male	585	1	2	4	8	284	9.0	19.8
Vonoprazan	60	1	4	7	22	65	13.8	14.3
Female	31	1	5	10	24	43	14.5	12.9
Male	29	1	3	5	14	65	13.0	15.8
Tirzepatide	447,862	1	3	7	17	654	17.0	33.7
Female	281,877	1	3	7	17	654	17.0	33.7
Male	165,985	1	3	7	17	630	17.1	33.7
Tapinarof	7,353	1	11	31	68	594	54.2	66.7

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	3,688	1	11	31	67	535	52.7	64.3
Male	3,665	1	11	32	69	594	55.8	69.0
Vutrisiran	1,088	1	83	90	91	287	84.9	29.0
Female	381	1	83	90	91	198	82.7	29.2
Male	707	1	83	90	91	287	86.1	28.8
Deucravacitinib	1,569	1	3	6	15	195	13.5	20.1
Female	794	1	3	6	15	195	13.0	19.3
Male	775	1	3	7	15	176	14.0	20.9
Terlipressin	*****	3	3	9	25	25	12.3	11.4
Female	*****	25	25	25	25	25	25.0	NaN
Male	*****	3	3	6	9	9	6.0	4.2
Gadopiclenol	1,522	1	20	55	96	330	66.3	55.9
Female	913	1	14	47	93	330	61.3	55.3
Male	609	1	29	63	100	299	73.9	56.0
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	2,298	1	3	7	19	314	15.9	26.7
Female	1,015	1	3	7	20	298	16.8	28.1
Male	1,283	1	3	7	18	314	15.1	25.5
Futibatinib	89	1	3	6	11	68	10.5	13.2
Female	50	1	3	7	11	56	9.7	10.9
Male	39	1	3	6	11	68	11.4	15.9
Olutasidenib	33	1	2	3	15	47	8.8	11.9
Female	19	1	1	3	9	19	5.9	6.5
Male	14	1	2	3	19	47	12.8	16.1
Adagrasib	236	1	4	9	20	167	16.0	20.8
Female	147	1	3	9	24	167	17.6	23.7
Male	89	1	4	8	16	89	13.2	14.6
Lenacapavir	58	1	5	19	148	305	66.1	79.1

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	10	2	14	80	167	184	87.8	80.5
Male	48	1	5	16	140	305	61.6	78.9
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tebentafusp-tebn	5,416	1	6	6	6	321	6.9	7.5
Female	2,909	4	6	6	6	244	6.9	6.5
Male	2,507	1	6	6	6	321	6.9	8.6
Faricimab-svoa	452,756	1	31	41	55	596	46.5	26.1
Female	266,603	1	32	41	55	596	46.7	26.0
Male	186,153	1	31	41	55	565	46.2	26.1
Sutimlimab-jome	2,346	1	13	13	13	265	14.8	10.3
Female	1,699	1	13	13	13	160	14.6	8.2
Male	647	5	13	13	13	265	15.3	14.5
Nivolumab and Relatlimab-rmbw	9,898	1	27	27	27	356	29.9	12.6
Female	3,594	1	27	27	28	356	30.0	12.4
Male	6,304	1	27	27	27	345	29.9	12.7
Olipudase Alfa-rpcp	90	2	13	13	13	88	16.3	11.8
Female	61	2	13	13	13	41	14.9	7.3
Male	29	8	13	13	13	88	19.2	17.7
Spesolimab-sbzo	39	5	12	20	65	219	43.7	51.8
Female	25	6	13	27	76	219	51.2	56.5
Male	14	5	9	15	32	158	30.4	40.4
Daxibotulinumtoxina-lanm	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	6,310	1	20	20	27	210	22.7	12.6
Female	3,341	1	20	20	26	210	23.1	13.0
Male	2,969	1	17	20	27	185	22.3	12.3
Tremelimumab-actl	263	1	20	20	27	267	29.0	24.3
Female	131	1	20	20	27	97	26.8	14.6

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by S

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	132	6	20	20	29	267	31.2	30.9
Teclistamab-cqyv	5,102	1	6	6	13	247	11.2	16.2
Female	2,437	1	6	6	13	247	11.5	17.2
Male	2,665	1	6	6	12	195	10.9	15.2
Mirvetuximab								
Soravtansine-gynx	970	6	20	20	22	378	24.4	16.6
Female	967	6	20	20	22	378	24.4	16.6
Male	3	19	19	23	33	33	25.0	7.2
Teplizumab-mzwv	16	1	1	3	5	13	3.9	3.5
Female	9	1	1	3	4	8	3.2	2.4
Male	7	1	1	4	9	13	4.7	4.6
Mosunetuzumab-axgb	215	4	6	20	20	160	17.9	14.3
Female	97	4	6	20	20	89	17.6	11.4
Male	118	5	6	20	20	160	18.3	16.3
Anacaulase-bcdb	*****	4	4	8	12	12	8.0	5.7
Female	*****	12	12	12	12	12	12.0	NaN
Male	*****	4	4	4	4	4	4.0	NaN
Ublituximab-xiiy	431	2	13	13	24	196	48.0	63.5
Female	315	3	13	13	23	196	47.6	63.4
Male	116	2	13	13	27	196	48.9	64.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	9,250	1	3	6	18	591	19.1	38.1
0-17 years	1	2	2	2	2	2	2.0	NaN
18-24 years	134	1	4	9	20	252	19.2	32.5
25-40 years	1,082	1	3	7	22	591	21.5	42.9
41-64 years	5,164	1	3	6	17	446	17.0	33.9
≥ 65 years	2,869	1	3	6	20	449	21.9	42.9
Abrocitinib	703	1	4	9	19	288	18.6	31.3
0-17 years	23	2	6	8	16	25	10.3	6.7
18-24 years	106	1	4	10	20	288	20.6	36.4
25-40 years	186	1	4	7	17	233	15.5	28.2
41-64 years	242	1	4	11	26	212	20.6	29.8
≥ 65 years	146	1	3	7	16	286	19.1	35.4
Mitapivat	29	1	3	7	21	62	12.9	14.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	5	1	1	2	4	21	5.8	8.6
25-40 years	7	4	5	14	14	31	12.4	9.4
41-64 years	8	1	2	5	8	34	8.0	10.8
≥ 65 years	9	2	7	24	29	62	21.7	19.3
Pacritinib	1,113	1	3	6	17	418	17.3	36.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	2	2	15	27	27	14.5	17.7
41-64 years	78	1	3	6	15	418	18.9	50.0
≥ 65 years	1,033	1	3	6	18	401	17.2	34.9
Ganaxolone	40	1	1	3	7	14	4.3	3.7
0-17 years	36	1	1	3	6	14	4.0	3.4
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	4	1	2	6	12	14	6.8	5.9
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Vipivotide								
Tetraxetan	9,501	2	41	41	44	283	44.9	12.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	499	33	41	41	43	259	44.0	12.3
≥ 65 years	9,002	2	41	41	44	283	44.9	12.8
Oteseconazole	*****	19	27	106	234	337	143.2	120.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	65	65	131	197	197	131.0	93.3
41-64 years	*****	19	84	127	234	337	160.2	126.0
≥ 65 years	*****	26	26	27	316	316	123.0	167.1
Mavacamten	1,781	1	2	4	8	356	8.9	21.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	6	1	2	4	5	5	3.3	1.6
25-40 years	87	1	2	3	6	63	6.5	9.5
41-64 years	471	1	2	5	10	320	12.2	30.2
≥ 65 years	1,217	1	2	3	7	356	7.8	17.5
Vonoprazan	60	1	4	7	22	65	13.8	14.3
0-17 years	2	4	4	5	6	6	5.0	1.4
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	5	2	5	14	15	36	14.4	13.3
41-64 years	26	1	3	7	23	65	13.9	15.9
≥ 65 years	27	1	3	9	25	46	14.2	13.7
Tirzepatide	447,862	1	3	7	17	654	17.0	33.7
0-17 years	131	1	3	7	16	172	16.5	28.6
18-24 years	3,521	1	4	8	21	410	19.3	33.5
25-40 years	46,860	1	3	7	18	553	18.4	36.3
41-64 years	243,351	1	3	7	16	654	16.9	33.7
≥ 65 years	153,999	1	3	7	16	630	16.8	32.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tapinarof	7,353	1	11	31	68	594	54.2	66.7
0-17 years	125	1	17	30	64	477	66.5	86.8
18-24 years	287	1	11	31	77	374	59.8	74.9
25-40 years	1,311	1	11	32	66	535	53.0	66.3
41-64 years	3,951	1	11	32	68	594	54.2	65.7
≥ 65 years	1,679	1	10	30	69	561	53.3	66.3
Vutrisiran	1,088	1	83	90	91	287	84.9	29.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	11	11	16	21	21	16.0	7.1
41-64 years	146	1	83	90	91	287	86.7	30.3
≥ 65 years	940	1	83	90	91	279	84.8	28.6
Deucravacitinib	1,569	1	3	6	15	195	13.5	20.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	67	1	4	9	18	84	14.2	17.0
25-40 years	274	1	3	7	16	173	15.4	23.6
41-64 years	800	1	3	6	14	180	12.8	19.8
≥ 65 years	428	1	3	8	16	195	13.4	18.6
Terlipressin	*****	3	3	9	25	25	12.3	11.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	3	3	9	25	25	12.3	11.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gadopichlenol	1,522	1	20	55	96	330	66.3	55.9
0-17 years	22	1	19	76	97	121	62.5	40.6
18-24 years	8	20	42	64	105	180	77.6	54.6
25-40 years	146	1	20	56	104	330	67.8	56.5
41-64 years	613	1	17	55	96	284	65.4	56.0
≥ 65 years	733	1	22	55	95	311	66.8	56.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	2,298	1	3	7	19	314	15.9	26.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	6	6	21	35	35	20.5	20.5
25-40 years	76	1	4	11	27	191	21.6	30.9
41-64 years	813	1	3	7	20	314	16.6	27.0
≥ 65 years	1,407	1	3	7	18	304	15.1	26.3
Futibatinib	89	1	3	6	11	68	10.5	13.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	3	3	5	20	20	9.3	9.3
41-64 years	37	1	3	7	14	68	12.3	15.8
≥ 65 years	49	1	3	6	11	64	9.2	11.2
Olutasidenib	33	1	2	3	15	47	8.8	11.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	7	1	1	7	18	19	9.0	8.1
≥ 65 years	26	1	2	3	9	47	8.8	12.9
Adagrasib	236	1	4	9	20	167	16.0	20.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	2	2	2	2	2	2.0	NaN
41-64 years	68	1	3	8	19	66	14.6	16.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	167	1	4	9	22	167	16.6	22.3
Lenacapavir	58	1	5	19	148	305	66.1	79.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	7	2	6	14	174	184	75.4	85.3
41-64 years	37	1	5	17	144	305	63.5	79.3
≥ 65 years	14	3	5	26	162	211	68.4	81.3
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tebentafusp-tebn	5,416	1	6	6	6	321	6.9	7.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	119	5	6	6	6	13	6.2	1.0
41-64 years	1,186	1	6	6	6	62	6.6	3.1
≥ 65 years	4,111	3	6	6	6	321	6.9	8.5
Faricimab-svoa	452,756	1	31	41	55	596	46.5	26.1
0-17 years	5	40	41	42	48	90	52.2	21.4
18-24 years	9	34	48	55	72	90	60.3	19.6
25-40 years	671	1	29	41	57	428	48.4	36.3
41-64 years	18,894	1	27	40	55	516	44.4	29.4
≥ 65 years	433,177	1	32	41	55	596	46.6	25.9
Sutimlimab-jome	2,346	1	13	13	13	265	14.8	10.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	43	6	13	13	13	41	14.0	5.7
41-64 years	130	5	13	13	14	97	15.3	9.9
≥ 65 years	2,173	1	13	13	13	265	14.8	10.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Nivolumab and Relatlimab-rmbw	9,898	1	27	27	27	356	29.9	12.6
0-17 years	2	27	27	27	27	27	27.0	0.0
18-24 years	14	27	27	27	28	33	27.6	1.6
25-40 years	115	24	27	27	28	167	31.2	16.1
41-64 years	1,576	4	27	27	28	304	30.3	14.5
≥ 65 years	8,191	1	27	27	27	356	29.9	12.2
Olipudase Alfa-rpcp	90	2	13	13	13	88	16.3	11.8
0-17 years	46	8	13	13	13	88	18.5	15.2
18-24 years	2	13	13	20	27	27	20.0	9.9
25-40 years	19	6	13	13	13	13	12.6	1.6
41-64 years	23	2	13	13	17	28	14.6	7.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	39	5	12	20	65	219	43.7	51.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	4	6	11	24	95	158	52.8	71.0
41-64 years	11	6	13	15	82	219	51.7	65.3
≥ 65 years	24	5	12	21	42	145	38.5	43.0
Daxibotulinumtoxina-	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	6,310	1	20	20	27	210	22.7	12.6
0-17 years	2	20	20	20	20	20	20.0	0.0
18-24 years	8	20	20	24	29	66	28.9	15.6
25-40 years	24	2	13	19	20	78	20.1	14.2
41-64 years	321	3	13	20	27	146	23.3	16.2
≥ 65 years	5,955	1	20	20	26	210	22.7	12.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tremelimumab-actl	263	1	20	20	27	267	29.0	24.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	56	4	20	21	31	267	32.6	35.5
≥ 65 years	207	1	20	20	27	190	28.1	20.2
Teclistamab-cqyv	5,102	1	6	6	13	247	11.2	16.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	11	5	6	6	12	104	16.1	29.3
41-64 years	1,306	1	6	6	13	181	11.0	15.4
≥ 65 years	3,785	1	6	6	13	247	11.2	16.4
Mirvetuximab								
Soravtansine-gynx	970	6	20	20	22	378	24.4	16.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	19	20	20	22	48	23.8	8.2
41-64 years	438	6	20	20	23	132	24.5	12.6
≥ 65 years	513	13	20	20	21	378	24.4	19.6
Teplizumab-mzwv	16	1	1	3	5	13	3.9	3.5
0-17 years	5	1	1	1	4	6	2.6	2.3
18-24 years	1	13	13	13	13	13	13.0	NaN
25-40 years	7	1	2	3	4	8	3.6	2.2
41-64 years	3	1	1	1	9	9	3.7	4.6
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	215	4	6	20	20	160	17.9	14.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	6	6	6	6	6	6.0	NaN
41-64 years	70	5	6	20	20	160	20.2	21.2
≥ 65 years	144	4	6	20	20	49	16.9	9.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Anacaulase-bcdb	*****	4	4	8	12	12	8.0	5.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	4	4	4	4	4	4.0	NaN
≥ 65 years	*****	12	12	12	12	12	12.0	NaN
Ublituximab-xiiy	431	2	13	13	24	196	48.0	63.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	10	13	13	14	19	160	42.8	60.0
25-40 years	141	11	13	13	152	196	56.3	68.7
41-64 years	238	3	13	13	24	196	46.9	62.8
≥ 65 years	42	2	13	13	13	175	27.1	43.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Daridorexant</i>	3,935	1	3	8	24	591	24.5	47.4
<i>Abrocitinib</i>	289	1	3	7	20	288	19.3	35.9
<i>Mitapivat</i>	13	1	4	8	21	34	12.4	11.1
<i>Pacritinib</i>	453	1	3	7	21	418	21.8	47.9
<i>Ganaxolone</i>	9	1	3	4	9	14	5.9	4.5
<i>Lutetium Vipivotide</i>								
<i>Tetraxetan</i>	3,401	2	41	41	45	209	45.1	11.3
<i>Oteseconazole</i>	*****	19	27	106	234	337	143.2	120.7
<i>Mavacamten</i>	879	1	2	4	9	356	9.8	22.0
<i>Vonoprazan</i>	52	1	4	7	24	65	14.0	14.3
<i>Tirzepatide</i>	207,136	1	3	7	17	654	18.5	38.2
<i>Tapinarof</i>	4,602	1	11	32	73	594	57.9	72.3
<i>Vutrisiran</i>	472	1	83	90	91	279	83.8	32.1
<i>Deucravacitinib</i>	727	1	3	7	16	195	14.8	22.9
<i>Terlipressin</i>	*****	9	9	17	25	25	17.0	11.3
<i>Gadopiclenol</i>	1,305	1	20	56	98	330	68.2	58.1
<i>Omidenepag Isopropyl</i>								
<i>Ophthalmic Solution</i>	0	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and</i>								
<i>Taurursodiol</i>	1,031	1	3	6	17	314	16.8	32.3
<i>Futibatinib</i>	40	1	3	6	13	68	10.7	13.2
<i>Olutasidenib</i>	22	1	2	3	7	47	8.2	12.8
<i>Adagrasib</i>	131	1	3	8	21	167	16.2	22.4
<i>Lenacapavir</i>	51	1	5	20	157	305	68.1	81.3
<i>Hyperpolarized 129-Xe</i>	0	.	.	.	.	.	.	.
<i>Tebentafusp-tebn</i>	188	4	6	6	6	103	8.8	11.0
<i>Faricimab-svoa</i>	95,483	1	30	41	55	573	47.5	30.9
<i>Sutimlimab-jome</i>	157	5	6	7	13	265	12.5	23.1
<i>Nivolumab and Relatlimab-</i>								
<i>rmbw</i>	2,091	1	27	27	28	304	29.9	12.6
<i>Olipudase Alfa-rpcp</i>	11	4	13	13	13	27	13.9	6.8
<i>Spesolimab-sbzo</i>	31	5	12	16	32	219	34.5	47.6

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>DaxibotulinumtoxinA-lanm</i>	0	.	.	.	.	.	.	.
<i>Eflapegrastim-xnst</i>	2,235	1	20	20	27	188	24.0	13.8
<i>Tremelimumab-actl</i>	113	4	20	20	27	267	28.3	31.8
<i>Teclistamab-cqyv</i>	642	1	7	13	26	247	24.9	30.9
<i>Mirvetuximab Soravtansine-gynx</i>	227	9	20	20	21	378	25.9	28.3
<i>Teplizumab-mzwv</i>	14	1	1	4	6	13	4.1	3.7
<i>Mosunetuzumab-axgb</i>	38	4	6	6	6	160	11.5	25.1
<i>Anacaulase-bcdb</i>	*****	4	4	8	12	12	8.0	5.7
<i>Ublituximab-xiiy</i>	341	2	13	13	14	196	20.0	30.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Daridorexant	3,935	1	3	8	24	591	24.5	47.4
Female	2,444	1	3	7	24	591	23.2	45.6
Male	1,491	1	3	8	26	414	26.8	50.3
Abrocitinib	289	1	3	7	20	288	19.3	35.9
Female	133	1	3	9	20	286	20.7	37.7
Male	156	1	3	7	20	288	18.2	34.5
Mitapivat	13	1	4	8	21	34	12.4	11.1
Female	7	4	4	14	29	34	15.9	12.5
Male	6	1	2	7	10	24	8.3	8.4
Pacritinib	453	1	3	7	21	418	21.8	47.9
Female	201	1	4	9	25	401	27.5	59.0
Male	252	1	3	6	19	418	17.4	36.1
Ganaxolone	9	1	3	4	9	14	5.9	4.5
Female	9	1	3	4	9	14	5.9	4.5
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lutetium Vipivotide								
Tetraxetan	3,401	2	41	41	45	209	45.1	11.3
Female	1	55	55	55	55	55	55.0	NaN
Male	3,400	2	41	41	45	209	45.1	11.4
Oteseconazole	*****	19	27	106	234	337	143.2	120.7
Female	*****	19	27	106	234	337	143.2	120.7
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mavacamten	879	1	2	4	9	356	9.8	22.0
Female	600	1	2	4	8	356	9.4	20.7
Male	279	1	2	4	10	284	10.6	24.6
Vonoprazan	52	1	4	7	24	65	14.0	14.3
Female	28	1	4	9	25	43	14.6	13.5
Male	24	1	4	6	19	65	13.2	15.5
Tirzepatide	207,136	1	3	7	17	654	18.5	38.2
Female	129,333	1	3	7	17	654	18.3	38.2
Male	77,803	1	3	7	18	630	18.8	38.3
Tapinarof	4,602	1	11	32	73	594	57.9	72.3

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	2,299	1	11	31	68	535	55.5	69.6
Male	2,303	1	11	33	76	594	60.2	74.9
Vutrisiran	472	1	83	90	91	279	83.8	32.1
Female	166	1	83	90	91	198	80.6	32.9
Male	306	1	83	90	91	279	85.6	31.6
Deucravacitinib	727	1	3	7	16	195	14.8	22.9
Female	368	1	3	7	16	195	14.3	22.6
Male	359	1	3	8	17	176	15.3	23.2
Terlipressin	*****	9	9	17	25	25	17.0	11.3
Female	*****	25	25	25	25	25	25.0	NaN
Male	*****	9	9	9	9	9	9.0	NaN
Gadopiclenol	1,305	1	20	56	98	330	68.2	58.1
Female	796	1	14	48	95	330	62.6	57.1
Male	509	1	31	64	105	299	77.0	58.7
Omidenepag Isopropyl Ophthalmic Solution	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and Taurursodiol	1,031	1	3	6	17	314	16.8	32.3
Female	454	1	3	7	18	298	17.6	32.9
Male	577	1	3	6	16	314	16.1	31.9
Futibatinib	40	1	3	6	13	68	10.7	13.2
Female	23	1	3	6	14	31	9.0	7.7
Male	17	1	3	6	11	68	13.0	18.2
Olutasidenib	22	1	2	3	7	47	8.2	12.8
Female	14	1	1	3	4	18	4.1	4.7
Male	8	2	2	5	31	47	15.4	18.9
Adagrasib	131	1	3	8	21	167	16.2	22.4
Female	85	1	3	8	19	167	17.1	24.6
Male	46	1	4	8	21	89	14.5	17.6
Lenacapavir	51	1	5	20	157	305	68.1	81.3

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	8	2	11	90	169	184	90.5	85.0
Male	43	1	5	17	144	305	63.9	80.9
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Tebentafusp-tebn	188	4	6	6	6	103	8.8	11.0
Female	99	5	6	6	6	103	9.2	14.5
Male	89	4	6	6	7	27	8.4	4.8
Faricimab-svoa	95,483	1	30	41	55	573	47.5	30.9
Female	56,159	1	31	41	55	573	47.7	30.9
Male	39,324	1	30	41	55	516	47.3	30.8
Sutimlimab-jome	157	5	6	7	13	265	12.5	23.1
Female	108	6	6	6	13	112	10.8	12.6
Male	49	5	6	7	13	265	16.2	36.9
Nivolumab and Relatlimab-rmbw	2,091	1	27	27	28	304	29.9	12.6
Female	769	3	27	27	28	174	29.6	10.5
Male	1,322	1	27	27	28	304	30.2	13.7
Olipudase Alfa-rpcp	11	4	13	13	13	27	13.9	6.8
Female	7	4	6	13	13	13	10.7	3.9
Male	4	13	13	19	26	27	19.5	7.5
Spesolimab-sbzo	31	5	12	16	32	219	34.5	47.6
Female	20	6	13	18	41	219	37.8	50.5
Male	11	5	9	13	27	158	28.6	43.7
Daxibotulinumtoxina-lanm	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	2,235	1	20	20	27	188	24.0	13.8
Female	1,250	1	20	20	27	188	24.0	12.9
Male	985	1	20	20	27	185	24.0	14.8
Tremelimumab-actl	113	4	20	20	27	267	28.3	31.8
Female	54	4	20	20	23	48	22.0	6.7

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	59	6	20	20	27	267	34.1	42.9
Teclistamab-cqyv	642	1	7	13	26	247	24.9	30.9
Female	306	1	6	13	27	247	26.3	33.5
Male	336	1	8	13	24	181	23.5	28.2
Mirvetuximab								
Soravtansine-gynx	227	9	20	20	21	378	25.9	28.3
Female	226	9	20	20	21	378	25.9	28.4
Male	1	33	33	33	33	33	33.0	NaN
Teplizumab-mzwv	14	1	1	4	6	13	4.1	3.7
Female	7	1	1	3	6	8	3.4	2.8
Male	7	1	1	4	9	13	4.7	4.6
Mosunetuzumab-axgb	38	4	6	6	6	160	11.5	25.1
Female	20	4	6	6	6	20	7.3	4.0
Male	18	5	6	6	6	160	16.1	36.2
Anacaulase-bcdb	*****	4	4	8	12	12	8.0	5.7
Female	*****	12	12	12	12	12	12.0	NaN
Male	*****	4	4	4	4	4	4.0	NaN
Ublituximab-xiiy	341	2	13	13	14	196	20.0	30.2
Female	250	5	13	13	14	196	20.9	32.1
Male	91	2	13	13	14	185	17.7	24.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Daridorexant	3,935	1	3	8	24	591	24.5	47.4
0-17 years	1	2	2	2	2	2	2.0	NaN
18-24 years	62	1	4	12	20	187	18.5	28.5
25-40 years	454	1	3	9	29	591	29.3	57.6
41-64 years	2,087	1	3	7	21	414	21.2	41.2
≥ 65 years	1,331	1	3	8	28	449	28.4	52.7
Abrocitinib	289	1	3	7	20	288	19.3	35.9
0-17 years	11	2	3	8	20	25	10.3	8.1
18-24 years	37	1	4	9	21	288	21.4	47.2
25-40 years	68	1	3	7	17	179	15.3	26.1
41-64 years	105	1	3	9	26	212	18.7	29.9
≥ 65 years	68	1	4	7	20	286	24.8	47.1
Mitapivat	13	1	4	8	21	34	12.4	11.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	3	1	1	4	21	21	8.7	10.8
25-40 years	3	4	4	5	14	14	7.7	5.5
41-64 years	3	5	5	8	34	34	15.7	15.9
≥ 65 years	4	2	6	17	27	29	16.3	12.4
Pacritinib	453	1	3	7	21	418	21.8	47.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	2	2	2	2	2	2.0	NaN
41-64 years	35	1	3	4	13	418	24.1	72.0
≥ 65 years	417	1	3	7	22	401	21.7	45.4
Ganaxolone	9	1	3	4	9	14	5.9	4.5
0-17 years	7	1	1	4	10	14	5.9	4.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	2	3	3	6	9	9	6.0	4.2
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Vipivotide								
Tetraxetan	3,401	2	41	41	45	209	45.1	11.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	210	33	41	41	44	97	44.5	9.2
≥ 65 years	3,191	2	41	41	45	209	45.1	11.5
Oteseconazole	*****	19	27	106	234	337	143.2	120.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	65	65	131	197	197	131.0	93.3
41-64 years	*****	19	84	127	234	337	160.2	126.0
≥ 65 years	*****	26	26	27	316	316	123.0	167.1
Mavacamten	879	1	2	4	9	356	9.8	22.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	4	4	5	5	5	4.5	0.7
25-40 years	30	1	2	2	6	33	6.7	9.4
41-64 years	203	1	3	5	11	284	13.7	31.2
≥ 65 years	644	1	2	4	8	356	8.7	18.6
Vonoprazan	52	1	4	7	24	65	14.0	14.3
0-17 years	1	6	6	6	6	6	6.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	5	2	5	14	15	36	14.4	13.3
41-64 years	25	1	3	7	23	65	14.3	16.1
≥ 65 years	21	1	4	9	25	41	13.9	13.2
Tirzepatide	207,136	1	3	7	17	654	18.5	38.2
0-17 years	67	1	3	6	12	167	13.7	25.1
18-24 years	1,609	1	3	7	19	410	19.8	37.9
25-40 years	20,985	1	3	7	17	553	19.2	41.3
41-64 years	110,842	1	3	7	17	654	18.2	38.3
≥ 65 years	73,633	1	3	7	18	630	18.8	37.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tapinarof	4,602	1	11	32	73	594	57.9	72.3
0-17 years	84	1	21	42	107	477	81.5	98.5
18-24 years	190	1	14	34	88	373	65.9	76.6
25-40 years	861	1	11	33	68	535	55.6	70.9
41-64 years	2,430	1	11	32	72	594	57.3	71.1
≥ 65 years	1,037	1	10	31	74	561	57.7	72.8
Vutrisiran	472	1	83	90	91	279	83.8	32.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	11	11	11	11	11	11.0	NaN
41-64 years	62	1	83	90	91	167	80.4	31.1
≥ 65 years	409	1	83	90	91	279	84.5	32.1
Deucravacitinib	727	1	3	7	16	195	14.8	22.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	29	1	4	9	18	83	15.8	18.8
25-40 years	135	1	3	9	17	173	16.3	23.2
41-64 years	362	1	3	6	16	180	14.6	24.2
≥ 65 years	201	1	4	8	16	195	14.0	20.9
Terlipressin	*****	9	9	17	25	25	17.0	11.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	9	9	17	25	25	17.0	11.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gadopiclenol	1,305	1	20	56	98	330	68.2	58.1
0-17 years	21	1	21	84	97	121	64.6	40.3
18-24 years	8	20	42	64	105	180	77.6	54.6
25-40 years	127	1	14	59	108	330	68.9	59.1
41-64 years	505	1	17	57	99	284	68.5	59.0
≥ 65 years	644	1	22	55	97	311	67.9	57.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Omidenepag Isopropyl								
Opthalmic Solution	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Sodium Phenylbutyrate and								
Taurursodiol	1,031	1	3	6	17	314	16.8	32.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	35	35	35	35	35	35.0	NaN
25-40 years	38	1	3	9	21	143	16.3	25.5
41-64 years	340	1	3	7	21	314	19.7	35.3
≥ 65 years	652	1	3	6	15	304	15.2	31.0
Futibatinib	40	1	3	6	13	68	10.7	13.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	3	3	12	20	20	11.5	12.0
41-64 years	15	1	2	7	14	68	12.7	18.1
≥ 65 years	23	1	4	6	11	39	9.4	9.4
Olutasidenib	22	1	2	3	7	47	8.2	12.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	4	1	1	2	5	7	2.8	2.9
≥ 65 years	18	1	2	3	9	47	9.4	13.9
Adagrasib	131	1	3	8	21	167	16.2	22.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	2	2	2	2	2	2.0	NaN
41-64 years	42	1	3	8	17	63	14.3	16.1

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	88	1	4	8	22	167	17.3	24.9
Lenacapavir	51	1	5	20	157	305	68.1	81.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	6	2	6	12	174	184	65.0	88.5
41-64 years	32	1	5	24	148	305	68.0	81.4
≥ 65 years	13	3	5	22	162	211	69.7	84.4
Hyperpolarized 129-Xe	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Tebentafusp-tebn	188	4	6	6	6	103	8.8	11.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	6	6	6	6	6	6.0	0.0
41-64 years	42	5	6	6	7	27	8.7	5.6
≥ 65 years	144	4	6	6	6	103	8.9	12.2
Faricimab-svoa	95,483	1	30	41	55	573	47.5	30.9
0-17 years	1	48	48	48	48	48	48.0	NaN
18-24 years	4	34	41	48	60	72	50.5	15.8
25-40 years	198	1	30	41	55	428	49.8	40.2
41-64 years	4,528	1	27	38	55	516	45.8	33.1
≥ 65 years	90,752	1	31	41	55	573	47.6	30.7
Sutimlimab-jome	157	5	6	7	13	265	12.5	23.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	4	6	6	7	10	13	8.0	3.4
41-64 years	15	6	6	9	13	24	10.7	5.7
≥ 65 years	138	5	6	7	13	265	12.8	24.6

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Nivolumab and Relatlimab-rmbw	2,091	1	27	27	28	304	29.9	12.6
0-17 years	1	27	27	27	27	27	27.0	NaN
18-24 years	2	27	27	28	28	28	27.5	0.7
25-40 years	31	25	27	27	31	76	31.8	11.0
41-64 years	315	4	27	27	28	304	31.0	18.4
≥ 65 years	1,742	1	27	27	28	174	29.7	11.3
Olipudase Alfa-rpcp	11	4	13	13	13	27	13.9	6.8
0-17 years	2	13	13	13	13	13	13.0	0.0
18-24 years	1	27	27	27	27	27	27.0	NaN
25-40 years	5	6	13	13	13	13	11.6	3.1
41-64 years	3	4	4	13	25	25	14.0	10.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Spesolimab-sbzo	31	5	12	16	32	219	34.5	47.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	4	6	11	24	95	158	52.8	71.0
41-64 years	9	7	13	15	82	219	54.9	70.8
≥ 65 years	18	5	9	17	27	65	20.3	15.7
Daxibotulinumtoxina-lanm	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
Eflapegrastim-xnst	2,235	1	20	20	27	188	24.0	13.8
0-17 years	1	20	20	20	20	20	20.0	NaN
18-24 years	2	20	20	24	27	27	23.5	4.9
25-40 years	9	2	14	20	28	78	25.8	22.1
41-64 years	123	3	15	20	27	118	24.7	15.7
≥ 65 years	2,100	1	20	20	27	188	23.9	13.7

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tremelimumab-actl	113	4	20	20	27	267	28.3	31.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	21	4	20	21	23	267	33.1	53.9
≥ 65 years	92	4	20	20	27	190	27.2	24.5
Teclistamab-cqyv	642	1	7	13	26	247	24.9	30.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	12	12	58	104	104	58.0	65.1
41-64 years	135	1	6	13	20	121	20.7	24.9
≥ 65 years	505	1	7	13	27	247	25.9	32.1
Mirvetuximab Soravtansine-gynx	227	9	20	20	21	378	25.9	28.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	6	19	20	20	20	21	20.0	0.6
41-64 years	110	9	20	20	22	132	24.9	16.5
≥ 65 years	111	13	20	20	21	378	27.2	37.1
Teplizumab-mzwv	14	1	1	4	6	13	4.1	3.7
0-17 years	5	1	1	1	4	6	2.6	2.3
18-24 years	1	13	13	13	13	13	13.0	NaN
25-40 years	5	1	3	4	4	8	4.0	2.5
41-64 years	3	1	1	1	9	9	3.7	4.6
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mosunetuzumab-axgb	38	4	6	6	6	160	11.5	25.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	6	6	6	6	6	6.0	NaN
41-64 years	12	5	6	6	6	160	19.9	44.3
≥ 65 years	25	4	6	6	6	20	7.6	4.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Anacaulase-bcdb	*****	4	4	8	12	12	8.0	5.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	4	4	4	4	4	4.0	NaN
≥ 65 years	*****	12	12	12	12	12	12.0	NaN
Ublituximab-xiiy	341	2	13	13	14	196	20.0	30.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	8	13	13	13	16	19	14.4	2.3
25-40 years	105	11	13	13	14	183	21.4	32.4
41-64 years	191	5	13	13	14	196	20.9	32.4
≥ 65 years	37	2	13	13	13	29	13.3	3.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024 ^{1,2}

Censoring Reason									
	End of Exposure Episode ³			Occurrence of User-Defined		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Daridorexant</i>	19,770	19,417	98.2%	0	0.0%	2,824	14.3%	2,635	13.3%
<i>Abrocitinib</i>	1,312	1,265	96.4%	0	0.0%	283	21.6%	279	21.3%
<i>Mitapivat</i>	55	54	98.2%	0	0.0%	16	29.1%	12	21.8%
<i>Pacritinib</i>	1,992	1,891	94.9%	0	0.0%	232	11.6%	213	10.7%
<i>Ganaxolone</i>	63	63	100.0%	0	0.0%	17	27.0%	14	22.2%
<i>Lutetium Vipivotide</i>									
<i>Tetraxetan</i>	13,804	13,804	100.0%	0	0.0%	*****	*****	14	0.1%
<i>Oteseconazole</i>	*****	169	98.8%	0	0.0%	29	17.0%	26	15.2%
<i>Mavacamten</i>	3,381	3,234	95.7%	0	0.0%	1,217	36.0%	1,276	37.7%
<i>Vonoprazan</i>	491	328	66.8%	0	0.0%	162	33.0%	325	66.2%
<i>Tirzepatide</i>	886,682	850,363	95.9%	0	0.0%	279,647	31.5%	278,061	31.4%
<i>Tapinarof</i>	21,395	21,028	98.3%	0	0.0%	2,394	11.2%	2,198	10.3%
<i>Vutrisiran</i>	1,695	1,686	99.5%	0	0.0%	79	4.7%	77	4.5%
<i>Deucravacitinib</i>	3,086	2,969	96.2%	0	0.0%	624	20.2%	661	21.4%
<i>Terlipressin</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Gadopiclenol</i>	24,270	24,270	100.0%	0	0.0%	126	0.5%	180	0.7%
<i>Omidenepag Isopropyl Ophthalmic Solution</i>	0	.	.	.	.	.	.	.	.
<i>Sodium Phenylbutyrate and Taurursodiol</i>	4,525	4,383	96.9%	0	0.0%	861	19.0%	770	17.0%
<i>Futibatinib</i>	171	164	95.9%	0	0.0%	33	19.3%	34	19.9%
<i>Olutasidenib</i>	84	76	90.5%	0	0.0%	18	21.4%	19	22.6%
<i>Adagrasib</i>	587	541	92.2%	0	0.0%	106	18.1%	103	17.5%
<i>Lenacapavir</i>	251	242	96.4%	0	0.0%	139	55.4%	134	53.4%
<i>Hyperpolarized 129-Xe</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tebentafusp-tebn</i>	5,612	5,612	100.0%	0	0.0%	*****	*****	*****	*****
<i>Faricimab-svoa</i>	567,077	567,034	100.0%	0	0.0%	566	0.1%	710	0.1%
<i>Sutimlimab-jome</i>	2,516	2,516	100.0%	0	0.0%	*****	*****	*****	*****
<i>Nivolumab and Relatlimab-rmbw</i>	12,443	12,441	100.0%	0	0.0%	15	0.1%	18	0.1%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024 ^{1,2}

Censoring Reason									
	End of Exposure Episode ³			Occurrence of User-Defined		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Olipudase Alfa-rpcp</i>	102	101	99.0%	0	0.0%	*****	*****	*****	*****
<i>Spesolimab-sbzo</i>	94	94	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Daxibotulinumtoxina-lanm</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Eflapegrastim-xnst</i>	9,613	9,610	100.0%	0	0.0%	13	0.1%	16	0.2%
<i>Tremelimumab-actl</i>	1,235	1,235	100.0%	0	0.0%	*****	*****	*****	*****
<i>Teclistamab-cqyv</i>	6,335	6,335	100.0%	0	0.0%	*****	*****	*****	*****
<i>Mirvetuximab</i>									
<i>Soravtansine-gynx</i>	1,250	1,250	100.0%	0	0.0%	*****	*****	*****	*****
<i>Teplizumab-mzwv</i>	58	58	100.0%	0	0.0%	*****	*****	*****	*****
<i>Mosunetuzumab-axgb</i>	278	278	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Anacaulase-bcdb</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Ublituximab-xiiy</i>	913	912	99.9%	0	0.0%	16	1.8%	17	1.9%

¹Please note that the following results (reasons for censoring) are for each exposure episode and patients may have more than one exposure episode. An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Daridorexant		Abrocitinib		Mitapivat		Pacritinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	12,335	91,482,621	710	91,494,246	*****	*****	924	91,494,032
Claim recorded during specified age range	12,335	0	710	0	*****	0	924	0
Episode defining index claim recorded during the query period	12,335	0	710	0	*****	0	924	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Daridorexant		Abrocitinib		Mitapivat		Pacritinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	10,520	1,815	609	101	*****	*****	879	45
Met inclusion and exclusion criteria	10,520	0	609	0	*****	0	879	0
Had sufficient post-index continuous enrollment	10,520	0	609	0	*****	0	879	0
Final cohort								
Number of members	10,520	N/A	609	N/A	26	N/A	879	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Ganaxolone		Lutetium Vipivotide Tetraxetan		Oteseconazole		Mavacamten	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	4,562	91,490,394	177	91,494,779	1,817	91,493,139
Claim recorded during specified age range	*****	0	4,562	0	177	0	1,817	0
Episode defining index claim recorded during the query period	*****	0	4,562	0	177	0	1,817	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Ganaxolone		Lutetium Vipivotide Tetraxetan		Oteseconazole		Mavacamten	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	*****	4,303	259	161	16	1,600	217
Met inclusion and exclusion criteria	*****	0	4,303	0	161	0	1,600	0
Had sufficient post-index continuous enrollment	*****	0	4,303	0	161	0	1,600	0
Final cohort								
Number of members	23	N/A	4,303	N/A	161	N/A	1,600	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Vonoprazan		Tirzepatide		Tapinarof		Vutrisiran	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	589	91,494,367	516,816	90,978,140	15,632	91,479,324	647	91,494,309
Claim recorded during specified age range	589	0	516,816	0	15,632	0	647	0
Episode defining index claim recorded during the query period	589	0	516,816	0	15,632	0	647	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Vonoprazan		Tirzepatide		Tapinarof		Vutrisiran	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	431	158	438,820	77,996	14,042	1,590	607	40
Met inclusion and exclusion criteria	431	0	438,820	0	14,042	0	607	0
Had sufficient post-index continuous enrollment	431	0	438,820	0	14,042	0	607	0
Final cohort								
Number of members	431	N/A	438,820	N/A	14,042	N/A	607	N/A

*****Data are not presented in

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Deucravacitinib		Terlipressin		Gadopiclenol		Omidenepag Isopropyl Ophthalmic Solution	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	1,717	91,493,239	*****	*****	26,314	91,468,642	0	91,494,956
Claim recorded during specified age range	1,717	0	*****	0	26,314	0	0	0
Episode defining index claim recorded during the query period	1,717	0	*****	0	26,314	0	0	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Deucravacitinib		Terlipressin		Gadopicienol		Omidenepag Isopropyl Ophthalmic Solution	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,517	200	*****	*****	22,748	3,566	0	0
Met inclusion and exclusion criteria	1,517	0	*****	0	22,748	0	0	0
Had sufficient post-index continuous enrollment	1,517	0	*****	0	22,748	0	0	0
Final cohort								
Number of members	1,517	N/A	42	N/A	22,748	N/A	0	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Sodium Phenylbutyrate and Taurursodiol		Futibatinib		Olutasidenib		Adagrasib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	2,682	91,492,274	*****	*****	*****	*****	394	91,494,562
Claim recorded during specified age range	2,682	0	*****	0	*****	0	394	0
Episode defining index claim recorded during the query period	2,682	0	*****	0	*****	0	394	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Sodium Phenylbutyrate and Taurursodiol		Futibatinib		Olutasidenib		Adagrasib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	2,227	455	*****	*****	*****	*****	351	43
Met inclusion and exclusion criteria	2,227	0	*****	0	*****	0	351	0
Had sufficient post-index continuous enrollment	2,227	0	*****	0	*****	0	351	0
Final cohort								
Number of members	2,227	N/A	82	N/A	51	N/A	351	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Lenacapavir		Hyperpolarized 129-Xe		Tebentafusp-tebn		Faricimab-svoa	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	223	91,494,733	*****	*****	217	91,494,739	119,344	91,375,612
Claim recorded during specified age range	223	0	*****	0	217	0	119,344	0
Episode defining index claim recorded during the query period	223	0	*****	0	217	0	119,344	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Lenacapavir		Hyperpolarized 129-Xe		Tebentafusp-tebn		Faricimab-svoa	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	193	30	*****	*****	196	21	114,321	5,023
Met inclusion and exclusion criteria	193	0	*****	0	196	0	114,321	0
Had sufficient post-index continuous enrollment	193	0	*****	0	196	0	114,321	0
Final cohort								
Number of members	193	N/A	61	N/A	196	N/A	114,321	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Sutimlimab-jome		Nivolumab and Relatlimab-rmbw		Olipudase Alfa-rpcp		Spesolimab-sbzo	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	181	91,494,775	2,736	91,492,220	12	91,494,944	*****	*****
Claim recorded during specified age range	181	0	2,736	0	12	0	*****	0
Episode defining index claim recorded during the query period	181	0	2,736	0	12	0	*****	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Sutimlimab-jome		Nivolumab and Relatlimab-rmbw		Olipudase Alfa-rpcp		Spesolimab-sbzo	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	170	11	2,545	191	12	0	*****	*****
Met inclusion and exclusion criteria	170	0	2,545	0	12	0	*****	0
Had sufficient post-index continuous enrollment	170	0	2,545	0	12	0	*****	0
Final cohort								
Number of members	170	N/A	2,545	N/A	12	N/A	55	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Daxibotulinumtoxina-lanm		Eflapegrastim-xnst		Tremelimumab-actl		Teclistamab-cqyv	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	3,514	91,491,442	1,123	91,493,833	1,320	91,493,636
Claim recorded during specified age range	*****	0	3,514	0	1,123	0	1,320	0
Episode defining index claim recorded during the query period	*****	0	3,514	0	1,123	0	1,320	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Daxibotulinumtoxina-lanm		Eflapegrastim-xnst		Tremelimumab-actl		Teclistamab-cqyv	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	*****	3,303	211	972	151	1,233	87
Met inclusion and exclusion criteria	*****	0	3,303	0	972	0	1,233	0
Had sufficient post-index continuous enrollment	*****	0	3,303	0	972	0	1,233	0
Final cohort								
Number of members	*****	N/A	3,303	N/A	972	N/A	1,233	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Mirvetuximab Soravtansine-gynx		Teplizumab-mzwv		Mosunetuzumab-axgb	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447	91,494,956	52,447
Members with a valid index event						
Had any cohort-defining claim during the query period	316	91,494,640	*****	*****	*****	*****
Claim recorded during specified age range	316	0	*****	0	*****	0
Episode defining index claim recorded during the query period	316	0	*****	0	*****	0

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Mirvetuximab Soravtansine-gynx		Teplizumab-mzwv		Mosunetuzumab-axgb	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	280	36	*****	*****	*****	*****
Met inclusion and exclusion criteria	280	0	*****	0	*****	0
Had sufficient post-index continuous enrollment	280	0	*****	0	*****	0
Final cohort						
Number of members	280	N/A	42	N/A	63	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Anacaulase-bcdb		Ublituximab-xiiy	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	143,913,518	N/A	143,913,518	N/A
Had required coverage type (medical and/or drug coverage)	91,547,990	52,365,528	91,547,990	52,365,528
Enrolled during specified age range	91,547,403	587	91,547,403	587
Had requestable medical charts	91,547,403	0	91,547,403	0
Met demographic requirements (sex, race, and Hispanic origin)	91,494,956	52,447	91,494,956	52,447
Members with a valid index event				
Had any cohort-defining claim during the query period	151	91,494,805	563	91,494,393
Claim recorded during specified age range	151	0	563	0
Episode defining index claim recorded during the query period	151	0	563	0


Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

	Anacaulase-bcdb		Ublituximab-xiiy	
	Remaining	Excluded	Remaining	Excluded
Members with required pre-index history				
Had sufficient pre-index continuous enrollment	127	24	482	81
Met inclusion and exclusion criteria	127	0	482	0
Had sufficient post-index continuous enrollment	127	0	482	0
Final cohort				
Number of members	127	N/A	482	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Daridorexant in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on January 7, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1b. Patient Entry into Study by Month for Abrocitinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on January 14, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>


******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1c. Patient Entry into Study by Month for Mitapivat in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on February 17, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1d. Patient Entry into Study by Month for Pacritinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on February 28, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1e. Patient Entry into Study by Month for Ganaxolone in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on March 18, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1f. Patient Entry into Study by Month for Lutetium Vipivotide Tetraxetan in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on March 23, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1g. Patient Entry into Study by Month for Oteseconazole in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on April 26, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1h. Patient Entry into Study by Month for Mavacamten in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on April 28, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1i. Patient Entry into Study by Month for Vonoprazan in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on May 3, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1j. Patient Entry into Study by Month for Tirzepatide in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on May 13 , 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1k. Patient Entry into Study by Month for Tapinarof in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on May 23, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 11. Patient Entry into Study by Month for Vutrisiran in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on June 13, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1m. Patient Entry into Study by Month for Deucravacitinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on September 9, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1n. Patient Entry into Study by Month for Terlipressin in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on September 14, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1o. Patient Entry into Study by Month for Gadopiclenol in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on September 21, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1p. Patient Entry into Study by Month for Omidenepag Isopropyl Ophthalmic Solution in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



*The FDA approval date for this drug was on September 22, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

Figure 1q. Patient Entry into Study by Month for Sodium Phenylbutyrate and Taurursodiol in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on September 29, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1r. Patient Entry into Study by Month for Futibatinib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on September 30, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1s. Patient Entry into Study by Month for Olutasidenib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on December 1, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1t. Patient Entry into Study by Month for Adagrasib in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on December 12, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1u. Patient Entry into Study by Month for Lenacapavir in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on December 22, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1v. Patient Entry into Study by Month for Hyperpolarized ^{129}Xe in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on December 23, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1w. Patient Entry into Study by Month for Tebentafusp-tebn in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on January 25, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1x. Patient Entry into Study by Month for Faricimab-svoa in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on January 28, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1y. Patient Entry into Study by Month for Sutimlimab-jome in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on February 4, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1z. Patient Entry into Study by Month for Nivolumab and Relatlimab-rmbw in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on March 18, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1aa. Patient Entry into Study by Month for Olipudase Alfa-rpcp in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on August 31, 2022 as listed on the FDA website

<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ab. Patient Entry into Study by Month for Spesolimab-sbzo in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on September 1, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ac. Patient Entry into Study by Month for Daxibotulinumtoxina-lanm in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on September 7, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ad. Patient Entry into Study by Month for Eflapegrastim-xnst in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024




The FDA approval date for this drug was on September 9, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1ae. Patient Entry into Study by Month for Tremelimumab-actl in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on October 21, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1af. Patient Entry into Study by Month for Teclistamab-cqyv in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on October 25, 2022 as listed on the FDA website <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Figure 1ag. Patient Entry into Study by Month for Mirvetuximab Soravtansine-gynx in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

The FDA approval date for this drug was on November 14, 2022 as listed on the FDA website

<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ah. Patient Entry into Study by Month for Teplizumab-mzwv in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on November 18, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ai. Patient Entry into Study by Month for Mosunetuzumab-axgb in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on December 22, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*


******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1aj. Patient Entry into Study by Month for Anacaulase-bcdb in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024

*The FDA approval date for this drug was on December 28, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>*

******Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ak. Patient Entry into Study by Month for Ublituximab-xiiy in the Sentinel Distributed Database from January 1, 2022 to May 31, 2024



The FDA approval date for this drug was on December 28, 2022 as listed on the FDA website
<https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022>

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (November 14, 2024)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2008	05/31/2024
DP02	01/01/2008	12/31/2023
DP03	01/01/2007	02/29/2024
DP04	01/01/2010	12/31/2023
DP05	01/01/2006	02/29/2024

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Daridorexant	
Daridorexant	Quviviq
Daridorexant HCl	Quviviq
Abrocitinib	
Abrocitinib	Cibinqo
Mitapivat	
Mitapivat	Pyrukynd
Mitapivat sulfate	Pyrukynd
Pacritinib	
Pacritinib citrate	Vonjo
Ganaxolone	
Ganaxolone	Ztalmy
Lutetium Vipivotide Tetraxetan	
Lutetium Lu-177 Vipivotide Tetraxetan	Pluvicto
Oteseconazole	
Oteseconazole	Vivjoa
Mavacamten	
Mavacamten	Camzyos
Vonoprazan	
Vonoprazan fumarate	Voquezna
Vonoprazan fumarate/amoxicillin trihydrate	Voquezna Dual Pak
Vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
Tirzepatide	
Tirzepatide	Mounjaro
Tirzepatide	Zepbound
Tapinarof	
Tapinarof	Vtama
Vutrisiran	
Vutrisiran sodium	Amvuttra
Deucravacitinib	
Deucravacitinib	Sotyktu
Terlipressin	
Terlipressin acetate	Terlivaz
Gadopiclenol	
Gadopiclenol	Elucirem
Gadopiclenol	Vueway

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Omidenepag Isopropyl Ophthalmic Solution	
Omidenepag Isopropyl	Omlonti
Sodium Phenylbutyrate and Taurursodiol	
Sodium Phenylbutyrate/Taurursodiol	Relyvrio
Futibatinib	
Futibatinib	Lytgobi
Olutasidenib	
Olutasidenib	Rezlidhia
Adagrasib	
Adagrasib	Krazati
Lenacapavir	
Lenacapavir sodium	Sunlenca
Hyperpolarized 129-xe	
Xenon Xe-129 hyperpolarized	Xenoview Patient Dose
Xenon Xe-129 hyperpolarized	Xenoview Preparation Gas Blend
Tebentafusp-tebn	
Tebentafusp-tebn	Kimmtrak
Faricimab-svoa	
Faricimab-svoa	Vabysmo
Sutimlimab-jome	
Sutimlimab-jome	Enjaymo
Nivolumab and Relatlimab-rmbw	
Nivolumab-Relatlimab-rmbw	Opdualag
Olipudase Alfa-rpcp	
Olipudase Alfa-rpcp	Xenpozyme
Spesolimab-sbzo	
Spesolimab-sbzo	Spevigo
Daxibotulinumtoxina-lanm	
Daxibotulinumtoxina-lanm	Daxxify
Eflapegrastim-xnst	
Eflapegrastim-xnst	Rolvedon
Tremelimumab-actl	
Tremelimumab-actl	Imjudo
Teclistamab-cqyv	
Teclistamab-cqyv	Tecvayli
Mirvetuximab Soravtansine-gynx	
Mirvetuximab Soravtansine-gynx	Elahere

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Teplizumab-mzwv	
Teplizumab-mzwv	Tziel
Mosunetuzumab-axgb	
Mosunetuzumab-axgb	Lunsumio
Anacaulase-bcdb	
Anacaulase-bcdb	NexoBrid
Anacaulase-bcdb	Nexobrid Powder Component
Ublituximab-xiiy	
Ublituximab-xiiy	Briumvi

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Lutetium Vipivotide Tetraxetan			
A9607	Lutetium Lu 177 Vipivotide Tetraxetan, therapeutic, 1 mCi	Procedure	HCPCS
Vutrisiran			
J0225	Injection, Vutrisiran, 1 mg	Procedure	HCPCS
Terlipressin			
XW03367	Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	Procedure	ICD-10-PCS
XW04367	Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7	Procedure	ICD-10-PCS
Gadopiclenol			
A9573	Injection, Gadopiclenol, 1 ml	Procedure	HCPCS
Lenacapavir			
J1961	Injection, Lenacapavir, 1 mg	Procedure	HCPCS
Hyperpolarized 129-xe			
C9150	Xenon Xe-129 hyperpolarized gas, diagnostic, per study dose	Procedure	HCPCS
C9791	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	Procedure	HCPCS
Tebentafusp-tebn			
C9095	Injection, Tebentafusp-tebn, 1 mcg	Procedure	HCPCS
J9274	Injection, Tebentafusp-tebn, 1 mcg	Procedure	HCPCS
Faricimab-svoa			
C9097	Injection, Faricimab-svoa, 0.1 mg	Procedure	HCPCS
J2777	Injection, Faricimab-svoa, 0.1 mg	Procedure	HCPCS
Sutimlimab-jome			
C9094	Injection, Sutimlimab-jome, 10 mg	Procedure	HCPCS
J1302	Injection, Sutimlimab-jome, 10 mg	Procedure	HCPCS
Nivolumab and Relatlimab-rmbw			
J9298	Injection, Nivolumab and Relatlimab-rmbw, 3 mg/1 mg	Procedure	HCPCS
Olipudase Alfa-rpcp			
J0218	Injection, Olipudase Alfa-rpcp, 1 mg	Procedure	HCPCS
Spesolimab-sbzo			
J1747	Injection, Spesolimab-sbzo, 1 mg	Procedure	HCPCS
XW03308	Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
XW04308	Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
Eflapegrastim-xnst			
J1449	Injection, Eflapegrastim-xnst, 0.1 mg	Procedure	HCPCS
Tremelimumab-actl			
C9147	Injection, Tremelimumab-actl, 1 mg	Procedure	HCPCS
J9347	Injection, Tremelimumab-actl, 1 mg	Procedure	HCPCS
Teclistamab-cqyv			
C9148	Injection, Teclistamab-cqyv, 0.5 mg	Procedure	HCPCS
XW01348	Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
Teplizumab-mzww			
C9149	Injection, Teplizumab-mzww, 5 mcg	Procedure	HCPCS

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
J9381	Injection, Teplizumab-mzwv, 5 mcg	Procedure	HCPCS
Mosunetuzumab-axgb			
XW03358	Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
XW04358	Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
Anacaulase-bcdb			
J7353	Anacaulase-bcdb, 8.8% gel, 1 gm	Procedure	HCPCS
XW00X27	Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7	Procedure	ICD-10-PCS
XW01X27	Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7	Procedure	ICD-10-PCS
Ublituximab-xiiy			
J2329	Injection, Ublituximab-xiiy, 1mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acute Myocardial Infarction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Alzheimer's Disease			
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Depression			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Rheumatoid Arthritis/Osteoarthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Stroke/ Transient Ischemic Attack			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Prostate Cancer			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
COPD and Bronchiectasis			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Glaucoma			
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Osteoporosis			
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Liver Disease Diagnosis Codes Only			
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Procedure and Diagnosis Codes			
06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Greater Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Drug Abuse or Dependence (diagnosis/procedure)			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment,	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Obesity (diagnosis/procedure)			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Smoking (diagnosis/procedure)			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Alcohol Abuse or Dependence (diagnosis/procedure)			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment,	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
History of Cardiac Arrest			
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
History of Coronary Angioplasty or Bypass			
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity (prescription)	
amino acids/multivit-minerals/dietary supplement/protein sup	Optifast 70
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
diethylpropion HCl	diethylpropion HCl (bulk)
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl	phentermine HCl (bulk)
phentermine HCl/topiramate	Qsymia
resveratrol/chromium pico/green tea/EGCG/caffeine/digestive3	Resveratrol Diet
Smoking (prescription)	
bupropion HCl	bupropion HCl (smoking deter)
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline

Appendix F. Specifications Defining Parameters Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp282_nsdg_v01											
The goal of the query was to execute the Cohort Identification and Descriptive Analysis (CIDA) tool, version 13.2.0, to assess utilization and uptake of the 2022 New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD). Query period: 01/01/2022 - Most recent available data Coverage requirement: Medical and Drug Coverage Pre-index enrollment requirement: 183 days Post-index requirement: 0 days Enrollment gap: 45 days Age groups: 0-17, 18-24, 25-40, 41-64, 65+ years Stratifications: Age group, Sex Restrictions: Male and Female Distribution of index-defining codes: No Envelope macro: Reclassify encounters during inpatient stay as inpatient Freeze data: No											
Exposure											
Scenario	Group	Index Exposure/ Event	Cohort definition	Incident exposure washout period	of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	darid	Daridorexant	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

2	abroc	Abrocitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	mitap	Mitapivat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

4	pacrit	Pacritinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	ganax	Ganaxolone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

6	lutet	lutetium (177lu) vipivotide tetraxetan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	otese	Oteseconazole	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

8	mavac	Mavacamten	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	voque	Vonoprazan (single ingredient, dual pak, and triple pak)	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

10	tirze	Tirzepatide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	tapin	Tapinarof	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

12	vutri	Vutrisiran	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	deucr	Deucravacitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

14	terlip	Terlipressin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	gadop	Gadopiclenol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

16	omide	Omidenepag Isopropyl Ophthalmic Solution	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	relyv	Sodium Phenylbutyrate and Taurursodiol (Relyvrio)	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

18	futib	Futibatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	oluta	Olutasidenib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

20	adagr	Adagrasib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	lenac	Lenacapavir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

22	hype	Hyperpolarized 129-Xe	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	teben	Tebentafusp-tebn	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

24	faric	Faricimab-svoa	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	sutim	Sutimlimab-jome	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

26	opdua	Nivolumab and Relatlimab-rmbw (Opdualag)	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
27	olipu	Olipudase Alfa-rpcp	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

28	speso	Spesolimab-sbzo	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
29	daxib	Daxibotulinumto xina-lanm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

30	eflap	Eflapegrastim-xnst	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
31	treme	Tremelimumab-actl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

32	teclis	Teclistamab-cqyv	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
33	mirve	Mirvetuximab Soravtansine-gynx	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

34	tepliz	Teplizumab-mzwv	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
35	mosun	Mosunetuzumab-axgb	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters Used in this Request

36	anaca	Anacaulase-bcdb	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
37	ublit	Ublituximab-xiiy	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360. National Drug Codes (NDC) are checked against First Data Bank's FDB MedKnowledge®. N/A: Not Applicable											

Appendix G. Specifications Defining Baseline Characteristic Parameters Used in this Request

Characteristics

Characteristics	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Acute Myocardial Infarction	1	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	3	IPP, IPS	-183	-1	N/A	1	N/A
	4	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	5	3 or 4	-183	-1	N/A	N/A	N/A
Diabetes Mellitus	6	IP*, IS*	-183	-1	N/A	1	N/A
	7	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	8	6 or 7	-183	-1	N/A	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	N/A	1	N/A
Hyperlipidemia	10	IP*, IS*	-183	-1	N/A	1	N/A
	11	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	12	10 or 11	-183	-1	N/A	N/A	N/A
Hypertension	13	IP*, IS*	-183	-1	N/A	1	N/A
	14	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	15	13 or 14	-183	-1	N/A	N/A	N/A
Depression	16	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	N/A	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	N/A	1	N/A
	20	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	21	19 or 20	-183	-1	N/A	N/A	N/A
Breast Cancer	22	IP*, IS*	-183	-1	N/A	1	N/A
	23	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	24	22 or 23	-183	-1	N/A	N/A	N/A
	25	IP*, IS*	-183	-1	N/A	1	N/A

Appendix G. Specifications Defining Baseline Characteristic Parameters Used in this Request

Characteristics

Characteristics	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Colorectal Cancer	26	AV*, ED* OA*	-183	-1	N/A	2	N/A
	27	25 or 26	-183	-1	N/A	N/A	N/A
Prostate Cancer	28	IP*, IS*	-183	-1	N/A	1	N/A
	29	AV*, ED* OA*	-183	-1	N/A	2	N/A
	30	28 or 29	-183	-1	N/A	N/A	N/A
Lung Cancer	31	IP*, IS*	-183	-1	N/A	1	N/A
	32	AV*, ED* OA*	-183	-1	N/A	2	N/A
	33	31 or 32	-183	-1	N/A	N/A	N/A
Endometrial Cancer	34	IP*, IS*	-183	-1	N/A	1	N/A
	35	AV*, ED* OA*	-183	-1	N/A	2	N/A
	36	34 or 35	-183	-1	N/A	N/A	N/A
Acquired Hypothyroidism	37	IP*, IS*	-183	-1	N/A	1	N/A
	38	AV*, ED* OA*	-183	-1	N/A	2	N/A
	39	37 or 38	-183	-1	N/A	N/A	N/A
Anemia	40	Any	-183	-1	N/A	1	N/A
Asthma	41	IP*, IS*	-183	-1	N/A	1	N/A
	42	AV*, ED* OA*	-183	-1	N/A	2	N/A
	43	41 or 42	-183	-1	N/A	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*	-183	-1	N/A	1	N/A
	45	AV*, ED* OA*	-183	-1	N/A	2	N/A
	46	44 or 45	-183	-1	N/A	N/A	N/A
Chronic Kidney Disease	47	IP*, IS*	-183	-1	N/A	1	N/A
	48	AV*, ED* OA*	-183	-1	N/A	2	N/A
	49	47 or 48	-183	-1	N/A	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*, or	-183	-1	N/A	1	N/A
	51	AV*, ED* OA*	-183	-1	N/A	2	N/A
	52	50 or 51	-183	-1	N/A	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	N/A	1	N/A
	54	IP*, IS*	-183	-1	N/A	1	N/A

Appendix G. Specifications Defining Baseline Characteristic Parameters Used in this Request

Characteristics

Characteristics	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Osteoporosis	55	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	56	54 or 55	-183	-1	N/A	N/A	N/A
<i>Other</i>							
Liver Disease: Diagnosis Codes Only	57	IP*	-183	-1	N/A	1	N/A
	58	IS*, AV*, ED*, OA*	-183	-1	N/A	2	N/A
	59	57 or 58	-183	-1	N/A	N/A	N/A
Liver Disease: Procedure and Diagnosis Codes	60	AV (PX)	-183	-1	N/A	1	N/A
	61	AV (DX)	-183	-1	N/A	1	N/A
	62	60 and 61	-183	-1	N/A	n/a	N/A
	63	ED (PX)	-183	-1	N/A	1	N/A
	64	ED (DX)	-183	-1	N/A	1	N/A
	65	63 and 64	-183	-1	N/A	n/a	N/A
	66	OA (PX)	-183	-1	N/A	1	N/A
	67	OA (DX)	-183	-1	N/A	1	N/A
	68	66 and 67	-183	-1	N/A	n/a	N/A
	69	IS (PX)	-183	-1	N/A	1	N/A
	70	IS (DX)	-183	-1	N/A	1	N/A
	71	69 and 70	-183	-1	N/A	n/a	N/A
	72	59 or 62 or 65 or 68 or 71	-183	-1	N/A	n/a	N/A

Appendix G. Specifications Defining Baseline Characteristic Parameters Used in this Request

Characteristics

Characteristics	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Obesity: diagnosed or identified by weight management procedures	73	Any	-183	-1	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	74	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	75	Any	-183	-1	N/A	1	N/A
Smoking: diagnosed or identified by smoking cessation procedures	76	Any	-183	-1	N/A	1	N/A

Appendix G. Specifications Defining Baseline Characteristic Parameters Used in this Request

Characteristics

Characteristics	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Smoking: identified by smoking-related prescriptions	77	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	78	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	79	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	80	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	81	Any	-183	-1	N/A	1	N/A

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

¹Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not Applicable

Appendix H. Design Diagrams of Cohort Entry Requirements

